WO2023202652A1 - Pharmaceutical combination and use thereof - Google Patents
Pharmaceutical combination and use thereof Download PDFInfo
- Publication number
- WO2023202652A1 WO2023202652A1 PCT/CN2023/089400 CN2023089400W WO2023202652A1 WO 2023202652 A1 WO2023202652 A1 WO 2023202652A1 CN 2023089400 W CN2023089400 W CN 2023089400W WO 2023202652 A1 WO2023202652 A1 WO 2023202652A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cancer
- aryl
- deuterium
- cycloalkyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 116
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 97
- 229940122697 Glutamine antagonist Drugs 0.000 claims abstract description 87
- 238000006467 substitution reaction Methods 0.000 claims abstract description 65
- 230000000155 isotopic effect Effects 0.000 claims abstract description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 30
- 125000003118 aryl group Chemical group 0.000 claims description 329
- 125000001072 heteroaryl group Chemical group 0.000 claims description 229
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 208
- 229910052805 deuterium Inorganic materials 0.000 claims description 208
- 125000000623 heterocyclic group Chemical group 0.000 claims description 196
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 191
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 151
- 150000001875 compounds Chemical class 0.000 claims description 148
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 119
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 115
- 125000001424 substituent group Chemical group 0.000 claims description 111
- 229910052740 iodine Inorganic materials 0.000 claims description 108
- 229910052739 hydrogen Inorganic materials 0.000 claims description 107
- 239000001257 hydrogen Substances 0.000 claims description 107
- 150000002431 hydrogen Chemical group 0.000 claims description 99
- -1 -OH Chemical group 0.000 claims description 97
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 96
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 93
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 90
- 125000004043 oxo group Chemical group O=* 0.000 claims description 89
- 229910052736 halogen Inorganic materials 0.000 claims description 87
- 150000002367 halogens Chemical group 0.000 claims description 86
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 81
- 229910052801 chlorine Inorganic materials 0.000 claims description 70
- 229910052731 fluorine Inorganic materials 0.000 claims description 70
- 201000011510 cancer Diseases 0.000 claims description 69
- 229910052794 bromium Inorganic materials 0.000 claims description 68
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 61
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 61
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 61
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 57
- 239000003112 inhibitor Substances 0.000 claims description 53
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 206010009944 Colon cancer Diseases 0.000 claims description 39
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 38
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 32
- 206010006187 Breast cancer Diseases 0.000 claims description 31
- 201000001441 melanoma Diseases 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 150000002772 monosaccharides Chemical class 0.000 claims description 24
- 208000026310 Breast neoplasm Diseases 0.000 claims description 23
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 23
- 208000020816 lung neoplasm Diseases 0.000 claims description 23
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 18
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 17
- 206010039491 Sarcoma Diseases 0.000 claims description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 16
- 206010017758 gastric cancer Diseases 0.000 claims description 16
- 201000011549 stomach cancer Diseases 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 15
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 15
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 15
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 14
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 14
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 14
- 208000005017 glioblastoma Diseases 0.000 claims description 14
- 201000010536 head and neck cancer Diseases 0.000 claims description 14
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 14
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 14
- 201000000849 skin cancer Diseases 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 12
- 229940125563 LAG3 inhibitor Drugs 0.000 claims description 11
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 11
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 11
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- 229960003301 nivolumab Drugs 0.000 claims description 11
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 11
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 11
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 9
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 9
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims description 8
- 206010057654 Breast cancer female Diseases 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 201000008228 Ependymoblastoma Diseases 0.000 claims description 8
- 206010014968 Ependymoma malignant Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 8
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 8
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 8
- 208000032612 Glial tumor Diseases 0.000 claims description 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 8
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 claims description 8
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 claims description 8
- 206010025219 Lymphangioma Diseases 0.000 claims description 8
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 8
- 206010027406 Mesothelioma Diseases 0.000 claims description 8
- 108091092878 Microsatellite Proteins 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims description 8
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 8
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 8
- 206010057644 Testis cancer Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 201000002313 intestinal cancer Diseases 0.000 claims description 8
- 238000007917 intracranial administration Methods 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 208000030758 lung non-Hodgkin lymphoma Diseases 0.000 claims description 8
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 230000001394 metastastic effect Effects 0.000 claims description 8
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 201000008968 osteosarcoma Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 8
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 201000003120 testicular cancer Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 206010046766 uterine cancer Diseases 0.000 claims description 8
- 208000012991 uterine carcinoma Diseases 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 239000002212 purine nucleoside Substances 0.000 claims description 6
- 239000002718 pyrimidine nucleoside Substances 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000006546 (C4-C10) cycloalkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 229950007217 tremelimumab Drugs 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 229950010773 pidilizumab Drugs 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940121420 cemiplimab Drugs 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 229950007213 spartalizumab Drugs 0.000 claims description 2
- IMPJIKIXNAGRCR-XTWDHKKOSA-N (2s)-2-[[(1s)-2-[hydroxy-[2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]cyclopentanecarbonyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)O)CCC1P(O)(=O)C(NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 IMPJIKIXNAGRCR-XTWDHKKOSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 13
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 152
- 239000000460 chlorine Substances 0.000 description 66
- 239000011541 reaction mixture Substances 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 28
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 26
- 125000000172 C5-C10 aryl group Chemical group 0.000 description 24
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 19
- 239000012453 solvate Substances 0.000 description 19
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 18
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 18
- 238000001990 intravenous administration Methods 0.000 description 18
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 18
- 229940125782 compound 2 Drugs 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 150000001721 carbon Chemical group 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 238000001802 infusion Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000003782 apoptosis assay Methods 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000005522 programmed cell death Effects 0.000 description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 125000001309 chloro group Chemical group Cl* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229920002554 vinyl polymer Polymers 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- IPBZDPXMOGWXJU-XPUUQOCRSA-N C[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)OC Chemical compound C[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O)=O)OC IPBZDPXMOGWXJU-XPUUQOCRSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 5
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 description 4
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- CERMJBOCMXFIQJ-WPRPVWTQSA-N CCOC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](C)OC)=O)=O Chemical compound CCOC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](C)OC)=O)=O CERMJBOCMXFIQJ-WPRPVWTQSA-N 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 4
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 229940125399 kras g12c inhibitor Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 125000004011 3 membered carbocyclic group Chemical group 0.000 description 3
- 125000001845 4 membered carbocyclic group Chemical group 0.000 description 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102000004000 Aurora Kinase A Human genes 0.000 description 3
- 108090000461 Aurora Kinase A Proteins 0.000 description 3
- ORPFFAMAZAPHMB-QHCPKHFHSA-N CC(C)(C)[Si](C)(C)O[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O ORPFFAMAZAPHMB-QHCPKHFHSA-N 0.000 description 3
- HRPYNGZLHBMGDY-IRXDYDNUSA-N CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C1=CC=C2)=CNC1=C2F)O)=O)=O Chemical compound CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C1=CC=C2)=CNC1=C2F)O)=O)=O HRPYNGZLHBMGDY-IRXDYDNUSA-N 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- CGPWHPWPXWCWOX-CBAPKCEASA-N C[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC)=O)=O)OC Chemical compound C[C@@H](C(N[C@@H](CCC(C=[N+]=[N-])=O)C(OC)=O)=O)OC CGPWHPWPXWCWOX-CBAPKCEASA-N 0.000 description 3
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000002309 glutamines Chemical class 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 2
- ICPWFHKNYYRBSZ-VKHMYHEASA-N (2s)-2-methoxypropanoic acid Chemical compound CO[C@@H](C)C(O)=O ICPWFHKNYYRBSZ-VKHMYHEASA-N 0.000 description 2
- UCJZOKGUEJUNIO-IINYFYTJSA-N (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=C(Cl)C(N)=NC=C3)C(N)=N2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 description 2
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KEYYOCJSFDOEMI-QMMMGPOBSA-N CC(C)OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] Chemical compound CC(C)OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] KEYYOCJSFDOEMI-QMMMGPOBSA-N 0.000 description 2
- IGHUCDKRGLINOK-ONGXEEELSA-N CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](C)OC)=O)=O Chemical compound CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](C)OC)=O)=O IGHUCDKRGLINOK-ONGXEEELSA-N 0.000 description 2
- LHSHUIDQOASAPF-OALUTQOASA-N CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C1=CC=C2)=CNC1=C2F)OC(C)=O)=O)=O Chemical compound CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C1=CC=C2)=CNC1=C2F)OC(C)=O)=O)=O LHSHUIDQOASAPF-OALUTQOASA-N 0.000 description 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 2
- CAXVPVQMZQERFI-JTQLQIEISA-N COC([C@H](CC(C1=CC=C2)=CNC1=C2F)O)=O Chemical compound COC([C@H](CC(C1=CC=C2)=CNC1=C2F)O)=O CAXVPVQMZQERFI-JTQLQIEISA-N 0.000 description 2
- HQPMMTYDDNGJHK-IBGZPJMESA-N CO[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O Chemical compound CO[C@@H](CC1=CN(C(OCC2=CC=CC=C2)=O)C2=CC=CC=C12)C(OC)=O HQPMMTYDDNGJHK-IBGZPJMESA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000007563 Galectins Human genes 0.000 description 2
- 108010046569 Galectins Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 description 2
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 description 2
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229940083338 MDM2 inhibitor Drugs 0.000 description 2
- 239000012819 MDM2-Inhibitor Substances 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PGZFBEKONTYRCM-VIFPVBQESA-N O[C@@H](CC(C1=CC=C2)=CNC1=C2F)C(O)=O Chemical compound O[C@@H](CC(C1=CC=C2)=CNC1=C2F)C(O)=O PGZFBEKONTYRCM-VIFPVBQESA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229940126002 RMC-4630 Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 2
- HISJAYUQVHMWTA-BLLLJJGKSA-N [6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol Chemical compound NC1=NC=CC(=C1Cl)SC1=C(N=C(C(=N1)CO)N1CCC2([C@@H]([C@@H](OC2)C)N)CC1)C HISJAYUQVHMWTA-BLLLJJGKSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229940125763 bromodomain inhibitor Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- LCFXLZAXGXOXAP-QPJJXVBHSA-N ethyl (2e)-2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=N\O)\C#N LCFXLZAXGXOXAP-QPJJXVBHSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229950009034 indoximod Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- YKNYRRVISWJDSR-VKHMYHEASA-N methyl (2s)-oxirane-2-carboxylate Chemical compound COC(=O)[C@@H]1CO1 YKNYRRVISWJDSR-VKHMYHEASA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 101150067958 plk-3 gene Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XBHQOMRKOUANQQ-BYPYZUCNSA-N (2s)-2-ethoxypropanoic acid Chemical compound CCO[C@@H](C)C(O)=O XBHQOMRKOUANQQ-BYPYZUCNSA-N 0.000 description 1
- RGCGBFIARQENML-JOCHJYFZSA-N (3R)-1'-[3-(3,4-dihydro-2H-1,5-naphthyridin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]spiro[3H-1-benzofuran-2,4'-piperidine]-3-amine Chemical compound N[C@@H]1c2ccccc2OC11CCN(CC1)c1cnc2c(n[nH]c2n1)N1CCCc2ncccc12 RGCGBFIARQENML-JOCHJYFZSA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
- PLAVWQHGBMTMFR-UHFFFAOYSA-N 1-(2,3-dichlorobenzoyl)-4-[[5-fluoro-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridin-2-yl]methyl]piperidine-4-carboxylic acid Chemical compound N1C(C)=CC(NC=2C(=CC=C(CC3(CCN(CC3)C(=O)C=3C(=C(Cl)C=CC=3)Cl)C(O)=O)N=2)F)=N1 PLAVWQHGBMTMFR-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZADWXFSZEAPBJS-JTQLQIEISA-N 1-methyl-L-tryptophan Chemical compound C1=CC=C2N(C)C=C(C[C@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-JTQLQIEISA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- OBKBMFMBHWUYHS-DQEYMECFSA-N 2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1[C@H](CN(CC1)C=1C2=C(N=C(N=1)OC[C@H]1N(CCC1)C)CN(CC2)C1=CC=CC2=CC=CC=C12)CC#N OBKBMFMBHWUYHS-DQEYMECFSA-N 0.000 description 1
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 1
- ONFOSYPQQXJWGS-UHFFFAOYSA-N 2-hydroxy-4-(methylthio)butanoic acid Chemical compound CSCCC(O)C(O)=O ONFOSYPQQXJWGS-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- ARMDOTZROBQMBF-UHFFFAOYSA-N 2-methoxy-3-(1-methylindol-3-yl)propanoic acid Chemical compound COC(Cc1cn(C)c2ccccc12)C(O)=O ARMDOTZROBQMBF-UHFFFAOYSA-N 0.000 description 1
- WICHYTQYSBNZQN-UHFFFAOYSA-N 2-methoxy-4-methylsulfanylbutanoic acid Chemical compound COC(C(O)=O)CCSC WICHYTQYSBNZQN-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- XONKJZDHGCMRRF-UHFFFAOYSA-N 7-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1NC=C2 XONKJZDHGCMRRF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 101100387225 Buchnera aphidicola subsp. Baizongia pistaciae (strain Bp) asd gene Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- LQNMCWOJACNQQM-PMACEKPBSA-N CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O Chemical compound CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(C)=O LQNMCWOJACNQQM-PMACEKPBSA-N 0.000 description 1
- WTRLCCDSRUPILA-NSHDSACASA-N CO[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O Chemical compound CO[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O WTRLCCDSRUPILA-NSHDSACASA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- VXIVLOIJOUPMRG-JTQLQIEISA-N O[C@@H](Cn1ccc2ccccc12)C(O)=O Chemical compound O[C@@H](Cn1ccc2ccccc12)C(O)=O VXIVLOIJOUPMRG-JTQLQIEISA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010059631 Penile squamous cell carcinoma Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229940126000 RLY-1971 Drugs 0.000 description 1
- 229940125999 RMC-4550 Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 206010041848 Squamous cell carcinoma of the cervix Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000032249 Squamous cell carcinoma of the penis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940124988 adagrasib Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124675 anti-cancer drug Drugs 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229940121530 balstilimab Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000006598 bladder squamous cell carcinoma Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 108091008033 coinhibitory receptors Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000008396 gallbladder adenocarcinoma Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- UJEWHZZRQBIEMD-LURJTMIESA-N methyl (2S)-2-amino-6-diazo-5-oxohexanoate Chemical compound COC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] UJEWHZZRQBIEMD-LURJTMIESA-N 0.000 description 1
- LPEKGGXMPWTOCB-VKHMYHEASA-N methyl (S)-lactate Chemical compound COC(=O)[C@H](C)O LPEKGGXMPWTOCB-VKHMYHEASA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000003879 microtubule-organizing center Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical group FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 208000021333 squamous cell carcinoma of penis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- BUJKNFNMGRYZBV-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+);hydrate Chemical compound O.[Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F BUJKNFNMGRYZBV-UHFFFAOYSA-K 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates a pharmaceutical combination comprising a glutamine antagonist, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof, and an additional therapeutic agent; pharmaceutical compositions thereof; commercial packages thereof; and uses of such pharmaceutical combinations and pharmaceutical compositions for the treatment of cancer and cancer occurrence-related diseases.
- WO 2017/023774 discloses isopropyl (S) -2- ( (S) -2-acetamido-3- (lH-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate and other prodrugs of DON.
- DON and DON prodrugs can be used to treat a variety of diseases, disorders, and conditions including, but not limited to, cancer, cognitive deficits, and metabolic reprogramming disorders. See WO 2017/023793, WO 2017/023791, WO 2017/023787, and WO2020/150639.
- the combination of the present invention may show improved efficacy compared to either single agent alone in the treatment of diseases, e.g. cancer.
- the present invention provides for a pharmaceutical combination comprising:
- an additional therapeutic agent selected from a immune checkpoint inhibitor, an activator of a costimulatory molecule, a chemotherapeutic agent, a radiotherapeutic agent, a immunotherapeutic agent, a targeted anti-cancer therapy, an anticancer agent, an oncolytic drug, a cytotoxic agent, or any of the therapeutic agents disclosed herein.
- the additional therapeutic agent can be chosen from: a PD-1 inhibitor, a PD-L1 inhibitor, a LAG-3 inhibitor, a CTL4 inhibitor, a TIM-3 inhibitor, a CD47 inhibitor, a CDK4/6 inhibitor, an Aurora A kinase inhibitor, chemotherapeutic drug (Taxol, Cisplatin, Carboplatin, 5-Fu, topotecan, cyclophosphamide, and so on) , radiotherapy, HDAC inhibitor, a SHP2 inhibtor, a KRASG12C inhibitor, a BET inhibitor, a EGFR inhibitor, a VEGFR inhibitor, a GITR agonist, a SERD, a Plk3 inhibitor, a CXCR2 inhibitor, a CSF-1/1R binding agent, a c-MET inhibitor, a TGF- ⁇ inhibitor, an A2aR antagonist, an IDO inhibitor, a STING inhibitor, a Galectin inhibitor, a MEK
- the pharmaceutical combination comprises:
- an immune checkpoint inhibitor e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, or a CD47 inhibitor.
- the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a PD-1 inhibitor or a pharmaceutically acceptable salt thereof.
- the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a PD-L1 inhibitor or a pharmaceutically acceptable salt thereof.
- the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a CTLA-4 inhibitor or a pharmaceutically acceptable salt thereof.
- the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a LAG3 inhibitor or a pharmaceutically acceptable salt thereof.
- the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a TIM3 inhibitor or a pharmaceutically acceptable salt thereof.
- the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a CD47 inhibitor or a pharmaceutically acceptable salt thereof.
- a glutamine antagonist or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor, or a pharmaceutically acceptable salt thereof are in the same formulation.
- a glutamine antagonist or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor, or a pharmaceutically acceptable salt thereof, are in the separate formulation.
- the pharmaceutical combination of the invention is for simultaneous or sequential (in any order) administration.
- the present disclosure is directed to a method of treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder or disease, e.g., a hyperproliferative condition or disorder (e.g., a cancer) , cognitive deficits, and metabolic reprogramming disorders etc. in a subject.
- the method includes administering to the subject a therapeutically effective amount of pharmaceutical combination comprising a glutamine antagonist and an additional therapeutic agent disclosed herein.
- the additional therapeutic agent is chosen from: a PD-1/PD-L1 inhibitor, a LAG-3 inhibitor, a CTL4 inhibitor, a TIM-3 inhibitor, a CD47 inhibitor, a CDK4/6 inhibitor, an Aurora A kinase inhibitor, chemotherapeutic drug (Taxol, Cisplatin, Carboplatin, 5-Fu, topotecan, cyclophosphamide, and so on) , radiotherapy, HDAC inhibitor, a SHP2 inhibtor, a KRASG12C inhibitor, a BET inhibitor, a EGFR inhibitor, a VEGFR inhibitor, a GITR agonist, a SERD, a Plk3 inhibitor, a CXCR2 inhibitor, a CSF-1/1R binding agent, a c-MET inhibitor, a TGF- ⁇ inhibitor, an A2aR antagonist, an IDO inhibitor, a STING inhibitor, a Galectin inhibitor, a MEK inhibitor, an IL
- the present disclosure is directed to a method of treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder or disease, e.g., a hyperproliferative condition or disorder (e.g., a cancer) , in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a glutamine antagonist or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, or a cd47 inhibitor, or a pharmaceutically acceptable salt thereof.
- an immune checkpoint inhibitor e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, or a cd47 inhibitor, or a pharmaceutically acceptable salt thereof.
- the invention provides the pharmaceutical combination of the invention defined herein for use in the treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder, e.g., a hyperproliferative condition or disorder (e.g., a cancer) .
- a disorder e.g., a hyperproliferative condition or disorder (e.g., a cancer) .
- the invention provides for the pharmaceutical combination of the invention for use in the manufacture of a medicament for treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder, e.g., a hyperproliferative condition or disorder (e.g., a cancer) .
- a disorder e.g., a hyperproliferative condition or disorder (e.g., a cancer)
- composition comprising the combination of the invention.
- the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients as detailed herein.
- the cancer is a solid tumor. In another embodiment, the cancer is a hematological cancer. In another embodiment, the cancer is any one or more of the cancers of Table 1.
- Exemplary hematological cancers include, but are not limited to, the cancers listed in Table 2.
- the hematological cancer is acute lymphocytic leukemia, chronic lymphocytic leukemia (including B-cell chronic lymphocytic leukemia) , or acute myeloid leukemia.
- the cancer is any one or more of the cancers of a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor,
- the cancer is selected from the group consisting of squamous cell carcinoma of the head and neck, adenocarcinoma squamous cell carcinoma of the esophagus, adenocarcinoma of the stomach, adenocarcinoma of the colon, hepatocellular carcinoma, cholangiocarcinoma of the biliary system, adenocarcinoma of gall bladder, adenocarcinoma of the pancreas, ductal carcinoma in situ of the breast, adenocarcinoma of the breast, adenocarcinoma of the lungs, squamous cell carcinoma of the lungs, transitional cell carcinoma of the bladder, squamous cell carcinoma of the bladder, squamous cell carcinoma of the cervix, adenocarcinoma of the cervix, endometrial carcinoma, penile squamous cell carcinoma, and squamous cell carcinoma of the skin.
- a precancerous tumor is selected from the group consisting of leukoplakia of the head and neck, Barrett's esophagus, metaplasia of the stomach, adenoma of the colon, chronic hepatitis, bile duct hyperplasia, pancreatic intraepithelial neoplasia, atypical adenomatous hyperplasia of the lungs, dysplasia of the bladder, cervical initraepithelial neoplasia, penile intraepithelial neoplasia, and actinic keratosis of the skin.
- the cancer is selected from the group consisting of hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, and colorectal cancer.
- the cancer is selected from the group consisting of colorectal cancer, breast cancer, lymphoma, melanoma, kidney cancer, and lung cancer.
- the cancer has become resistant to conventional cancer treatments.
- conventional cancer treatments refers to any cancer drugs, biologies, or radiotherapy, or combination of cancer drugs and/or biologies and/or radiotherapy that have been tested and/or approved for therapeutic use in humans by the U.S. Food and Drug Administration, European Medicines Agency, or similar regulatory agency.
- the glutamine antagonist comprises a compound disclosed in International Application No. PCT/CN2021/123674 hereby incorporated by reference in its entirety.
- the glutamine antagonist a compound having the structure of formula I, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof:
- Z is OR 1 or SR 1 ;
- R 1 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, C 1-6 alkoxy, -C 3-8 cycloalkyl, -C 0-6 alkylene-C 3-8 heterocyclyl, -C 0-6 alkylene-NH-C 0-6 alkylene C 6-10 aryl, -C 0-6 alkylene-NH-C 0-6 alkylene-5-12 membered heteroaryl, -C 0-6 alkylene-C 6-10 aryl and -C 0-6 alkylene-5-12 membered heteroaryl; and each of which can be optional substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 al
- W is oxygen, CO or a bond
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
- R X1 and R X3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-12 membered heterocyclyl, wherein said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
- R 5 and R 5 ’ are each independently selected from the group consisting of hydrogen, deuterium, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, C 5-12 aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclyl, and wherein said -C 1-6 alkyl, said -C 1-6 alkoxy, said -C 3-8 cycloalkyl, said C 5-12 aryl, said 5-12 membered heteroaryl, said 5-12 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, -C 1-6 alkyl, -C 3-8 cycloalkyl, 5-12 membered heterocyclyl ring, -C 1-6 alkenyl, and -C 3-8 cycloalkenyl, and wherein said -C 1-6 alkyl, said -C 3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said -C 1-6 alkenyl, and said -C 3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, C 3-8 cycloalkyl, 5-12 membered heterocyclyl ring, C 1-6 alkenyl, C 3-8 cycloalkenyl, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said C 1-6 alkenyl, said C 3-8 cycloalkenyl, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl)
- R 8 and R 9 are each independently selected from the group consisting of C 1-6 alkyl, C 3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-12 aryl, and 5-12 membered heteroaryl, and wherein said C 1-6 alkyl, said C 3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- G is C 5-12 aryl, or 5-12 membered heteroaryl, wherein C 5-12 aryl, and 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- Y is a bond, oxygen, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-6 alkyl, and C 1-6 alkoxy, and wherein said C 1-6 alkyl, and said C 1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl.
- R 1 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, C 1-3 alkoxy, -C 3-8 cycloalkyl, -C 0-3 alkylene-C 3-8 heterocyclyl, -C 0-3 alkylene-NH-C 0-3 alkylene C 6-10 aryl, -C 0-3 alkylene-NH-C 0-3 alkylene-5-12membered heteroaryl, -C 0-3 alkylene-C 6-10 aryl and -C 0-3 alkylene-5-12 membered heteroaryl; and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN,
- R 1 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, C 1-3 alkoxy, -C 3-8 cycloalkyl, -C 0-3 alkylene-C 3-8 heterocyclyl, -C 0-3 alkylene-NH-C 0-3 alkylene C 6-10 aryl, -C 0-3 alkylene-NH-C 0-3 alkylene-5-12 membered heteroaryl, -C 0-3 alkylene-C 6-10 aryl and -C 0-3 alkylene-5-12 membered heteroaryl; each of the heteroaryl and heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and wherein each of which can be optional substituted with one or more substituents, which are independently selected from
- R 1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -NH-C 3-6 cycloalkyl, -N (C 1-3 alkyl) 2 , carboxyl, -CO-C 1-3 al
- R 1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -NH 2 , -NH
- R 1 is seleted from hydrogen, deuterium, isopropyl, methyl, ethyl, -tert-butyl, -CF 3 , -CH 2 CF 3 , -CH(CH 3 ) CF 3 , -CH (CH 3 ) CH 2 CF 3 , - (CH 2 ) 2 CF 3 , - (CH 2 ) 2 CF 3 , - (CH 2 ) 2 -CH (CH 3 ) 2 , -C (CH 3 ) 2 CF 3 , -C (CH 3 ) 2 CH 2 CF 3 , -CN, -CH 2 CN, -CH (CH 3 ) CN, -CH 2 CH 2 CN, -CH (CH 3 ) CH 2 CN, -C (CH 3 ) 2 CN, -C
- W is oxygen, CO or a bond
- n is selected from 1, 2 or 3;
- p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
- R X1 and R X3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-10 membered heterocyclyl, wherein said 5-10 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
- R 5 and R 5 ’ are each independently selected from the group consisting of hydrogen, deuterium, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl, and wherein said -C 1-3 alkyl, -C 1-3 alkoxy, said -C 3-6 cycloalkyl, said C 5-10 aryl, said 5-10 membered heteroaryl, said 5-10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, -C 1-3 alkyl, -C 3-6 cycloalkyl, 5-10 membered heterocyclyl ring, -C 1-3 alkenyl, and -C 3-6 cycloalkenyl, and wherein said -C 1-3 alkyl, said -C 3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said -C 1-3 alkenyl, and said -C 3-6 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl;or R
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, C 3-6 cycloalkyl, 5-10 membered heterocyclyl ring, C 1-3 alkenyl, C 3-6 cycloalkenyl, C 5-10 aryl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said C 3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said C 1-3 alkenyl, said C 3-6 cycloalkenyl, said C 5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl)
- R 8 and R 9 are each independently selected from the group consisting of C 1-3 alkyl, C 3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-10 aryl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said C 3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl; or
- G is C 5-10 aryl, or 5-10 membered heteroaryl, wherein C 5-10 aryl, and 5-10 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl.
- substituents which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , carboxyl.
- W is oxygen or a bond
- n is selected from 1, 2 or 3;
- p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
- R X1 and R X2 together with the carbon atom to which they are attached form C 4-6 carbocyclic ring, C 4-6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -NH 2 , -CN, -OH, -NO 2 , oxo, carboxyl, C 1-3 alkoxy, C 1-3 alkyl;
- R X1 and R X3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-10 membered heterocyclyl, wherein said 5-10 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
- R 5 and R 5 ’ are each independently selected from the group consisting of hydrogen, deuterium, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, C 5-10 aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl, and wherein said -C 1-3 alkyl, -C 1-3 alkoxy, said -C 3-6 cycloalkyl, said C 5-10 aryl, said 5-10 membered heteroaryl, said 5-10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 ,
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, -C 1-3 alkyl, -C 3-6 cycloalkyl, 5-10 membered heterocyclyl ring, -C 1-3 alkenyl, and -C 3-6 cycloalkenyl, and wherein said -C 1-3 alkyl, said -C 3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said -C 1-3 alkenyl, and said -C 3-6 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , carboxy
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, C 3-6 cycloalkyl, 5-10 membered heterocyclyl ring, C 1-3 alkenyl, C 3-6 cycloalkenyl, C 5-10 aryl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said C 3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said C 1-3 alkenyl, said C 3-6 cycloalkenyl, said C 5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3
- R 8 and R 9 are each independently selected from the group consisting of C 1-3 alkyl, C 3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-10 aryl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said C 3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , carboxyl; or
- G is C 5-10 aryl, or 5-10 membered heteroaryl, wherein C 5-10 aryl, and 5-10 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , carboxyl.
- substituents which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2
- W is oxygen or a bond
- n is selected from 1, 2 or 3;
- p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
- R X1 and R X3 together with the carbon atom and the oxygen atom to which they are attached respectively form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH(C 1-3 al
- R 5 and R 5 ’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heteroaryl, 10 membered heteroaryl, 5 membered heterocyclyl, 6 membered heterocycl
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, -C 3 cycloalkenyl, -C 4 cycloalkenyl, -C 5 cycloalkenyl, -C 6 cycloalkenyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said -C 3 cycloalkyl, said -C 4 cycloalkyl, said
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, C 6 cycloalkyl, 5-10 membered heterocyclyl ring, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, C 3 cycloalkenyl, C 4 cycloalkenyl, C 5 cycloalkenyl, C 6 cycloalkenyl, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, 5 membered heteroaryl, 6 membered heteroaryl,
- R 8 and R 9 are each independently selected from the group consisting of C 1-3 alkyl, C 3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-10 aryl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said C 3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , or carboxyl; or
- G is C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, or 10 membered heteroaryl, wherein said C 5 aryl, said C 6 aryl, said C 7 aryl, said C 8 aryl, said C 9 aryl, said C 10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, or said 10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -
- W is oxygen or a bond
- n is selected from 1, 2 or 3;
- p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
- R X1 and R X2 together with the carbon atom to which they are attached form 3-membered carbocyclic ring, 4-membered carbocyclic ring, 5-membered carbocyclic ring, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N or O; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, -F, -Cl, -Br, -I, -NH 2 , -CN, -OH, -NO 2 , oxo, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy;
- R X1 and R X3 together with the carbon atom and the oxygen atom to which they are attached respectively form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloal
- R 5 and R 5 ’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heteroaryl, 10 membered heteroaryl, 5 membered heterocyclyl, 6 membered heterocycl
- each of R 6 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, -C 3 cycloalkenyl, -C 4 cycloalkenyl, -C 5 cycloalkenyl, -C 6 cycloalkenyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said -C 3 cycloalkyl, said -C 4 cycloalkyl, said
- each of R 7 is independent selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, C 3 cycloalkyl, C 4 cycloalkyl, C 5 cycloalkyl, C 6 cycloalkyl, 5-10 membered heterocyclyl ring, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, C 3 cycloalkenyl, C 4 cycloalkenyl, C 5 cycloalkenyl, C 6 cycloalkenyl, C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, 5 membered heteroaryl, 6 membered heteroaryl,
- R 8 and R 9 are each independently selected from the group consisting of C 1-3 alkyl, C 3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C 5-10 aryl, and 5-10 membered heteroaryl, and wherein said C 1-3 alkyl, said C 3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C 5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -
- G is C 5 aryl, C 6 aryl, C 7 aryl, C 8 aryl, C 9 aryl, C 10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, or 10 membered heteroaryl, wherein said C 5 aryl, said C 6 aryl, said C 7 aryl, said C 8 aryl, said C 9 aryl, said C 10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, or said 10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, me
- W is a bond
- n 1 or 2;
- R X1 and R X2 together with the carbon atom to which they are attached form 3-membered carbocyclic ring, 4-membered carbocyclic ring, 5-membered carbocyclic ring, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N or O; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; or
- R X1 and R X3 together with the carbon atom and the oxygen atom to which they are attached respectively form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloal
- W is a bond
- n 1 or 2;
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , and carboxyl.
- R 2 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , and carboxyl.
- R 2 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 al
- R 2 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloal
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , and carboxyl.
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , and carboxyl.
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -
- R 3 and R 3 ’ are each independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -
- Y is a bond, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, or 3;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , and carboxyl.
- Y is a bond, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, or 3;
- R Y1 and R Y2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2, and carboxyl.
- substituents which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 ,
- Y is a bond, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, or 3;
- R Y1 and R Y2 are each independently selected from the group consisting of F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2, and carboxyl.
- substituents which are independently selected from the group consisting of deuterium, F, Cl, Br, I,
- Y is a bond, or - (CR Y1 R Y2 ) n -;
- n is selected from 1, 2, or 3;
- R Y1 and R Y2 are each independently selected from the group consisting of F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloalkyl, -C 4 cycloalkyl, -C 5 cycloalkyl, -C 6 cycloalkyl, -NH 2 , -NHCH 3 ,
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , and carboxyl.
- R 4 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , and carboxyl.
- R 4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 al
- R 4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloal
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C 1-6 alkyl, -C 1-6 alkoxy, -C 3-8 cycloalkyl, -NH 2 , -NH (C 1-6 alkyl) , -N (C 1-6 alkyl) 2 , and carboxyl.
- R 10 is selected from the group consisting of hydrogen, deuterium, halogen, C 1-3 alkyl, and C 1-3 alkoxy, and wherein said C 1-3 alkyl, and said C 1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , and carboxyl.
- R 10 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 al
- R 10 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C 3 cycloal
- the glutamine antagonist is a compound of Formula I-C, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof:
- the glutamine antagonist is a compound of Formula II, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof:
- the glutamine antagonist is a compound of Formula III, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
- R 1 , R X1 , R X2 , R X3 , and m are the same as defined herein.
- the glutamine antagonist is a compound of Formula IV, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof :
- the glutamine antagonist is a compound of Formula V, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
- the glutamine antagonist is a compound of Formula VI, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
- the glutamine antagonist is a compound of Formula VII, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
- the glutamine antagonist is a compound of Formula VIII or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic substitution thereof:
- R 1 , R X1 , R X2 , R X3 , and m are the same as defined herein
- the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention wherein one or more hydrogen is optionally substitued with deuterium.
- the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention wherein one or more hydrogen in R 1 or R X3 is substitued with deuterium, preferably, all hydrogens on one or more methyl groups, methylene groups, or methane groups are substituted with deuterium.
- R 1 is selected from the group consisting of hydrogen, deuterium, hydrogen, deuterium, C 1-3 alkyl, C 1-3 alkoxy, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy;
- R X1 and R X2 are each independently selected from the group consisting of hydrogen, deuterium, CN, OH,
- R X3 is independently selected from the group consisting of hydrogen, deuterium, C 1-3 alkyl, C 1-3 alkoxy, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C 1-3 alkyl, -C 1-3 alkoxy, -C 3-6 cycloalkyl, -NH 2 , -NH (C 1-3 alkyl) , -N (C 1-3 alkyl) 2 , carboxy, -S-C 1-3 alkyl.
- R 1 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy;
- R X1 and R X2 are each independently selected from the group consisting of hydrogen, deuterium, CN, CF 3 ,
- oxo carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy;
- R X3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, each of which can be substituted with deuterium.
- R 1 is seleted from hydrogen, deuterium, isopropyl, methyl, ethyl, -tert-butyl, isopentyl, -CD 3 , -CH 2 CD 3 , -CD 2 CD 3 , -CD (CD 3 ) 2 , -CH (CD 3 ) 2 ,
- R X1 and R X2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN,
- R X3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, -CD 3 , -CH 2 CD 3 , -CD 2 CD 3 .
- R 1 is selected from -CD 3 , -CH 2 CD 3 , -CD 2 CD 3 , -CD (CD 3 ) 2 , -CH(CD 3 ) 2
- the deuterated R X3 is selected from -CD 3 , -CH 2 CD 3 , -CD 2 CD 3 , -CD 2 CD 3
- the glutamine antagonist is a compound selected from the compounds in the following table (table 3) , or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
- the glutamine antagobist is selected from a compound in Table 3, or a pharmaceutically acceptable salt thereof.
- the glutamine antagonist is selected from compound 1, compound 2, compound 3, compound 4, compound 5, or compound 6, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- the glutamine antagonist is compound 1, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- the glutamine antagonist is compound 2, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- the glutamine antagonist is compound 3, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- the glutamine antagonist is compound 4, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- the glutamine antagonist is compound 5, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- the glutamine antagonist is compound 6, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
- Immune checkpoint inhibitors are therapies that blockade immune system inhibitor checkpoints.
- Immune checkpoints can be stimulatory or inhibitory. Blockade of inhibitory immune checkpoint activates immune system function and can be used for cancer immunotherapy. Pardoll, Nature Reviews. Cancer 72: 252-64 (2012) . Tumor cells turn off activated T cells when they attach to specific T-cell receptors. Immune checkpoint inhibitors prevent tumor cells from attaching to T cells, which results in T cells remaining activated. In effect, the coordinated action by cellular and soluble components combats pathogens and injuries by cancers.
- the modulation of immune system pathways may involve changing the expression or the functional activity of at least one component of the pathway to then modulate the response by the immune system.
- immune checkpoint inhibitors include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG3 inhibitors, TIM3 inhibitors, cd47 inhibitors, and B7-H1 inhibitors.
- the immune checkpoint inhibitor is selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, and a cd47 inhibitor.
- the immune checkpoint inhibitor is a programmed cell death (PD-1) inhibitor.
- PD-1 is a T-cell coinhibitory receptor that plays a pivotal role in the ability of tumor cells to evade the host's immune system. Blockage of interactions between PD-1 and PD-L1, a ligand of PD-1, enhances immune function and mediates antitumor activity.
- PD-1 inhibitors include antibodies that specifically bind to PD-1.
- Particular anti-PD-1 antibodies include, but are not limited to nivolumab, pembrolizumab, STI-A1014, and pidilzumab.
- the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, STI-A1110, PDR001, MEDI-0680, Balstilimab (AGEN2034) , Tislelizumab (BGB-A317) , AB122, TSR-042, PF-06801591, cemiplimab, SYM021, JNJ-63723283, HLX10, LZM009, and MGA012.
- the immune checkpoint inhibitor is a PD-L1 (also known as B7-H1 or CD274) inhibitor.
- PD-L1 inhibitors include antibodies that specifically bind to PD-L1.
- Particular anti-PD-Ll antibodies include, but are not limited to, avelumab, atezolizumab, durvalumab, STI-A1014 and BMS-936559.
- the immune checkpoint inhibitor is a CTLA-4 inhibitor.
- CTLA-4 also known as cytotoxic T-lymphocyte antigen 4
- CTLA-4 is a protein receptor that downregulates the immune system.
- CTLA-4 is characterized as a "brake” that binds costimulatory molecules on antigen-presenting cells, which prevents interaction with CD28 on T cells and also generates an overtly inhibitory signal that constrains T cell activation.
- CTLA-4 inhibitors include antibodies that specifically bind to CTLA-4.
- Particular anti-CTLA-4 antibodies include, but are not limited to, ipilimumab and tremelimumab.
- the immune checkpoint inhibitor is a LAG3 inhibitor.
- LAG3, Lymphocyte Activation Gene 3 is a negative co-simulatory receptor that modulates T cell homeostatis, proliferation, and activation.
- LAG3 has been reported to participate in regulatory T cells (Tregs) suppressive function. A large proportion of LAG3 molecules are retained in the cell close to the microtubule-organizing center, and only induced following antigen specific T cell activation.
- Tregs regulatory T cells
- Examples of LAG3 inhibitors include antibodies that specifically bind to LAG3.
- Particular anti-LAG3 antibodies include, but are not limited to, GSK2831781.
- the immune checkpoint inhibitor is a TIM3 inhibitor.
- TIM3, T-cell immunoglobulin and mucin domain 3 is an immune checkpoint receptor that functions to limit the duration and magnitude of T H 1 and T C 1 T-cell responses.
- the TIM3 pathway is considered a target for anticancer immunotherapy due to its expression on dysfunctional CD8 + T cells and Tregs, which are two reported immune cell populations that constitute immunosuppression in tumor tissue.
- Anderson, Cancer Immunology Research 2: 393-98 (2014) .
- Examples of TIM3 inhibitors include antibodies that specifically bind to TIM3.
- the immune checkpoint inhibitor is a cd47 inhibitor. See Unanue, E.R., PNAS 110: 10886-87 (2013) .
- an Aurora A kinase inhibitor is selected from VX-689, VIC-1911, LY3295668, or a pharmaceutically acceptable salt thereof.
- a SHP2 inhibitor selecte from compounds described in WO2015/107493, WO2015/107494, WO2015/107495, WO2016/203406, WO2016/203404, WO2016/203405, WO2017/216708, WO2018/013597, WO2018/136264, WO2018/13265, WO2019/051084, WO2019/075265, WO2019/118909, WO2019/199792, WO2017/211303, WO2018/172984, WO2017/156397, WO2018/057884, WO2018/081091, WO2019/067843, WO2019/165073, WO2019/183367, WO2017210134, WO2019213318, WO2020033828, WO2019051469, WO2019158019, WO2019182960, WO2021061515, WO2020022323, WO2019167000, WO2021033153, WO2020061101, WO2020061103, WO20
- the SHP2 inhibitor comprises or consists of RMC-4630, RMC-4550, RLY-1971, BBP-398, ERAS-601, RG001 , GH-21 , SH3809 , ET0038 , ICP-189 , BT-102 , PF-07284892 , SNG-201 , (3S, 4S) -8- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3-methyl-2-oxa-8-azaspiro [4.5] decan-4-amine (TN0155) , or a pharmaceutically acceptable salt thereof; 6- (4-amino-4-methylpiperidin-l-yl) -3 - (2, 3 -dichlorophenyl) pyrazin -2-amine (SHP099) or a pharmaceutically acceptable salt thereof, and any one of pharmaceutical combination thereof.
- a “KRASG12C inhibitor” is a compound selected from the compounds detailed in WO2013/155223, WO2014/143659, WO2014/152588, WO2014/160200, WO2015/054572, WO2016/044772, WO2016/049524, WO2016164675, WO2016168540, W02017/058805, WO2017015562, WO2017058728, WO2017058768, WO2017058792, W02017058805, W02017058807, W02017058902, WO2017058915, WO2017087528, W02017100546, WO2017/201161, WO2018/064510, WO2018/068017, WO2018/119183, WO2018/217651, W02018/140512, W02018/140513, W02018/140514, WO2018/140598, WO2018/140599, W02018/140600, WO2018/143315,
- the KRASG12C inhibitor is selected from AMG 510, MRTX849, RMC-6291, GH-35 , LY-3537982 , BEBT-607 , BPI-421286, D-1553, YL-15293, JDQ-443, 1 - (4- (6-chloro-8-fluoro-7- (3-hydroxy-5 -vinylphenyl) quinazolin-4-yl) piperazin-1 -yl) prop-2-en-l -one-methane (1/2) ; (S) -l- (4- (6-chloro-8-fluoro-7- (2-fluoro-6-hydroxyphenyl) quinazolin-4-yl) piperazin-l-yl) prop-2-en-l-one ; 2- ( (S) -l-acryloyl-4- (2- ( ( (S) -l-methylpyrrolidin-2 -yl) methoxy) -7- (naphthal
- antibody is meant to include intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.
- antibody is meant to include soluble receptors that do not possess the Fc portion of the antibody.
- the antibodies are humanized monoclonal antibodies and fragments thereof made by means of recombinant genetic engineering.
- Another class of immune checkpoint inhibitors include polypeptides that bind to and block PD-1 receptors on T-cells without triggering inhibitor signal transduction.
- Such peptides include B7-DC polypeptides, B7-H1 polypeptides, B7-1 polypeptides and B7-2 polypeptides, and soluble fragments thereof, as disclosed in U.S. Pat. 8,114,845.
- immune checkpoint inhibitors include compounds with peptide moieties that inhibit PD-1 signaling. Examples of such compounds are disclosed in U.S. Pat. 8,907,053 and have the structure:
- the compound comprises at least 5 amino acids useful as therapeutic agents capable of inhibiting the PD-1 signaling pathway.
- IDO indoleamine 2, 3 dioxygenase
- the IDO enzyme inhibits immune responses by depleting amino acids that are necessary for anabolic functions in T cells or through the synthesis of particular natural ligands for cytosolic receptors that are able to alter lymphocyte functions.
- Particular IDO blocking agents include, but are not limited to levo-l-methyl typtophan (L-1MT) and 1 -methyl-tryptophan (1MT) .
- the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, STI-A1110, avelumab, atezolizumab, durvalumab, STI-A1014, ipilimumab, tremelimumab, GSK2831781, BMS-936559 or MED14736.
- compositions or commercial package comprising the pharmaceutical combination of the invention, and at least one pharmaceutically acceptable carrier.
- the present application provides a use of the pharmaceutical combination defined herein and/or the pharmaceutical composition or the commercial package of the present invention for the manufacture of a medicament.
- the medicament prepared can be used for the treatment or prevention of cancer or cancer metastasis.
- the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanom
- a breast cancer
- the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
- the present application provides a use of the pharmaceutical combination of defined herein or the pharmaceutical composition or the commercial package of the present invention, wherein a medicament prepared can be used for the treatment or prevention of cancer or cancer metastasis.
- the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma,
- the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
- the pharmaceutical combination of defined herein or the pharmaceutical composition or the commercial package of the present invention for use in the treatment of cancer or the prevention of cancer metastasis.
- the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma,
- the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
- the present invention relates to a method of treating cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor,
- the glutamine antagonist is administered to the patient according to an intermittent dosing schedule. In some embodiments, the glutamine antagonist is subcutaneously administered to the patient according to an intermittent dosing schedule. In some embodiments, the glutamine antagonist is intravenously administered to the patient according to an intermittent dosing schedule.
- the glutamine antagonist is administered prior to the immune checkpoint inhibitor, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks prior to the administration of the immune checkpoint inhibitor.
- the glutamine antagonist is administered after the immune checkpoint inhibitor, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks after the administration of the immune checkpoint inhibitor.
- the glutamine antagonist, and the immune checkpoint inhibitor are administered concurrently but on different schedules, e.g, the glutamine antagonist is administered daily while the immune checkpoint inhibitor is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the glutamine antagonist is administered once a day while the immune checkpoint inhibitor is administered once a week, once every two weeks, once every three weeks, or once every four weeks.
- the therapeutic methods provided herein comprise administering a glutamine antagonist to a cancer patient in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
- the glutamine antagonist is administered in an amount from about 0.05 mg/kg to about 500 mg/kg, about 0.05 mg/kg to about 100 mg/kg, about 0.05 mg/kg to about 50 mg/kg, or about 0.05 mg/kg to about 10 mg/kg.
- the dosage of a composition can be at any dosage including, but not limited to, about 0.05 mg/week to about 25 mg/week. Particular doses include 0.05, 1, 2, 5, 10, 20, 50, and 100 mg/kg once weekly. In one embodiment, the glutamine antagonist is administered once a week.
- dosages are exemplary, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this disclosure.
- the physician determines the actual dosing regimen that is most suitable for an individual patient, which can vary with the age, weight, and response of the particular patient. In one embodiment, about 0.1 mg/kg to about 2 mg/kg of DON is administered to the subject.
- the unit oral dose of the glutamine antagonist may comprise from about 0.01 to about 1000 mg, e.g., about 0.01 to about 100 mg of the glutamine antagonist.
- the unit oral dose of the glutamine antagonist is 0.05 mg, 1 mg, 3 mg, 5 mg, 7 mg, 9 mg, 10 mg 12 mg, 14 mg, 15 mg, 17 mg, 20 mg, 22 mg, 25 mg, 27 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg.
- the unit dose may be administered one or more times daily, e.g., as one or more tablets or capsules.
- the unit does may also be administered by IV or subcutaneously to the subject. In practice, the physician determines the actual dosing regimen that is most suitable for an individual patient, which can vary with the age, weight, and response of the particular patient.
- the glutamine antagonist in addition to administering the glutamine antagonist as a raw chemical, it may be administered as part of a pharmaceutical preparation or composition.
- the pharmaceutical preparation or composition can include one or more pharmaceutically acceptable carriers, excipients, and/or auxiliaries.
- the one or more carriers, excipients, and auxiliaries facilitate processing of the glutamine antagonist into a preparation or composition which can be used pharmaceutically.
- the preparations particularly those preparations which can be administered orally, subcutaneously, intravenously, or topically, and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, and shampoos, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, subcutaneous injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound (s) , together with the one or more carriers, excipients, and/or auxiliaries.
- compositions of provided herein may be administered to any subject which may experience the beneficial effects of the glutamine antagonist.
- mammals e.g., humans, although the methods and compositions provided herein are not intended to be so limited.
- Other subjects include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like) .
- the subject is a human cancer patient.
- compositions provided herein are manufactured by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes.
- pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose,
- disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Auxiliaries can be suitable flow-regulating agents and lubricants. Suitable auxiliaries include, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
- stabilizers may be added.
- Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base.
- Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
- gelatin rectal capsules which consist of a combination of the active compounds with a base.
- Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
- Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers.
- solvates of the glutamine antagonist typically do not significantly alter the physiological activity or toxicity of a compound, and as such may function as pharmacological equivalents.
- solvate as used herein is a combination, physical association and/or solvation of the glutamine antagonist with a solvent molecule such as, e.g ., a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to the glutamine antagonist is about 2: 1, about 1 : 1 or about 1 : 2, respectively.
- This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
- the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid.
- solvate encompasses both solution-phase and isolatable solvates.
- the glutamine antagonist can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the disclosure includes both solvated and unsolvated forms of the glutamine antagonist.
- a pharmaceutically acceptable solvent such as water, methanol, ethanol, and the like
- solvate is a hydrate.
- a "hydrate” relates to a particular subgroup of solvates where the solvent molecule is water.
- Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M.
- a typical, non-limiting, process of preparing a solvate involves dissolvingthe glutamine antagonist in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20°C to about 25°C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g ., filtration.
- Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
- Therapeutically effective amounts of the glutamine antagonist, and the immune checkpoint inhibitor formulated in accordance with standard pharmaceutical practices, are administered to a human patient in need thereof. Whether such a treatment is indicated depends on the individual case and is subject to medical assessment (diagnosis) that takes into consideration signs, symptoms, and/or malfunctions that are present, the risks of developing particular signs, symptoms and/or malfunctions, and other factors.
- the glutamine antagonist, and the immune checkpoint inhibitor can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracistemal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and/or surgical implantation at a particular site) administration.
- Parenteral administration can be accomplished using a needle and syringe or using a high pressure technique.
- the glutamine antagonist is administered subcutaneously to the subject.
- the glutamine antagonist is administered intraveneously to the subject.
- compositions include those wherein the glutamine antagonist, and the immune checkpoint inhibitor are administered in an effective amount to achieve its intended purpose.
- the exact formulation, route of administration, and dosage is determined by an individual physician in view of the diagnosed condition or disease. Dosage amount and interval can be adjusted individually to provide levels of the glutamine antagonist, and the immune checkpoint inhibitor that is sufficient to maintain therapeutic effects.
- Toxicity and therapeutic efficacy of the glutamine antagonist, and the immune checkpoint inhibitor can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) of a compound, which defines as the highest dose that causes no toxicity in a patient.
- MTD maximum tolerated dose
- the dose ratio between the maximum tolerated dose and therapeutic effects (e.g. inhibiting of tumor growth) is the therapeutic index.
- the dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- a therapeutically effective amount of the glutamine antagonist, and the immune checkpoint inhibitor required for use in therapy varies with the nature of the condition being treated, the length of time that activity is desired, and the age and the condition of the subject, and ultimately is determined by the attendant physician.
- dosage amounts and intervals can be adjusted individually to provide plasma levels of the glutamine antagonist, and immune checkpoint inhibitor that are sufficient to maintain the desired therapeutic effects.
- the desired dose conveniently can be administered in a single dose, or as multiple doses administered at appropriate intervals, for example as one, two, three, four or more subdoses per day. Multiple doses often are desired, or required.
- the glutamine antagonist, and immune checkpoint inhibitor can be administered at a frequency of: one dose per day; four doses delivered as one dose per day at four-day intervals (q4d x 4) ; four doses delivered as one dose per day at three-day intervals (q3d x 4) ; one dose delivered per day at five-day intervals (qd x 5) ; one dose per week for three weeks (qwk3) ; five daily doses, with two days rest, and another five daily doses (5/2/5) ; or, any dose regimen determined to be appropriate for the circumstance.
- the immune checkpoint inhibitor is administered in therapeutically effective amounts.
- the immune checkpoint inhibitor is a monoclonal antibody, 1-20 mg/kg is administered as an intravenous infusion every 2-4 weeks.
- 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 1900 mg and 2000 mg of the antibody may be administered.
- the immune checkpoint inhibitor when the immune checkpoint inhibitor is the anti-PD-1 antibody nivolumab, 3 mg/kg may be administered by intravenous infusion over 60 minutes every two weeks.
- the immune checkpoint inhibitor is the anti-PD-1 antibody pembrolizumab, mg/kg may be administered by intravenous infusion over 30 minutes every two or three weeks.
- the immune checkpoint inhibitor is the anti-PD-Ll antibody avelumab, 10 mg/kg may be administered by intravenous infusion as frequently as every 2 weeks.
- the immune checkpoint inhibitor is the anti-PD-Ll antibody MPDL3280A
- 20 mg/kg may be administered by intravenous infusion every 3 weeks.
- the immune checkpoint inhibitor is the anti-CTLA-4 antibody ipilumumab
- 3 mg/kg may be administered by intravenous infusion over 90 minutes every 3 weeks.
- the immune checkpoint inhibitor is the anti-CTLA-4 antibody tremelimumab
- 15 mg/kg may be administered by intravenous infusion every 12 weeks.
- the immune checkpoint inhibitor is the anti-LAG3 antibody GSK2831781, 1.5 to 5 mg/kg may be administered by intravenous infusion over 120 minutes every 2-4 weeks.
- the immune checkpoint inhibitor is an anti-TIM3 antibody, 1-5 mg/kg may be administered by intravenous infusion over 30-90 minutes every 2-4 weeks.
- an inhibitor of indoleamine 2, 3 -di oxygenase (IDO) pathway is inhibitor indoximod in combination with temozolomide, 18.5 mg/kg/dose BID with an escalation to 27.7 mg/kg/dose BID of indoximod with 200 mg/m 2 every 5 days of temozolomide.
- the immune checkpoint inhibitor is an antibody and 1-20 mg/kg is administered by intravenous infusion every 2-4 weeks. In another embodiment, 50-2000 mg of the antibody is administered by intravenous infusion every 2-4 weeks.
- the glutamine antagonist is administered prior to administration of the antibody. In another embodiment, the glutamine antagonist is administered 3-7 days prior to the day of administration of the antibody. In another embodiment, the glutamine antagonist is also administered the day the antibody is administered and on consecutive days thereafter until disease progression or untilthe glutamine antagonist administration is no longer beneficial.
- the cancer patient receives 2 mg/kg pembrolizumab administered by intravenous infusion every three weeks and about 0.1 to 100 mg of the glutamine antagonist administered for 1-7 days prior to pembrolizumab administration, optionally, on the day of pembrolizumab administration, and, optionally, thereafter until disease progression or until there is no therapeutic benefit.
- the cancer patient receives 3 mg/kg nivolumab administered by intravenous infusion every 2 weeks and about 0.1 to 100 mg of the glutamine antagonist administered for 1-7 days prior to nivolumab administration, optionally, on the day of nivolumab administration, and, optionally, thereafter until disease progression or until there is no therapeutic benefit.
- the cancer patient receives 3 mg/kg nivolumab administered by intravenous infusion every 2 weeks and about 0.1 to 100 mg of the glutamine antagonist administered for 1-7 days prior to nivolumab administration, optionally, on the day of nivolumab administration, and, optionally, thereafter until disease progression or until there is no therapeutic benefit.
- the treatment of the cancer patient with a glutamine antagonist, and an immune checkpoint inhibitor induces anti proliferative response faster than when the immune checkpoint inhibitor is administered alone.
- halogen means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include F, Cl and Br.
- haloC 1-6 alkyl means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include F, Cl and Br.
- haloC 1-6 alkyl means fluoro, chloro, bromo or iodo.
- the preferred halogen groups include F, Cl and Br.
- haloC 1-6 alkyl , “haloC 2-6 alkenyl” , “haloC 2-6 alkynyl” and “haloC 1-6 alkoxy” mean a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkoxy in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms.
- fluoroC 1-6 alkyl, fluoroC 2-6 alkenyl, fluoroC 2-6 alkynyl and fluoroC 1-6 alkoxy groups in particular fluoroC 1-3 alkyl, for example, CF 3 , CHF 2 , CH 2 F, CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 and fluoroC 1-3 alkoxy groups, for example, OCF 3 , OCHF 2 , OCH 2 F, OCH 2 CH 2 F, OCH 2 CHF 2 or OCH 2 CF 3 , and most especially CF 3 , OCF 3 and OCHF 2 .
- fluoroC 1-3 alkyl for example, CF 3 , CHF 2 , CH 2 F, CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 and fluoroC 1-3 alkoxy groups, for example, OCF 3 , OCHF 2 , OCH 2 F, OCH 2 CH 2 F, OCH 2 CHF 2 or OCH
- alkyl includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties.
- alkyl radicals include methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-hexyl, 2-methylpentyl and cyclohexyl.
- C 1-8 as in C 1-8 alkyl is defined to identify the group as having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or branched arrangement.
- Alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
- methylene i.e., -CH 2 -
- ethylene i.e., -CH 2 -CH 2 -or –CH (CH 3 ) -
- propylene i.e., -CH 2 -CH 2 -CH 2 -, -CH (-CH 2 -CH 3 ) -or –CH 2 -CH (CH 3 ) -
- Alkenyl and alkynyl groups include straight, branched chain or cyclic alkenes and alkynes.
- C 2-8 alkenyl and “C 2-8 alkynyl” means an alkenyl or alkynyl radicals having 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or brached arrangement.
- Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like.
- Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
- Alkoxy radicals are oxygen ethers formed from the previously described straight, branched chain or cyclic alkyl groups.
- aryl refers to an unsubstituted or substituted mono-or polycyclic ring system containing carbon ring atoms.
- the preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
- heterocyclic ring or “heterocyclyl” , as used herein, unless otherwise indicated, refers to unsubstituted and substituted mono-or polycyclic non-aromatic ring system containing one or more heteroatoms.
- Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides.
- the ring is three to eight membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition.
- heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
- heteroaryl represents an aromatic ring system containing carbon (s) and at least one heteroatom.
- Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted.
- a monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms.
- a polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclic heteroaryl is a polycyclic heteroaryl.
- Bicyclic heteroaryl rings may contain from 8 to 12 member atoms.
- Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) .
- heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
- cycloalkyl refers to a substituted or unsubstituted monocyclic, bicyclic or polycyclic non-aromatic saturated ring, which optionally includes an alkylene linker through which the cycloalkyl may be attached.
- Examplary "cycloalkyl” groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
- alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aralky or dialkylamino) it shall be interpreted as including those limitations given above for “alkyl” and “aryl” .
- Designated numbers of carbon atoms e.g., C l - 6 ) shall refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
- substituted refers to a group mentioned above in which one or more (preferably 1-6, more preferably 1-3) hydrogen atoms are each independently replaced with the same or different substituent (s) .
- the substituent (s) is independently selected from the group consisting of -F, -Cl, -Br, -I, -OH, trifluromethoxy, ethoxy, propyloxy, iso-propyloxy, n-butyloxy, isobutyloxy, t-butyloxy, -SCH 3 , -SC 2 H 5 , formaldehyde group, -C (OCH 3 ) , cyano, nitro, CF 3 , -OCF 3 , amino, dimethylamino, methyl thio, sulfonyl and acetyl.
- Particularly preferred substituent (s) is -F, -Cl or -Br.
- Compounds described herein such as certain compounds of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, may contain asymmetrically substituted carbon atoms (or chiral centers) in the R or S configuration.
- the present invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
- enriched R-or S-designated isomer can be substantially free (e.g., with less than 5%, less than 1%, or non-detectable, as determined by chiral HPLC) of the other isomer for the respective chiral center.
- the enriched R-or S-isomers can be prepared by methods exemplified in this application, such as by using a chiral auxiliary such as R-or S-tert-butylsulfinamide in the synthetic process.
- chiral HPLC purifications of a stereoisomeric mixture such as a racemic mixture.
- General methods for separating stereoisomers (such as enantiomers and/or diastereomers) using HPLC are known in the art.
- Isotopes can be radioactive or non-radioactive isotopes.
- Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to 2H, 3H, 13C, 14C, 15N, 18O, 32P, 35S, 18F, 36Cl, and 125I.
- Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
- one or more hydrogen atoms of any of the compounds described herein can be substituted with deuterium to provide the corresponding deterium-labeled or -enriched compounds.
- any asymmetric carbon atom may be present in the (R) -, (S) -or (R, S) -configuration, preferably in the (R) -or (S) -configuration.
- the compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as pure diastereomers or pure enantiomers.
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from pharmaceutical combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
- the compounds of the present invention may also be present in the form of pharmaceutically acceptable salts.
- the salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts” .
- the pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
- the pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid.
- organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic.
- Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
- the present invention includes within its scope the prodrugs of the compounds of this invention.
- such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound.
- the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
- the present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
- the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
- the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
- the present invention includes any possible solvates and polymorphic forms.
- a type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable.
- water, ethanol, propanol, acetone or the like can be used.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
- the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
- the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
- compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous) .
- the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient.
- the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion.
- the pharmaceutical combination of the invention may also be administered by controlled release means and/or delivery devices.
- compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
- the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
- solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- liquid carriers are sugar syrup, peanut oil, olive oil, and water.
- gaseous carriers include carbon dioxide and nitrogen.
- oral liquid preparations such as suspensions, elixirs and solutions
- carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets.
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
- tablets may be coated by standard aqueous or nonaqueous techniques.
- a tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.
- a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
- Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or l000mg.
- compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form must be sterile and must be effectively fluid for easy syringability.
- the pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
- compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing The pharmaceutical combination of the invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
- compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
- the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
- other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient.
- dosage levels on the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day.
- inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
- subject or “patient” as used herein is intended to include animals, which are capable of suffering from or afflicted with a cancer or any disorder involving, directly or indirectly, a cancer.
- subjects include mammals, e.g., humans, apes, monkeys, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals.
- the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from cancers.
- treating comprises a treatment relieving, reducing or alleviating at least one symptom in a subject or effecting a delay of progression of a disease.
- treatment can be the diminishment of one or several symptoms of a disorder or complete eradication of a disorder, such as cancer.
- the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
- glutamine antagonist refers to a glutamine analog that interfers with a glutamine metabolic pathway, e.g., the inhibition or blocking of a metabolic pathway downstream of glutamine in which glutamine acts as a precursor of one or more non-glutamine compounds.
- glutamine metabolic pathway e.g., the inhibition or blocking of a metabolic pathway downstream of glutamine in which glutamine acts as a precursor of one or more non-glutamine compounds.
- Examples of such metabolic pathways are well known (see, e.g., Hensley et al, "Glutamine and cancer: cell biology, physiology, and clinical opportunities” J Clin Invest. 2013; 123 (9) : 3678-3684; DeBerardinis et al, "Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer” Oncogene.
- glutamine antagonist also includes glutamine analogs that inhibit glutamine uptake by cells, thereby reducing its biological activity. Diseases or conditions wherein excess and/or aberrant glutamine.
- a “therapeutically effective amount” when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
- pharmaceutical combination therapy refers to the administration of two or more therapeutic agents to treat a condition or disorder described in the present disclosure (e.g., cancer) .
- Such administration encompasses co -administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients.
- Such administration encompasses coadministration in multiple, or in separate containers (e.g., capsules, powders, and liquids) for each active ingredient. Powders and/or liquids may be reconstituted or diluted to a desired dose prior to administration.
- such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. In either case, the treatment regimen will provide beneficial effects of the drug pharmaceutical combination in treating the conditions or disorders described herein.
- the combination therapy can provide “synergy” and prove “synergistic” , i.e., the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately.
- a synergistic effect can be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined, unit dosage formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen.
- a synergistic effect can be attained when the compounds are administered or delivered sequentially, e.g., by different injections in separate syringes.
- an effective dosage of each active ingredient is administered sequentially, i.e., serially
- effective dosages of two or more active ingredients are administered together.
- pharmaceutical combination refers to either a fixed pharmaceutical combination in one dosage unit form, or non-fixed pharmaceutical combination or a kit of parts for the combined administration where two or more therapeutic agents may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the pharmaceutical combination partners show a cooperative, e.g. synergistic effect.
- synergistic effect refers to action of two or more therapeutic agents such as, for example, a glutamine antagonist, and the immune checkpoint inhibitor, producing an effect, for example, slowing the symptomatic progression of a proliferative disease, particularly cancer, or symptoms thereof, which is greater than the simple addition of the effects of each drug administered by themselves.
- a synergistic effect can be calculated, for example, using suitable methods such as the Sigmoid-Emax equation (Holford, N. H. G. and Scheiner, L. B., Clin. Pharmacokinet. 6: 429-453 (1981) ) , the equation of Loewe additivity (Loewe, S. and Muischnek, H., Arch. Exp.
- Each equation referred to above can be applied to experimental data to generate a corresponding graph to aid in assessing the effects of the drug pharmaceutical combination.
- the corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and pharmaceutical combination index curve, respectively.
- the pharmaceutical combination of the invention, a glutamine antagonist and an immune checkpoint inhibitor is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
- Isotopically labeled compounds have one or more atoms replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into the glutamine antagonist and the immune checkpoint inhibitor include isotopes of hydrogen, carbon, nitrogen, oxygen, and chlorine, for example, 2 H, 3 H, n C, 13 C, 14 C, 15 N, 35 S, 36 C1.
- the invention includes isotopically labeled a glutamine antagonist and a immune checkpoint inhibitor, for example into which radioactive isotopes, such as 3 H and 14 C, or non-radio active isotopes, such as 2 H and 13 C, are present.
- Isotopically labelled the glutamine antagonist and the immune checkpoint inhibitor are useful in metabolic studies (with 14 C) , reaction kinetic studies (with, for example 2 H or 3 H) , detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using appropriate isotopically-labeled reagents.
- Fig. 1 shows anti-tumor effect of the test compound alone and in combination with Anti-PD-1 mAb in MC38 Model
- FIG. 2 shows survival curve for different treatment groups in MC38 Model
- Fig. 3 shows body weight change of different treatment groups in MC38 Model
- Fig. 4 shows anti-tumor effect of the test compound alone and in combination with Anti-PD-L1 mAb in H22 Model
- Fig. 5 shows the tumor volume of Individual Mice in H22 Model
- Fig. 6 shows survival curve for different treatment groups in H22 Model
- Fig. 7 shows body weight change of different treatment groups in H22 Model
- Step a To a solution of 7-Fluoroindole (308 mg, 2.279 mmol) and Ytterbium (III) triflate hydrate (219 mg, 343.119 ⁇ mol) in Chloroform (3 mL) was added (2S) -Methylglycidate (121 mg, 1.185 mmol) under N 2 . The mixture was heated to 85°C and stirred for 3 h. The reaction mixture was cooled to RT. The reaction mixture was quenched with Na 2 CO 3 (aq) (10 mL) , and adjusted the pH to 5-6 with 2M HCl. The aqueous layer was separated and extracted with DCM (2 ⁇ 10 mL) .
- Step b To a solution of methyl (2S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxy-propanoate (136 mg, 573.292 ⁇ mol) in water (1 mL) was added LiOH (2M solution in water, 1 mL) . The mixture was stirred for overnight at RT-60°C, Citric acid (solid) was added, diluted with water (5 mL) and extracted with EA (2 ⁇ 10 mL) .
- Step a To a solution of Indole (302 mg, 2.578 mmol) in DMF (3 mL) was added NaH (217 mg, 9.043 mmol) at ice-water bath for 1h .
- (2S) -Methylglycidate (685 mg, 6.710 mmol) was added and the mixture was stirred over night at RT.
- the reaction mixture was quenched with H 2 O, and adjusted the pH to 3-4 with citric acid.
- the aqueous layers were extracted with EA. The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step a To a solution of Methyl (S) - (-) -lactate (1099 mg, 10.5567 mmol) , Iodoethane (3726 mg, 23.8900 mmol) in Diethyl ether (10 mL) was added Ag 2 O (4772 mg, 20.5925 mmol) under N 2. The reaction mixture was stirred over night at RT by light-avoiding. The reaction mixture was monitored by TLC. The reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved by THF (3 mL) , MeOH (3 mL) , H 2 O (3 mL) and then the reaction mixture was added LiOH (246 mg, 10.2721 mmol) .
- reaction mixture was stirred for 3h at RT.
- the reaction mixture was monitored by TLC and adjusted the pH to 2 with 1N HCl.
- the reaction mixture was concentrated under reduced pressure to 5 mL.
- the aqueous layers were extracted with EA (3 ⁇ 10 mL) .
- the combined organic layers were washed with saturated solution of NaCl (3 ⁇ 10 mL) and dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to afford (S) -2-ethoxypropanoic acid (772 mg, 6.5351 mmol) .
- Step a To a solution of 2-hydroxy-4- (methylthio) butanoic acid (0.68 g, 4.5274 mmol) , CH 3 I (3.35 g, 23.6019 mmol) in Diethyl ether (10 mL) was added Ag 2 O (4.41 g, 19.0303 mmol) . The reaction mixture was stirred over night at RT. The reaction mixture was monitored by LC-MS. The reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved by MeOH (6 mL) , H 2 O (2 mL) and then the reaction mixture was added NaOH (318 mg, 7.9506 mmol) . The reaction mixture was stirred for 3h at RT.
- reaction mixture was monitored by TLC and adjusted the pH to 3 with 1M HCl.
- the reaction mixture was concentrated under reduced pressure to 5 mL.
- the aqueous layers were extracted with EA (3 ⁇ 10 mL) .
- the combined organic layers were washed with saturated solution of NaCl (3 ⁇ 10 mL) and dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure to afford 2-methoxy-4- (methylthio) butanoic acid (128 mg, 779.4318 ⁇ mol) .
- Step a To a solution of 2-hydroxy-3- (1H-indol-3-yl) propanoic acid (152 mg, 740.706 ⁇ mol) in THF (10 mL) was added NaH (55 mg, 2.292 mmol) . The reaction mixture was stirred for 20 min at RT and then CH 3 I (370 mg, 2.607 mmol) was added. The reaction mixture was monitored by LC-MS. CH 3 I (358 mg, 2.522 mmol) was added again. The reaction mixture was monitored by LC-MS. The reaction mixture was stirred for 3h at 40°C. The reaction mixture was added H 2 O (5 mL) and extracted with EA (10 mL) .
- Step a To a solution of methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate (2 g, 9.123 mmol) in DCM (20 mL) was added Imidazole (2061 mg, 30.274 mmol) and TBDMS-Cl (2980 mg, 19.772 mmol) . The mixture was stirred for overnight at RT. The reaction mixture was quenched with Water (10 mL) and extracted with DCM (10 mL). The reaction mixture was separated and organic extracts were collected. The aqueous solution was extracted with DCM (2 ⁇ 10 mL) . The residue was purified by wet column chromatography with EA/Hex (0-20%) .
- Step b To a -78°C solution of methyl (S) -2- ( (tert-butyldimethylsilyl) oxy) -3- (1H-indol-3-yl) propanoate (3.099g, 9.292 mmol) in THF (30 mL) was added LiHMDS (10.5 mL, 10.491 mmol) . The mixture was stirred for 30min at -78°C. Then Carbobenzyloxy chloride (4623 mg, 27.100 mmol) was dropped into the mixture at -78°C. The reaction mixture was stirred for 1h at this temperature. Quenched the reaction with sat.
- Step c To a solution of benzyl (S) -3- (2- ( (tert-butyldimethylsilyl) oxy) -3-methoxy-3-oxopropyl) -1H-indole-1-carboxylate (4.345 g, 9.292 mmol) in THF (30 mL) was added Tetrabutylammonium fluoride (5 mL) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by FLASH with EA/Hex (0-60%) . The product’s solution was concentrated under reduced pressure.
- Step d To a solution of benzyl 3- [ (2S) -2-hydroxy-3-methoxy-3-oxo-propyl] indole-1-carboxylate (103 mg, 291.481 ⁇ mol) , and 4A molecular sieve in CH 3 I (1mL) was added Silver oxide (216 mg, 932.098 ⁇ mol) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The reaction mixture was diluted with EA (5mL) and filtered, the filtrate was concentrated to afford benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (107.088 mg, 100.000%yield) . MS: m/z 368(M+H) + .
- Step e To a solution of benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (0.107g, 291.240 ⁇ mol) in THF (5 mL) and MeOH (5mL) was added NaOH (3mL, 3M/L) . The mixture was stirred for 1h at RT. The reaction mixture was adjusted the pH to 3 with 1M HCl. The aqueous solution was extracted with EA (2 ⁇ 10 mL) . The combined organic extracts were washed with brine (3 ⁇ 10 mL) , dried over anhydrous Na 2 SO 4 . The organic phase was concentrated under reduced pressure and (S) -3- (1H-indol-3-yl) -2-methoxypropanoic acid (71 mg) was obtained. MS: m/z 220 (M+H) + .
- Each C57BL/6 mouse was inoculated subcutaneously in the right flank region with MC38 cells (1 x 10 6 ) for tumor development.
- the treatments were started when the mean tumor size reached approximately 75 mm 3 .
- the experimental animals were divided using stratified randomization with 7 mice per group based upon their tumor volumes. The treatment was started from the day of randomization, Group 1 was treated with Vehicle s. c. QD, Group 2 was treated with anti-PD-1 10 mg/kg i. p. BIW, Group 3 was treated with Compound 2 1.2 mg/kg s.c. Q2D, Group 4 was treated with Compound 2 1.2 mg/kg s. c. Q2D and anti-PD-1 10 mg/kg i. p. BIW.
- TGI tumor growth inhibition
- Compound 2 in combination with anti-PD-1 mAb further enhanced tumor growth inhibition and showed improved survival compared to single agent treatment in MC38 model.
- EXAMPLE B Efficacy of Compound 2 in Combination with Anti-PD-L1 mAb in H22 Syngeneic Model
- Each BALB/c mouse was inoculated subcutaneously in the right flank region with H22 cells (1 x 10 6 ) for tumor development. The treatments were started when the mean tumor size reached 146 mm 3 .
- the experimental animals were divided using stratified randomization with 8 mice per group based upon their tumor volumes. The treatment was started from the day of randomization.
- Group 1 was treated with Vehicle s. c. QD
- Group 2 was treated with anti-PD-L1 5 mg/kg i.p. BIW
- Group 3 was treated with Compound 2 1.2 mg/kg s.c. 5 days on/2 days off
- Group 4 was treated with Compound 2 1.2 mg/kg s.c. 5 days on/2 days off and anti-PD-L1 5 mg/kg i.p. BIW.
- the in vivo efficacy was examined according to tumor growth inhibition (TGI) and the safety was evaluated according to weight change and survival in mice.
- TGI tumor growth inhibition
- Treatments were ended at day 20 and survival curves from different groups were analyzed. Median survival of the groups was 20 days, 24 days, 42 days and undefined, respectively. The result showed that combination of Compound 2 and anti-PD-L1 further improved mouse survival compared to single agent treatment.
- the tumor growth curves of individual mice are shown in Fig. 5.
- the survival curves are shown in Fig. 6.
- Compound 2 in combination with anti-PD-L1 mAb further enhanced tumor growth inhibition and showed improved survival compared to single agent treatment in H22 model.
- the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration.
- Such pharmaceutical compositions and processes for preparing the same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds., 19 th ed., Mack Publishing Co., 1995) .
- the combinations are generally effective over a wide dosage range.
- dosages per day normally fall within the range of about 1 mg to about 200 mg total daily dose, preferably 0.2 mg to 50 mg total daily dose, more preferably 0.2 mg to 20 mg total daily dose. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed.
- the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
Abstract
Provided herein is a pharmaceutical combination comprising a Glutamine antagonist, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof, and an additional therapeutic agent; pharmaceutical compositions thereof; commercial packages thereof; and uses of such pharmaceutical combinations and pharmaceutical compositions for the treatment or prevention of diseases, for example, the treatment of cancers.
Description
The present invention relates a pharmaceutical combination comprising a glutamine antagonist, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof, and an additional therapeutic agent; pharmaceutical compositions thereof; commercial packages thereof; and uses of such pharmaceutical combinations and pharmaceutical compositions for the treatment of cancer and cancer occurrence-related diseases.
WO 2017/023774 discloses isopropyl (S) -2- ( (S) -2-acetamido-3- (lH-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate and other prodrugs of DON. DON and DON prodrugs can be used to treat a variety of diseases, disorders, and conditions including, but not limited to, cancer, cognitive deficits, and metabolic reprogramming disorders. See WO 2017/023793, WO 2017/023791, WO 2017/023787, and WO2020/150639.
The combination of the present invention, may show improved efficacy compared to either single agent alone in the treatment of diseases, e.g. cancer.
The present invention provides for a pharmaceutical combination comprising:
(i) a glutamine antagonist, or a pharmaceutical acceptable salt thereof; and
(ii) an additional therapeutic agent selected from a immune checkpoint inhibitor, an activator of a costimulatory molecule, a chemotherapeutic agent, a radiotherapeutic agent, a immunotherapeutic agent, a targeted anti-cancer therapy, an anticancer agent, an oncolytic drug, a cytotoxic agent, or any of the therapeutic agents disclosed herein.
In some embodiments, the additional therapeutic agent can be chosen from: a PD-1 inhibitor, a PD-L1 inhibitor, a LAG-3 inhibitor, a CTL4 inhibitor, a TIM-3 inhibitor, a CD47 inhibitor, a CDK4/6 inhibitor, an Aurora A kinase inhibitor, chemotherapeutic drug (Taxol, Cisplatin, Carboplatin, 5-Fu, topotecan, cyclophosphamide, and so on) , radiotherapy, HDAC inhibitor, a SHP2 inhibtor, a KRASG12C inhibitor, a BET inhibitor, a EGFR inhibitor, a VEGFR inhibitor, a GITR agonist, a SERD, a Plk3 inhibitor, a CXCR2 inhibitor, a CSF-1/1R binding agent, a c-MET inhibitor, a TGF-β inhibitor, an A2aR antagonist, an IDO inhibitor, a STING inhibitor, a Galectin inhibitor, a MEK inhibitor, an IL-15/IL-15RA complex, an IL-1β inhibitor, an MDM2 inhibitor, or a pharmaceutically acceptable salt thereof; or any pharmaceutical combination thereof. Preferably, a PD-1 inhibitor, a PD-L1 inhibitor, a CTL4 inhibitor, a LAG-3 inhibitor, a TIM-3 inhibitor, a CD47 inhibitor.
In some embodiments, the pharmaceutical combination comprises:
(i) a glutamine antagonist, or a pharmaceutical acceptable salt thereof; and
(ii) an immune checkpoint inhibitor, e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, or a CD47 inhibitor.
In some embodiments, the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a PD-1 inhibitor or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a PD-L1 inhibitor or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a CTLA-4 inhibitor or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a LAG3 inhibitor or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a TIM3 inhibitor or a pharmaceutically acceptable salt thereof.
In some embodiments, the pharmaceutical combination comprises: (i) a glutamine antagonist, or a pharmaceutically acceptable salt thereof; and (ii) a CD47 inhibitor or a pharmaceutically acceptable salt thereof.
In another embodiment of the pharmaceutical combination of the invention, a glutamine antagonist or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor, or a pharmaceutically acceptable salt thereof, are in the same formulation.
In another embodiment of the pharmaceutical combination of the invention, a glutamine antagonist or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor, or a pharmaceutically acceptable salt thereof, are in the separate formulation.
In another embodiment, the pharmaceutical combination of the invention is for simultaneous or sequential (in any order) administration.
In a further embodiment, the present disclosure is directed to a method of treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder or disease, e.g., a hyperproliferative condition or disorder (e.g., a cancer) ,
cognitive deficits, and metabolic reprogramming disorders etc. in a subject. The method includes administering to the subject a therapeutically effective amount of pharmaceutical combination comprising a glutamine antagonist and an additional therapeutic agent disclosed herein. In some embodiments, the additional therapeutic agent is chosen from: a PD-1/PD-L1 inhibitor, a LAG-3 inhibitor, a CTL4 inhibitor, a TIM-3 inhibitor, a CD47 inhibitor, a CDK4/6 inhibitor, an Aurora A kinase inhibitor, chemotherapeutic drug (Taxol, Cisplatin, Carboplatin, 5-Fu, topotecan, cyclophosphamide, and so on) , radiotherapy, HDAC inhibitor, a SHP2 inhibtor, a KRASG12C inhibitor, a BET inhibitor, a EGFR inhibitor, a VEGFR inhibitor, a GITR agonist, a SERD, a Plk3 inhibitor, a CXCR2 inhibitor, a CSF-1/1R binding agent, a c-MET inhibitor, a TGF-β inhibitor, an A2aR antagonist, an IDO inhibitor, a STING inhibitor, a Galectin inhibitor, a MEK inhibitor, an IL-15/IL-15RA complex, an IL-1βinhibitor, an MDM2 inhibitor, or a pharmaceutically acceptable salt thereof; or any pharmaceutical combination thereof.
In a further embodiment, the present disclosure is directed to a method of treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder or disease, e.g., a hyperproliferative condition or disorder (e.g., a cancer) , in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a glutamine antagonist or a pharmaceutically acceptable salt thereof, and an immune checkpoint inhibitor e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, or a cd47 inhibitor, or a pharmaceutically acceptable salt thereof.
In a further embodiment, the invention provides the pharmaceutical combination of the invention defined herein for use in the treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder, e.g., a hyperproliferative condition or disorder (e.g., a cancer) .
In a further embodiment, the invention provides for the pharmaceutical combination of the invention for use in the manufacture of a medicament for treating (e.g., inhibiting, reducing, ameliorating, or preventing) a disorder, e.g., a hyperproliferative condition or disorder (e.g., a cancer) .
In another embodiment, there is a pharmaceutical composition comprising the combination of the invention.
In a further embodiment, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients as detailed herein.
In one embodiment of method and use defined herein, the cancer is a solid tumor. In another embodiment, the cancer is a hematological cancer. In another embodiment, the cancer is any one or more of the cancers of Table 1.
Table 1
Exemplary hematological cancers include, but are not limited to, the cancers listed in Table 2. In another embodiment, the hematological cancer is acute lymphocytic leukemia, chronic lymphocytic leukemia (including B-cell chronic lymphocytic leukemia) , or acute myeloid leukemia.
Table 2
In another embodiment, the cancer is any one or more of the cancers of a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof. In some embodiments, the skin cancer is a melanoma (e.g., a refractory melanoma) .
In another embodiment, the cancer is selected from the group consisting of squamous cell carcinoma of the head and neck, adenocarcinoma squamous cell carcinoma of the esophagus, adenocarcinoma of the stomach, adenocarcinoma of the colon, hepatocellular carcinoma, cholangiocarcinoma of the biliary system, adenocarcinoma of gall bladder, adenocarcinoma of the pancreas, ductal carcinoma in situ of the breast, adenocarcinoma of the breast, adenocarcinoma of the lungs, squamous cell carcinoma of the lungs, transitional cell carcinoma of the bladder, squamous cell carcinoma of the bladder, squamous cell carcinoma of the cervix, adenocarcinoma of the cervix, endometrial carcinoma, penile squamous cell carcinoma, and squamous cell carcinoma of the skin.
In another embodiment, a precancerous tumor is selected from the group consisting of leukoplakia of the head and neck, Barrett's esophagus, metaplasia of the stomach, adenoma of the colon, chronic hepatitis, bile duct hyperplasia, pancreatic intraepithelial neoplasia, atypical adenomatous hyperplasia of the lungs, dysplasia of the bladder, cervical initraepithelial neoplasia, penile intraepithelial neoplasia, and actinic keratosis of the skin.
In another embodiment, the cancer is selected from the group consisting of hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, and colorectal cancer.
In another embodiment, the cancer is selected from the group consisting of colorectal cancer, breast cancer, lymphoma, melanoma, kidney cancer, and lung cancer.
In another embodiment, the cancer has become resistant to conventional cancer treatments. The term "conventional cancer treatments" as used herein refers to any cancer drugs, biologies, or radiotherapy, or combination of cancer drugs and/or biologies and/or radiotherapy that have been tested and/or approved for therapeutic use in humans by the U.S. Food and Drug Administration, European Medicines Agency, or similar regulatory agency.
In some embodiments of the pharmaceutical combination of the invention, the glutamine antagonist comprises a compound disclosed in International Application No. PCT/CN2021/123674 hereby incorporated by reference in its entirety.
In some embodiments, the glutamine antagonist a compound having the structure of formula I, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof:
Wherein,
Z is OR1 or SR1; R1 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, C1-6alkoxy, -C3-8cycloalkyl, -C0-6alkylene-C3-8heterocyclyl, -C0-6alkylene-NH-C0-6alkylene C6-10aryl, -C0-6alkylene-NH-C0-6alkylene-5-12 membered heteroaryl, -C0-6alkylene-C6-10aryl and -C0-6alkylene-5-12 membered heteroaryl; and each of which can be optional substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8cycloalkyl, -NH2, -NH (C1-6alkyl) , -N (C1-6alkyl) 2, -NH-C3-8cycloalkyl, carboxyl, -CO-C1-6alkyl; each of the heteroaryl and heterocyclyl contains 1, 2 or 3 heteroatoms selected from N, O or S;
X is selected from the group consisting of hydrogen, deuterium, C1-6alkyl, -C (=O) -G, -C (=O) -W- (CRX1RX2) m-O-RX3, -C (=O) -W- (CRX1RX2) m-S-RX3, C (=O) -W- (CRX1RX2) m-SO-RX3, C (=O) -W- (CRX1RX2) m-SO2-RX3, -C (=O) -W- (CRX1RX2) m-G, -C (=O) -W- (CRX1RX2) m-NR5R5’, -P (=O) (OR6) p (NHR7) q, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -R8, -C (=O) -W- (CRX1RX2) m-G-O-R8, -C (=O) -O- (CRX1RX2) m-O-C (=O) -R9, -C (=O) -O-R7, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -G, and -C (=O) -W- (CRX1RX2) m-G-NR5R5’;
W is oxygen, CO or a bond;
m is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, NH2, C1-6 alkyl, C1-6alkoxy, C4-10 cycloalkyl, -C (=O) -C1-6alkyl, C5-12aryl, –C1-6 alkylene-C5-12aryl, -5-12 membered heteroaryl, and –C1-6 alkylene-5-12 membered heteroaryl, and wherein said C1-6 alkyl, said C1-6alkoxy, said C4-10 cycloalkyl, said C5-12aryl, said–C1-6 alkylene-C5-12aryl, said -5-12 membered heteroaryl, and said–C1-6 alkylene-5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, -S-C1-6alkyl, carboxyl; and each of the heteroaryl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
or RX1 and RX2 together with the carbon atom to which they are attached form C3-10carbocyclic ring, C3-10 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -NH2, -CN, -OH, -NO2, carbonyl, =O, oxo, carboxyl, C1-6alkoxy, C1-6alkyl;
RX3 is independently selected from the group consisting of hydrogen, deuterium, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, -C (=O) -C1-6 alkyl, and -C1-6alkylenen-C5-12 aryl, wherein said C1-6 alkyl, said C1-6 alkoxy, said C3-8 cycloalkyl, said -C (=O) -C1-6 alkyl, and said -C1-6alkylenen-C5-12 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl, 4-8 membered heterocyclyl, -C6-12aryl, -C (=O) -C1-6alkyl, -NH-C (=O) -C1-6alkyl, -C (=O) -NH2, -C (=O) -NH-C1-6alkyl, and -C (=O) -N (C1-6 alkyl) 2;
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-12 membered heterocyclyl, wherein said 5-12 membered heterocyclyl can be
optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
R5 and R5’ are each independently selected from the group consisting of hydrogen, deuterium, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, C5-12 aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclyl, and wherein said -C1-6 alkyl, said -C1-6 alkoxy, said -C3-8 cycloalkyl, said C5-12 aryl, said 5-12 membered heteroaryl, said 5-12 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
each of R6 is independently selected from the group consisting of hydrogen, deuterium, -C1-6 alkyl, -C3-8 cycloalkyl, 5-12 membered heterocyclyl ring, -C1-6 alkenyl, and -C3-8 cycloalkenyl, and wherein said -C1-6 alkyl, said -C3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said -C1-6 alkenyl, and said -C3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
or R6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, C3-8 cycloalkyl, 5-12 membered heterocyclyl ring, C1-6 alkenyl, C3-8 cycloalkenyl, C5-12 aryl, and 5-12 membered heteroaryl, and wherein said C1-6 alkyl, said C3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said C1-6 alkenyl, said C3-8 cycloalkenyl, said C5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
R8 and R9 are each independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C5-12 aryl, and 5-12 membered heteroaryl, and wherein said C1-6 alkyl, said C3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
G is C5-12 aryl, or 5-12 membered heteroaryl, wherein C5-12 aryl, and 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
R3 and R3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
Y is a bond, oxygen, or - (CRY1RY2) n-;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
RY1 and RY2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6alkyl, -C1-6alkoxy, -C3-8cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
R10 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6alkyl, -C1-6alkoxy, -C3-8cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl.
In some embodiments of the compound of Formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereofe of the present invention, wherein the compound is of formula I-A:
In some embodiments of the compound of Formula I, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereofe of the present invention, wherein the compound is of formula I-B:
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, C1-3 alkoxy, -C3-8cycloalkyl, -C0-3alkylene-C3-8heterocyclyl, -C0-3alkylene-NH-C0-3alkylene C6-10aryl, -C0-3alkylene-NH-C0-3alkylene-5-12membered heteroaryl, -C0-3alkylene-C6-10aryl and -C0-3alkylene-5-12 membered heteroaryl; and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -NH-C3-8 cycloalkyl, -N (C1-6alkyl) 2, carboxyl, -CO-C1-6alkyl; each of the heteroaryl and heterocyclyl contains 1 or 2 heteroatoms selected from N, O or S.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, C1-3 alkoxy, -C3-8cycloalkyl, -C0-3alkylene-C3-8heterocyclyl, -C0-3alkylene-NH-C0-3alkylene C6-10aryl, -C0-3alkylene-NH-C0-3alkylene-5-12 membered heteroaryl, -C0-3alkylene-C6-10aryl and -C0-3alkylene-5-12 membered heteroaryl; each of the heteroaryl and heterocyclyl contains 1 or 2 heteroatoms selected from N or O; and wherein each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -NH-C3-6 cycloalkyl, -N (C1-3alkyl) 2, carboxyl, -CO-C1-3alkyl; each of the heteroaryl and heterocyclyl contains 1 or 2 heteroatoms selected from N or O.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy,
and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -NH-C3-6 cycloalkyl, -N (C1-3alkyl) 2, carboxyl, -CO-C1-3alkyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy,
and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, carboxyl and -CO-tert-butyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is seleted from hydrogen, deuterium, isopropyl, methyl, ethyl, -tert-butyl, -CF3, -CH2CF3, -CH(CH3) CF3, -CH (CH3) CH2CF3, - (CH2) 2CF3, - (CH2) 2-CH (CH3) 2, -C (CH3) 2CF3, -C (CH3) 2CH2CF3, -CN, -CH2CN, -CH (CH3) CN, -CH2CH2CN, -CH (CH3) CH2CN, -C (CH3) 2CN, -C (CH3) 2CH2CN, -CH2OH, -CH2-O-CH3, -CH2-O-CH2CH3, -CH2-O-CH (CH3) 2,
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof,
the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is selected from the group consisting of hydrogen, deuterium, C1-6 alkyl, -C (=O) -G, -C (=O) -W- (CRX1RX2) m-O-RX3, -C (=O) -W- (CRX1RX2) m-S-RX3, C (=O) -W- (CRX1RX2) m-SO-RX3, C (=O) -W- (CRX1RX2) m-SO2-RX3, -C (=O) -W- (CRX1RX2) m-G, -C (=O) -W- (CRX1RX2) m-NR5R5’, -P (=O) (OR6) p (NHR7) q, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -R8, -C (=O) -W- (CRX1RX2) m-G-O-R8, -C (=O) -O- (CRX1RX2) m-O-C (=O) -R9, -C (=O) -O-R7, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -G, and -C (=O) -W- (CRX1RX2) m-G-NR5R5’;
W is oxygen, CO or a bond;
m is selected from 1, 2 or 3;
p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, C1-4alkyl, C1-3alkoxy, C4-8 cycloalkyl, -C (=O) -C1-3alkyl, C5-10aryl, -C1-3 alkylene-C5-10aryl, 5-10 membered heteroaryl, and -C1-3 alkylene-5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C1-3alkoxy, said C4-8 cycloalkyl, said C5-10aryl, said -C1-3 alkylene-C5-10aryl, said 5-10 membered heteroaryl, and said -C1-3 alkylene-5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, -S-C1-6alkyl or carboxyl; and each of the heteroaryl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
or RX1 and RX2 together with the carbon atom to which they are attached form C4-8carbocyclic ring, C4-8 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -NH2, -CN, -OH, -NO2, carbonyl, =O, oxo, carboxyl, C1-6alkoxy, C1-6alkyl;
RX3 is independently selected from the group consisting of hydrogen, deuterium, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl, -C (=O) -C1-3 alkyl, and -C1-3alkylenen-C5-10 aryl, wherein said C1-3 alkyl, said C1-3 alkoxy, said C3-6 cycloalkyl, said -C (=O) -C1-3 alkyl, and said -C1-3alkylenen-C5-10 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl, 4-8 membered heterocyclyl, -C6-12aryl, -C (=O) -C1-6alkyl, -NH-C (=O) -C1-6alkyl, -C (=O) -NH2, -C (=O) -NH-C1-6alkyl, and -C (=O) -N (C1-6 alkyl) 2;
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-10 membered heterocyclyl, wherein said 5-10 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
R5 and R5’ are each independently selected from the group consisting of hydrogen, deuterium, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, C5-10 aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl, and wherein said -C1-3 alkyl, -C1-3 alkoxy, said -C3-6 cycloalkyl, said C5-10 aryl, said 5-10 membered heteroaryl, said 5-10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;
each of R6 is independently selected from the group consisting of hydrogen, deuterium, -C1-3 alkyl, -C3-6 cycloalkyl, 5-10 membered heterocyclyl ring, -C1-3alkenyl, and -C3-6 cycloalkenyl, and wherein said -C1-3 alkyl, said -C3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said -C1-3alkenyl, and said -C3-6 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;or R6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, C3-6 cycloalkyl, 5-10 membered heterocyclyl ring, C1-3 alkenyl, C3-6 cycloalkenyl, C5-10 aryl, and 5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said C1-3 alkenyl, said C3-6 cycloalkenyl, said C5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6
alkyl) , -N (C1-6alkyl) 2, carboxyl;
R8 and R9 are each independently selected from the group consisting of C1-3 alkyl, C3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C5-10 aryl, and 5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl; or
G is C5-10 aryl, or 5-10 membered heteroaryl, wherein C5-10 aryl, and 5-10 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is selected from the group consisting of hydrogen, deuterium, C1-3 alkyl, –C (=O) -G, -C (=O) -W- (CRX1RX2) m-O-RX3, -C (=O) -W- (CRX1RX2) m-S-RX3, C (=O) -W- (CRX1RX2) m-SO-RX3, C (=O) -W- (CRX1RX2) m-SO2-RX3, -C (=O) -W- (CRX1RX2) m-G, -C (=O) -W- (CRX1RX2) m-NR5R5’, -P (=O) (OR6) p (NHR7) q, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -R8, -C (=O) -W- (CRX1RX2) m-G-O-R8, -C (=O) -O- (CRX1RX2) m-O-C (=O) -R9, -C (=O) -O-R7, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -G, and -C (=O) -W- (CRX1RX2) m-G-NR5R5’;
W is oxygen or a bond;
m is selected from 1, 2 or 3;
p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, C1-4 alkyl, C1-3alkoxy, C4-8 cycloalkyl, -C (=O) -C1-3alkyl, C5-10aryl, -C1-3 alkylene-C5-10aryl, 5-10 membered heteroaryl, and –C1-3 alkylene-5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C1-3alkoxy, said C4-8cycloalkyl, said C5-10aryl, said–C1-3 alkylene-C5-10aryl, said 5-10 membered heteroaryl, and said–C1-3 alkylene-5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-3alkyl) 2, -S-C1-3alkyl carboxyl; and each of the heteroaryl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
or RX1 and RX2 together with the carbon atom to which they are attached form C4-6carbocyclic ring, C4-6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -NH2, -CN, -OH, -NO2, oxo, carboxyl, C1-3alkoxy, C1-3alkyl;
RX3 is independently selected from the group consisting of hydrogen, deuterium, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl, -C (=O) -C1-3 alkyl, and -C1-3alkylenen-C5-10 aryl, wherein said C1-3 alkyl, said C1-3 alkoxy, said C3-6 cycloalkyl, said -C (=O) -C1-3 alkyl, and said -C1-3alkylenen-C5-10 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, -S-C1-3alkyl carboxyl, 4-6 membered heterocyclyl, -C6-10aryl, -C (=O) -C1-3alkyl, -NH-C (=O) -C1-3alkyl, -C (=O) -NH2, -C (=O) -NH-C1-3alkyl, -C (=O) -N (C1-3alkyl) 2;
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-10 membered heterocyclyl, wherein said 5-10 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;
R5 and R5’ are each independently selected from the group consisting of hydrogen, deuterium, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, C5-10 aryl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl, and wherein said -C1-3 alkyl, -C1-3 alkoxy, said -C3-6 cycloalkyl, said C5-10 aryl, said 5-10 membered heteroaryl, said 5-10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl;
each of R6 is independently selected from the group consisting of hydrogen, deuterium, -C1-3 alkyl, -C3-6 cycloalkyl, 5-10 membered heterocyclyl ring, -C1-3alkenyl, and -C3-6 cycloalkenyl, and wherein said -C1-3
alkyl, said -C3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said -C1-3alkenyl, and said -C3-6 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl;
or R6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, C3-6 cycloalkyl, 5-10 membered heterocyclyl ring, C1-3 alkenyl, C3-6 cycloalkenyl, C5-10 aryl, and 5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C3-6 cycloalkyl, said 5-10 membered heterocyclyl ring, said C1-3 alkenyl, said C3-6 cycloalkenyl, said C5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl;
R8 and R9 are each independently selected from the group consisting of C1-3 alkyl, C3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C5-10 aryl, and 5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl; or
G is C5-10 aryl, or 5-10 membered heteroaryl, wherein C5-10 aryl, and 5-10 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C (=O) -G, -C (=O) -W- (CRX1RX2) m-O-RX3, -C (=O) -W- (CRX1RX2) m-S-RX3, C (=O) -W- (CRX1RX2) m-SO-RX3, C (=O) -W- (CRX1RX2) m-SO2-RX3, -C (=O) -W- (CRX1RX2) m-G, -C (=O) -W- (CRX1RX2) m-NR5R5’, -P (=O) (OR6) p (NHR7) q, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -R8, -C (=O) -W- (CRX1RX2) m-G-O-R8, -C (=O) -O- (CRX1RX2) m-O-C (=O) -R9, -C (=O) -O-R7, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -G, and -C (=O) -W- (CRX1RX2) m-G-NR5R5’;
W is oxygen or a bond;
m is selected from 1, 2 or 3;
p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -CH2CH2CH3, -C (=O) -CH (CH3) 2, C5 aryl, C6aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, -CH2-C5 aryl, -CH2-C6aryl, -CH2-C7 aryl, -CH2-C8 aryl, -CH2-C9 aryl, -CH2-C10 aryl, - (CH2) 2-C5 aryl, - (CH2) 2-C6aryl, - (CH2) 2-C7 aryl, - (CH2) 2-C8 aryl, - (CH2) 2-C9 aryl, - (CH2) 2-C10 aryl, - (CH2) 3-C5 aryl, - (CH2) 3-C6aryl, - (CH2) 3-C7 aryl, - (CH2) 3-C8 aryl, - (CH2) 3-C9 aryl, - (CH2) 3-C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, -CH2-5 membered heteroaryl, -CH2-6 membered heteroaryl, -CH2-7 membered heteroaryl, -CH2-8 membered heteroaryl, -CH2-9 membered heteroaryl, -CH2-10 membered heteroaryl, - (CH2) 2-5 membered heteroaryl, - (CH2) 2-6 membered heteroaryl, - (CH2) 2-7 membered heteroaryl, - (CH2) 2-8 membered heteroaryl, - (CH2) 2-9 membered heteroaryl, - (CH2) 2-10 membered heteroaryl, - (CH2) 3-5 membered heteroaryl, - (CH2) 3-6 membered heteroaryl, - (CH2) 3-7 membered heteroaryl, - (CH2) 3-8 membered heteroaryl, - (CH2) 3-9 membered heteroaryl, and - (CH2) 3-10 membered heteroaryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said C5 aryl, said C6aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said -CH2-C5 aryl, said -CH2-C6aryl, said -CH2-C7 aryl, said -CH2-C8 aryl, said -CH2-C9 aryl, said -CH2-C10 aryl, said - (CH2) 2-C5 aryl, said - (CH2) 2-C6aryl, said - (CH2) 2-C7 aryl, said - (CH2) 2-C8 aryl, said - (CH2) 2-C9 aryl, said - (CH2) 2-C10 aryl, said - (CH2) 3-C5 aryl, said - (CH2) 3-C6aryl, said - (CH2) 3-C7 aryl, said - (CH2) 3-C8 aryl, said - (CH2) 3-C9 aryl, said - (CH2) 3-C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, said -CH2-5 membered heteroaryl, said -CH2-6 membered heteroaryl, said -CH2-7 membered heteroaryl, said -CH2-8 membered heteroaryl, said -CH2-9 membered heteroaryl, said -CH2-10 membered heteroaryl, said - (CH2) 2-5 membered heteroaryl, said - (CH2) 2-6 membered heteroaryl, said - (CH2) 2-7 membered heteroaryl, said - (CH2) 2-8 membered heteroaryl, said - (CH2) 2-9 membered heteroaryl, said - (CH2) 2-10 membered
heteroaryl, said - (CH2) 3-5 membered heteroaryl, said - (CH2) 3-6 membered heteroaryl, said - (CH2) 3-7 membered heteroaryl, said - (CH2) 3-8 membered heteroaryl, said - (CH2) 3-9 membered heteroaryl, and said - (CH2) 3-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-3alkyl) 2, -S-C1-3alkyl, carboxyl; and each of the heteroaryl independently optionally contains 1 or 2 heteroatoms selected from N, O or S; or RX1 and RX2 together with the carbon atom to which they are attached form 3-membered carbocyclic ring, 4-membered carbocyclic ring, 5-membered carbocyclic ring, or 6-membered carbocyclic ring, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N or O; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, -F, -Cl, -Br, -I, -NH2, -CN, -OH, -NO2, oxo, carboxyl, C1-3alkoxy, C1-3alkyl;
RX3 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -CH2CH2CH3, -C (=O) -CH (CH3) 2, -CH2-C5 aryl, - (CH2) 2-C5 aryl, - (CH2) 3-C5 aryl, -CH2-C6 aryl, - (CH2) 2-C6 aryl, - (CH2) 3-C6 aryl, -CH2-C7 aryl, - (CH2) 2-C7 aryl, - (CH2) 3-C7 aryl, -CH2-C8 aryl, - (CH2) 2-C8 aryl, - (CH2) 3-C8 aryl, -CH2-C9 aryl, - (CH2) 2-C9 aryl, - (CH2) 3-C9 aryl, -CH2-C10 aryl, - (CH2) 2-C10 aryl, - (CH2) 3-C10 aryl, wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said C3 cycloalkyl, said C4 cycloalkyl, said C5 cycloalkyl, said C6 cycloalkyl, said -C (=O) -CH3, said -C (=O) -CH2CH3, said -C (=O) -CH2CH2CH3, said -C (=O) -CH (CH3) 2, said -CH2-C5 aryl, said - (CH2) 2-C5 aryl, said - (CH2) 3-C5 aryl, said -CH2-C6 aryl, said - (CH2) 2-C6 aryl, said - (CH2) 3-C6 aryl, said -CH2-C7 aryl, said - (CH2) 2-C7 aryl, said - (CH2) 3-C7 aryl, said -CH2-C8 aryl, said - (CH2) 2-C8 aryl, said - (CH2) 3-C8 aryl, said -CH2-C9 aryl, said - (CH2) 2-C9 aryl, said - (CH2) 3-C9 aryl, said -CH2-C10 aryl, said - (CH2) 2-C10 aryl, and said - (CH2) 3-C10 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl, 4-6 membered heterocyclyl, -C6-10aryl, -C (=O) -C1-3alkyl, -NH-C (=O) -C1-3alkyl, -C (=O) -NH2, -C (=O) -NH-C1-3alkyl, and -C (=O) -N (C1-3alkyl) 2;
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH(C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl; and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N, O or S;
R5 and R5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, C5 aryl, C6 aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said -C3 cycloalkyl, said -C4 cycloalkyl, said -C5 cycloalkyl, said -C6 cycloalkyl, said C5 aryl, said C6 aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl;
each of R6 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, -C3 cycloalkenyl, -C4
cycloalkenyl, -C5 cycloalkenyl, -C6 cycloalkenyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said -C3 cycloalkyl, said -C4 cycloalkyl, said -C5 cycloalkyl, said -C6 cycloalkyl, said 5 membered heterocyclyl ring, said 6 membered heterocyclyl ring, said 7 membered heterocyclyl ring, said 8 membered heterocyclyl ring, said 9 membered heterocyclyl ring, said 10 membered heterocyclyl ring, said vinyl, said allyl, said -C3 cycloalkenyl, said -C4 cycloalkenyl, said -C5 cycloalkenyl, said -C6 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl;
or R6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R7 is independent selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, 5-10 membered heterocyclyl ring, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, C3 cycloalkenyl, C4 cycloalkenyl, C5 cycloalkenyl, C6 cycloalkenyl, C5 aryl, C6 aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said C3 cycloalkyl, said C4 cycloalkyl, said C5 cycloalkyl, said C6 cycloalkyl, said 5-10 membered heterocyclyl ring, said 5 membered heterocyclyl ring, said 6 membered heterocyclyl ring, said 7 membered heterocyclyl ring, said 8 membered heterocyclyl ring, said 9 membered heterocyclyl ring, said 10 membered heterocyclyl ring, said vinyl, said allyl, said C3 cycloalkenyl, said C4 cycloalkenyl, said C5 cycloalkenyl, said C6 cycloalkenyl, said C5 aryl, said C6 aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxyl;
R8 and R9 are each independently selected from the group consisting of C1-3 alkyl, C3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C5-10 aryl, and 5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3alkyl, -C1-3alkoxy, -C3-6cycloalkyl, -NH2, -NH (C1-3alkyl) , -N (C1-3alkyl) 2, or carboxyl; or
G is C5 aryl, C6 aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, or 10 membered heteroaryl, wherein said C5 aryl, said C6 aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, or said 10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3alkyl, -C1-3alkoxy, -C3-6cycloalkyl, -NH2, -NH (C1-3alkyl) , -N (C1-3alkyl) 2, carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, –C (=O) -G, -C (=O) -W- (CRX1RX2) m-O-RX3, -C (=O) -W- (CRX1RX2) m-S-RX3, C (=O) -W- (CRX1RX2) m-SO-RX3, C (=O) -W- (CRX1RX2) m-SO2-RX3, –C (=O) -W- (CRX1RX2) m-G, –C (=O) -W- (CRX1RX2) m-NR5R5’, -P (=O) (OR6) p (NHR7) q, –C (=O) -W- (CRX1RX2) m-G-O-C (=O) -R8, –C (=O) -W- (CRX1RX2) m-G-O-R8, –C (=O) -O- (CRX1RX2) m-O-C (=O) -R9, -C (=O) -O-R7, –C (=O) -W- (CRX1RX2) m-G-O-C (=O) -G, and –C (=O) -W- (CRX1RX2) m-G-NR5R5’;
W is oxygen or a bond;
m is selected from 1, 2 or 3;
p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -CH2CH2CH3, -C (=O) -CH (CH3) 2, C5 aryl, C6aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, -CH2-C5 aryl, -CH2-C6aryl, -CH2-C7 aryl, -CH2-C8 aryl, -CH2-C9 aryl, -CH2-C10 aryl, - (CH2) 2-C5 aryl, - (CH2) 2-C6aryl, - (CH2) 2-C7 aryl, - (CH2) 2-C8 aryl, - (CH2) 2-C9 aryl, - (CH2) 2-C10 aryl, - (CH2) 3-C5 aryl, - (CH2) 3-C6aryl, - (CH2) 3-C7 aryl, - (CH2) 3-C8 aryl, - (CH2) 3-C9 aryl, - (CH2) 3-C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, -CH2-5
membered heteroaryl, -CH2-6 membered heteroaryl, -CH2-7 membered heteroaryl, -CH2-8 membered heteroaryl, -CH2-9 membered heteroaryl, -CH2-10 membered heteroaryl, - (CH2) 2-5 membered heteroaryl, - (CH2) 2-6 membered heteroaryl, - (CH2) 2-7 membered heteroaryl, - (CH2) 2-8 membered heteroaryl, - (CH2) 2-9 membered heteroaryl, - (CH2) 2-10 membered heteroaryl, - (CH2) 3-5 membered heteroaryl, - (CH2) 3-6 membered heteroaryl, - (CH2) 3-7 membered heteroaryl, - (CH2) 3-8 membered heteroaryl, - (CH2) 3-9 membered heteroaryl, and - (CH2) 3-10 membered heteroaryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said C5 aryl, said C6aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said -CH2-C5 aryl, said -CH2-C6aryl, said -CH2-C7 aryl, said -CH2-C8 aryl, said -CH2-C9 aryl, said -CH2-C10 aryl, said - (CH2) 2-C5 aryl, said - (CH2) 2-C6aryl, said - (CH2) 2-C7 aryl, said - (CH2) 2-C8 aryl, said - (CH2) 2-C9 aryl, said - (CH2) 2-C10 aryl, said - (CH2) 3-C5 aryl, said - (CH2) 3-C6aryl, said - (CH2) 3-C7 aryl, said - (CH2) 3-C8 aryl, said - (CH2) 3-C9 aryl, said - (CH2) 3-C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, said -CH2-5 membered heteroaryl, said -CH2-6 membered heteroaryl, said -CH2-7 membered heteroaryl, said -CH2-8 membered heteroaryl, said -CH2-9 membered heteroaryl, said -CH2-10 membered heteroaryl, said - (CH2) 2-5 membered heteroaryl, said - (CH2) 2-6 membered heteroaryl, said - (CH2) 2-7 membered heteroaryl, said - (CH2) 2-8 membered heteroaryl, said - (CH2) 2-9 membered heteroaryl, said - (CH2) 2-10 membered heteroaryl, said - (CH2) 3-5 membered heteroaryl, said - (CH2) 3-6 membered heteroaryl, said - (CH2) 3-7 membered heteroaryl, said - (CH2) 3-8 membered heteroaryl, said - (CH2) 3-9 membered heteroaryl, and said - (CH2) 3-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N(CH2CH2CH3) 2, -N (CH (CH3) 2) 2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, -S-methyl and carboxyl; and each of the heteroaryl independently optionally contains 1 or 2 heteroatoms selected from N, O or S;
or RX1 and RX2 together with the carbon atom to which they are attached form 3-membered carbocyclic ring, 4-membered carbocyclic ring, 5-membered carbocyclic ring, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N or O; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, -F, -Cl, -Br, -I, -NH2, -CN, -OH, -NO2, oxo, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy;
RX3 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -CH2CH2CH3, -C (=O) -CH (CH3) 2, -CH2-C5 aryl, - (CH2) 2-C5 aryl, - (CH2) 3-C5 aryl, -CH2-C6 aryl, - (CH2) 2-C6 aryl, - (CH2) 3-C6 aryl, -CH2-C7 aryl, - (CH2) 2-C7 aryl, - (CH2) 3-C7 aryl, -CH2-C8 aryl, - (CH2) 2-C8 aryl, - (CH2) 3-C8 aryl, -CH2-C9 aryl, - (CH2) 2-C9 aryl, - (CH2) 3-C9 aryl, -CH2-C10 aryl, - (CH2) 2-C10 aryl, - (CH2) 3-C10 aryl, wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said C3 cycloalkyl, said C4 cycloalkyl, said C5 cycloalkyl, said C6 cycloalkyl, said -C (=O) -CH3, said -C (=O) -CH2CH3, said -C (=O) -CH2CH2CH3, said -C (=O) -CH (CH3) 2, said -CH2-C5 aryl, said - (CH2) 2-C5 aryl, said - (CH2) 3-C5 aryl, said -CH2-C6 aryl, said - (CH2) 2-C6 aryl, said - (CH2) 3-C6 aryl, said -CH2-C7 aryl, said - (CH2) 2-C7 aryl, said - (CH2) 3-C7 aryl, said -CH2-C8 aryl, said - (CH2) 2-C8 aryl, said - (CH2) 3-C8 aryl, said -CH2-C9 aryl, said - (CH2) 2-C9 aryl, said - (CH2) 3-C9 aryl, said -CH2-C10 aryl, said - (CH2) 2-C10 aryl, and said - (CH2) 3-C10 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, -C6aryl, -C (=O) -CH3, -NH-C (=O) -CH3, -C (=O) -NH2, -C (=O) -NH-CH3, -C (=O) -N (CH3) 2, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl;
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group
consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl; and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N, O or S;
R5 and R5’ are each independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, C5 aryl, C6 aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said -C3 cycloalkyl, said -C4 cycloalkyl, said -C5 cycloalkyl, said -C6 cycloalkyl, said C5 aryl, said C6 aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl;
each of R6 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, -C3 cycloalkenyl, -C4 cycloalkenyl, -C5 cycloalkenyl, -C6 cycloalkenyl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said -C3 cycloalkyl, said -C4 cycloalkyl, said -C5 cycloalkyl, said -C6 cycloalkyl, said 5 membered heterocyclyl ring, said 6 membered heterocyclyl ring, said 7 membered heterocyclyl ring, said 8 membered heterocyclyl ring, said 9 membered heterocyclyl ring, said 10 membered heterocyclyl ring, said vinyl, said allyl, said -C3 cycloalkenyl, said -C4 cycloalkenyl, said -C5 cycloalkenyl, said -C6 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl;
or R6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;
each of R7 is independent selected from the group consisting of hydrogen, deuterium, halogen, methyl, ethyl, propyl, isopropyl, C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, 5-10 membered heterocyclyl ring, 5 membered heterocyclyl ring, 6 membered heterocyclyl ring, 7 membered heterocyclyl ring, 8 membered heterocyclyl ring, 9 membered heterocyclyl ring, 10 membered heterocyclyl ring, vinyl, allyl, C3 cycloalkenyl, C4 cycloalkenyl, C5 cycloalkenyl, C6 cycloalkenyl, C5 aryl, C6 aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said C3 cycloalkyl, said C4 cycloalkyl, said C5 cycloalkyl, said C6 cycloalkyl, said 5-10 membered heterocyclyl ring, said 5 membered heterocyclyl ring, said 6 membered heterocyclyl ring, said 7 membered heterocyclyl ring, said 8 membered heterocyclyl ring, said 9 membered heterocyclyl ring, said 10 membered heterocyclyl ring, said vinyl, said allyl, said C3 cycloalkenyl, said C4 cycloalkenyl, said C5 cycloalkenyl, said C6 cycloalkenyl, said C5 aryl, said C6 aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl;
R8 and R9 are each independently selected from the group consisting of C1-3 alkyl, C3-6 cycloalkyl, monosaccharide, acylated monosaccharide, C5-10 aryl, and 5-10 membered heteroaryl, and wherein said C1-3 alkyl, said C3-6 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C5-10 aryl, and said 5-10 membered heteroaryl, can be optional substituted with one or more substituents, which are
independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl; or
G is C5 aryl, C6 aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, or 10 membered heteroaryl, wherein said C5 aryl, said C6 aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, or said 10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N(CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is -C (=O) -W- (CRX1RX2) m-O-RX3;
W is a bond;
m is 1 or 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -CH2CH2CH3, -C (=O) -CH (CH3) 2, C5 aryl, C6aryl, C7 aryl, C8 aryl, C9 aryl, C10 aryl, -CH2-C5 aryl, -CH2-C6aryl, -CH2-C7 aryl, -CH2-C8 aryl, -CH2-C9 aryl, -CH2-C10 aryl, - (CH2) 2-C5 aryl, - (CH2) 2-C6aryl, - (CH2) 2-C7 aryl, - (CH2) 2-C8 aryl, - (CH2) 2-C9 aryl, - (CH2) 2-C10 aryl, - (CH2) 3-C5 aryl, - (CH2) 3-C6aryl, - (CH2) 3-C7 aryl, - (CH2) 3-C8 aryl, - (CH2) 3-C9 aryl, - (CH2) 3-C10 aryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, 10 membered heteroaryl, -CH2-5 membered heteroaryl, -CH2-6 membered heteroaryl, -CH2-7 membered heteroaryl, -CH2-8 membered heteroaryl, -CH2-9 membered heteroaryl, -CH2-10 membered heteroaryl, - (CH2) 2-5 membered heteroaryl, - (CH2) 2-6 membered heteroaryl, - (CH2) 2-7 membered heteroaryl, - (CH2) 2-8 membered heteroaryl, - (CH2) 2-9 membered heteroaryl, - (CH2) 2-10 membered heteroaryl, - (CH2) 3-5 membered heteroaryl, - (CH2) 3-6 membered heteroaryl, - (CH2) 3-7 membered heteroaryl, - (CH2) 3-8 membered heteroaryl, - (CH2) 3-9 membered heteroaryl, and - (CH2) 3-10 membered heteroaryl, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said C5 aryl, said C6aryl, said C7 aryl, said C8 aryl, said C9 aryl, said C10 aryl, said -CH2-C5 aryl, said -CH2-C6aryl, said -CH2-C7 aryl, said -CH2-C8 aryl, said -CH2-C9 aryl, said -CH2-C10 aryl, said - (CH2) 2-C5 aryl, said - (CH2) 2-C6aryl, said - (CH2) 2-C7 aryl, said - (CH2) 2-C8 aryl, said - (CH2) 2-C9 aryl, said - (CH2) 2-C10 aryl, said - (CH2) 3-C5 aryl, said - (CH2) 3-C6aryl, said - (CH2) 3-C7 aryl, said - (CH2) 3-C8 aryl, said - (CH2) 3-C9 aryl, said - (CH2) 3-C10 aryl, said 5 membered heteroaryl, said 6 membered heteroaryl, said 7 membered heteroaryl, said 8 membered heteroaryl, said 9 membered heteroaryl, said 10 membered heteroaryl, said -CH2-5 membered heteroaryl, said -CH2-6 membered heteroaryl, said -CH2-7 membered heteroaryl, said -CH2-8 membered heteroaryl, said -CH2-9 membered heteroaryl, said -CH2-10 membered heteroaryl, said - (CH2) 2-5 membered heteroaryl, said - (CH2) 2-6 membered heteroaryl, said - (CH2) 2-7 membered heteroaryl, said - (CH2) 2-8 membered heteroaryl, said - (CH2) 2-9 membered heteroaryl, said - (CH2) 2-10 membered heteroaryl, said - (CH2) 3-5 membered heteroaryl, said - (CH2) 3-6 membered heteroaryl, said - (CH2) 3-7 membered heteroaryl, said - (CH2) 3-8 membered heteroaryl, said - (CH2) 3-9 membered heteroaryl, and said - (CH2) 3-10 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, -S-methyl and carboxyl; and each of the heteroaryl independently optionally contains 1 or 2 heteroatoms selected from N, O or S;
or RX1 and RX2 together with the carbon atom to which they are attached form 3-membered carbocyclic ring, 4-membered carbocyclic ring, 5-membered carbocyclic ring, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N or O; each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; or
RX3 is independently selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -CH2CH2CH3, -C (=O) -CH (CH3) 2, -CH2-C5 aryl, - (CH2) 2-C5 aryl, - (CH2) 3-C5 aryl, -CH2-C6 aryl, - (CH2) 2-C6 aryl, - (CH2) 3-C6 aryl, -CH2-C7 aryl, - (CH2) 2- C7 aryl, - (CH2) 3-C7 aryl, -CH2-C8 aryl, - (CH2) 2-C8 aryl, - (CH2) 3-C8 aryl, -CH2-C9 aryl, - (CH2) 2-C9 aryl, - (CH2) 3-C9 aryl, -CH2-C10 aryl, - (CH2) 2-C10 aryl, - (CH2) 3-C10 aryl, wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, said isopropoxy, said C3 cycloalkyl, said C4 cycloalkyl, said C5 cycloalkyl, said C6 cycloalkyl, said -C (=O) -CH3, said -C (=O) -CH2CH3, said -C (=O) -CH2CH2CH3, said -C (=O) -CH (CH3) 2, said -CH2-C5 aryl, said - (CH2) 2-C5 aryl, said - (CH2) 3-C5 aryl, said -CH2-C6 aryl, said - (CH2) 2-C6 aryl, said - (CH2) 3-C6 aryl, said -CH2-C7 aryl, said - (CH2) 2-C7 aryl, said - (CH2) 3-C7 aryl, said -CH2-C8 aryl, said - (CH2) 2-C8 aryl, said - (CH2) 3-C8 aryl, said -CH2-C9 aryl, said - (CH2) 2-C9 aryl, said - (CH2) 3-C9 aryl, said -CH2-C10 aryl, said - (CH2) 2-C10 aryl, and said - (CH2) 3-C10 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, -C6aryl, -C (=O) -CH3, -NH-C (=O) -CH3, -C (=O) -NH2, -C (=O) -NH-CH3, -C (=O) -N (CH3) 2, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl;
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form 4 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, 7 membered heterocyclyl, 8 membered heterocyclyl, 9 membered heterocyclyl, 10 membered heterocyclyl, wherein said 4 membered heterocyclyl, said 5 membered heterocyclyl, said 6 membered heterocyclyl, said 7 membered heterocyclyl, said 8 membered heterocyclyl, said 9 membered heterocyclyl, said 10 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl; and each of the heterocyclyl independently optionally contains 1 or 2 heteroatoms selected from N, O or S.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is -C (=O) -W- (CRX1RX2) m-O-RX3;
W is a bond;
m is 1 or 2;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, CN, CF3, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, cyclobutyl, cyclopentyl, -C (=O) -CH3,
and each of which is independently optionally subsitituted with deuterium, -F, -Cl, -Br, -I, -NH2, -CN, -OH, oxo, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -NHmethyl, -NHethyl, -NHpropyl, -NHcyclopropyl, -NHisopropyl, -N (CH3) 2, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, or -S-methyl;
or RX1 and RX2 together with the carbon atom to which they are attached form
RX3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, -CD3, -C (=O) -CH2-CN, -C (=O) -C (CH3) 3, -C (=O) -CH3, -C (=O) -CH2CH3, -C (=O) -NH-CH3, -C (=O) -CH2-N (CH3) 2, -CH2-C (=O) -CH3, -CH2-C (=O) -NHCH3, -CH2-C (=O) -N (CH3) 2, -CH2-NH2, -CH2-NH-CH3, -CH2CH2-OH, -CH2CH2-CN, -CH2-CN, -CH2CH2-C (=O) -NH2, -CH2CH2-C (=O) -NH-CH3, -CH2CH2-NH-C (=O) -CH3,
or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
X is -C (=O) -CRX1RX2-O-RX3;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, CN, CF3, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, cyclobutyl, cyclopentyl, -C (=O) -CH3, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclopentyl, -CH2-cyclohexyl,
RX3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, -CD3, -C (=O) -CH2-CN, -C (=O) -C (CH3) 3, -C (=O) -CH3, -C (=O) -CH2CH3,
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention,
wherein R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R2 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R2 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N(CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl. Preferably, R2 is selected from hydrogen or deuterium.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R3 and R3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R3 and R3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R3 and R3’ are each independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R3 and R3’ are each independently selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, -N (CH (CH3) 2) 2, and carboxyl. Preferably, R3 and R3’ are each independently selected from hydrogen or deuterium.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention,
wherein
Y is a bond, or - (CRY1RY2) n-;
n is selected from 1, 2, or 3;
RY1 and RY2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
Y is a bond, or - (CRY1RY2) n-;
n is selected from 1, 2, or 3;
RY1 and RY2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
Y is a bond, or - (CRY1RY2) n-;
n is selected from 1, 2, or 3;
RY1 and RY2 are each independently selected from the group consisting of F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein
Y is a bond, or - (CRY1RY2) n-;
n is selected from 1, 2, or 3;
RY1 and RY2 are each independently selected from the group consisting of F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, and -N (CH (CH3) 2) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein Y is -CH2-.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo,
-CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, and -N (CH (CH3) 2) 2, and carboxyl. Preferably, R4 is selected from hydrogen or deuterium.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R10 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R10 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyl, and C1-3 alkoxy, and wherein said C1-3 alkyl, and said C1-3 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R10 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, and carboxyl.
In some embodiments of the compound of Formula I, I-A, I-B, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R10 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, and isopropoxy, and wherein said methyl, said ethyl, said propyl, said isopropyl, said methoxy, said ethoxy, said propoxy, and said isopropoxy, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -C3 cycloalkyl, -C4 cycloalkyl, -C5 cycloalkyl, -C6 cycloalkyl, -NH2, -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH (CH3) 2, -N (CH3) 2, -N (CH2CH3) 2, -N (CH2CH2CH3) 2, and -N (CH (CH3) 2) 2, and carboxyl. Preferably, R10 is hydrogen or deuterium.
In some embodiments, the glutamine antagonist is a compound of Formula I-C, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof:
wherein Q is O, S, SO, or SO2; Z, RX1, RX2, RX3, and m are the same as defined herein.
In some embodiments, the glutamine antagonist is a compound of Formula II, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof:
wherein Z, RX1, RX2, RX3, and m are the same as defined herein.
In some embodiments, the glutamine antagonist is a compound of Formula III, or the pharmaceutically
acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
wherein R1, RX1, RX2, RX3, and m are the same as defined herein.
In some embodiments, the glutamine antagonist is a compound of Formula IV, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof :
In some embodiments, the glutamine antagonist is a compound of Formula V, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
In some embodiments, the glutamine antagonist is a compound of Formula VI, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
In some embodiments, the glutamine antagonist is a compound of Formula VII, or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
In some embodiments, the glutamine antagonist is a compound of Formula VIII or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic substitution thereof:
wherein R1, RX1, RX2, RX3, and m are the same as defined herein
In some embodiments of the compound of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein one or more hydrogen is optionally substitued with deuterium.
In some embodiments of the compound of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein one or more hydrogen in R1 or RX3 is substitued with deuterium, preferably, all hydrogens on one or more methyl groups, methylene groups, or methane groups are
substituted with deuterium.
In some embodiments of the compound of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from the group consisting of hydrogen, deuterium, hydrogen, deuterium, C1-3 alkyl, C1-3 alkoxy, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, CN, OH,
C1-4alkyl, C1-3alkoxy, each of which can be optional substituted with one or more substituents, which are
independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3
alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-3alkyl) 2, -S-C1-3alkyl; or
RX3 is independently selected from the group consisting of hydrogen, deuterium, C1-3 alkyl, C1-3 alkoxy, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxy, -S-C1-3alkyl.
In some embodiments of the compound of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy;
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, CN, CF3,
methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl,
and each of which is independently optionally subsitituted with deuterium, -F, -Cl, -Br, -I, -NH2, -CN, -OH,
oxo, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; or
RX3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, each of which can be substituted with deuterium.
In some embodiments of the compound of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is seleted from hydrogen, deuterium, isopropyl, methyl, ethyl, -tert-butyl, isopentyl, -CD3, -CH2CD3, -CD2CD3, -CD (CD3) 2, -CH (CD3) 2,
RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN,
OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, or
RX3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, -CD3, -CH2CD3, -CD2CD3.
In some embodiments of the compound of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof of the present invention, wherein R1 is selected from -CD3, -CH2CD3, -CD2CD3, -CD (CD3) 2, -CH(CD3) 2, the deuterated RX3 is selected from -CD3, -CH2CD3, -CD2CD3
In some embodiments, the glutamine antagonist is a compound selected from the compounds in the following table (table 3) , or the pharmaceutically acceptable salt thereof, the stereoisomer thereof, the tautomer thereof, and the isotopic substitution thereof:
Table 3
The invention is further illustrated by the following examples, which may be synthesized and isolated as free bases or as salts.
In some embodiments of the pharmaceutical combination of the invention, the glutamine antagobist is selected from a compound in Table 3, or a pharmaceutically acceptable salt thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is selected from compound 1, compound 2, compound 3, compound 4, compound 5, or compound 6, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is compound 1, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is compound 2, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is compound 3, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is compound 4, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is compound 5, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
In some embodiments of the pharmaceutical combination defined herein, wherein the glutamine antagonist is compound 6, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof.
Immune checkpoint inhibitors are therapies that blockade immune system inhibitor checkpoints. Immune checkpoints can be stimulatory or inhibitory. Blockade of inhibitory immune checkpoint activates immune system function and can be used for cancer immunotherapy. Pardoll, Nature Reviews. Cancer 72: 252-64 (2012) . Tumor cells turn off activated T cells when they attach to specific T-cell receptors. Immune checkpoint inhibitors prevent tumor cells from attaching to T cells, which results in T cells remaining activated. In effect, the coordinated action by cellular and soluble components combats pathogens and injuries by cancers. The modulation of immune system pathways may involve changing the expression or the functional activity of at least one component of the pathway to then modulate the response by the immune system. U.S. 2015/0250853. Examples of immune checkpoint inhibitors include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG3 inhibitors, TIM3 inhibitors, cd47 inhibitors, and B7-H1 inhibitors. Thus, in one embodiment, the immune checkpoint inhibitor is selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, and a cd47 inhibitor.
In another embodiment, the immune checkpoint inhibitor is a programmed cell death (PD-1) inhibitor. PD-1 is a T-cell coinhibitory receptor that plays a pivotal role in the ability of tumor cells to evade the host's immune system. Blockage of interactions between PD-1 and PD-L1, a ligand of PD-1, enhances immune function and mediates antitumor activity. Examples of PD-1 inhibitors include antibodies that specifically bind to PD-1. Particular anti-PD-1 antibodies include, but are not limited to nivolumab, pembrolizumab, STI-A1014, and pidilzumab. For a general discussion of the availability, methods of production, mechanism of action, and clinical studies of anti-PD-1 antibodies, see U.S. 2013/0309250, U.S. 6,808,710, U.S. 7,595,048, U.S. 8,008,449, U.S. 8,728,474, U.S. 8,779,105, U.S. 8,952,136, U.S. 8,900,587, U.S. 9,073,994, U.S. 9,084,776, and Naido et al., British Journal of Cancer 777: 2214-19 (2014) . In some embodiments, the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, STI-A1110, PDR001, MEDI-0680, Balstilimab (AGEN2034) , Tislelizumab (BGB-A317) , AB122, TSR-042, PF-06801591, cemiplimab, SYM021, JNJ-63723283, HLX10, LZM009, and MGA012.
In another embodiment, the immune checkpoint inhibitor is a PD-L1 (also known as B7-H1 or CD274) inhibitor. Examples of PD-L1 inhibitors include antibodies that specifically bind to PD-L1. Particular anti-PD-Ll antibodies include, but are not limited to, avelumab, atezolizumab, durvalumab, STI-A1014 and BMS-936559. For a general discussion of the availability, methods of production, mechanism of action, and clinical studies, see U.S. 8,217,149, U.S. 2014/0341917, U.S. 2013/0071403, WO 2015036499, and Naido et al., British Journal of Cancer 777: 2214-19 (2014) .
In another embodiment, the immune checkpoint inhibitor is a CTLA-4 inhibitor.
CTLA-4, also known as cytotoxic T-lymphocyte antigen 4, is a protein receptor that downregulates the immune system. CTLA-4 is characterized as a "brake" that binds costimulatory molecules on antigen-presenting cells, which prevents interaction with CD28 on T cells and also generates an overtly inhibitory signal that constrains T cell activation. Examples of CTLA-4 inhibitors include antibodies that specifically bind to CTLA-4. Particular anti-CTLA-4 antibodies include, but are not limited to, ipilimumab and tremelimumab. For a general discussion of the availability, methods of production, mechanism of action, and clinical studies, see U.S. 6,984,720, U.S. 6,207,156, and Naido et al., British Journal of Cancer 777: 2214-19 (2014) .
In another embodiment, the immune checkpoint inhibitor is a LAG3 inhibitor.
LAG3, Lymphocyte Activation Gene 3, is a negative co-simulatory receptor that modulates T cell homeostatis, proliferation, and activation. In addition, LAG3 has been reported to participate in regulatory T cells (Tregs) suppressive function. A large proportion of LAG3 molecules are retained in the cell close to the microtubule-organizing center, and only induced following antigen specific T cell activation. U.S. 2014/0286935. Examples of LAG3 inhibitors include antibodies that specifically bind to LAG3. Particular anti-LAG3 antibodies include, but are not limited to, GSK2831781. For a general discussion of the availability, methods of production, mechanism of action, and studies, see, U.S. 2011/0150892, U.S. 2014/0093511, U.S. 20150259420, and Huang et ah, Immunity 21 : 503-13 (2004) .
In another embodiment, the immune checkpoint inhibitor is a TIM3 inhibitor.
TIM3, T-cell immunoglobulin and mucin domain 3, is an immune checkpoint receptor that functions to limit the duration and magnitude of TH1 and TC1 T-cell responses. The TIM3 pathway is considered a target for anticancer immunotherapy due to its expression on dysfunctional CD8+T cells and Tregs, which are two reported immune cell populations that constitute immunosuppression in tumor tissue. Anderson, Cancer Immunology Research 2: 393-98 (2014) . Examples of TIM3 inhibitors include antibodies that specifically bind to TIM3. For a general discussion of the availability, methods of production, mechanism of action, and studies of TIM3 inhibitors, see U.S. 20150225457, U.S. 20130022623, U.S. 8,522,156, Ngiow et al., Cancer Res 71: 6567-71 (2011) , Ngiow, et al., Cancer Res 77: 3540-51 (2011) , and Anderson , Cancer Immunology Res 2: 393-98 (2014) .
In another embodiment, the immune checkpoint inhibitor is a cd47 inhibitor. See Unanue, E.R., PNAS 110: 10886-87 (2013) .
In another embodiments of the pharmaceutical combination of the invention, an Aurora A kinase inhibitor is selected from VX-689, VIC-1911, LY3295668, or a pharmaceutically acceptable salt thereof.
In some embodiments, a SHP2 inhibitor selecte from compounds described in WO2015/107493, WO2015/107494, WO2015/107495, WO2016/203406, WO2016/203404, WO2016/203405, WO2017/216708, WO2018/013597, WO2018/136264, WO2018/13265, WO2019/051084, WO2019/075265, WO2019/118909, WO2019/199792, WO2017/211303, WO2018/172984, WO2017/156397, WO2018/057884, WO2018/081091, WO2019/067843, WO2019/165073, WO2019/183367, WO2017210134, WO2019213318, WO2020033828, WO2019051469, WO2019158019, WO2019182960, WO2021061515, WO2020022323, WO2019167000, WO2021033153, WO2020061101, WO2020061103, WO2020072656, WO2020073945, WO2020073949, WO2020081848, WO2020201991, WO2021043077, WO2020094018, WO2021018287, WO2020094104, CN111704611A, WO2020108590, WO2020259679, WO2020156242, WO2020156243, WO2021147879, WO2020177653, WO2020181283, WO2020210384, CN111825700A, WO2020249079, WO2021028362, WO2021073439, WO2021088945, WO2021115286, WO2021143823, WO2021143680, WO2021143701, WO2021148010 &CN113248449A, each of which is incorporated herein by reference in its entirety.
In some embodiments of the disclosure, the SHP2 inhibitor comprises or consists of RMC-4630, RMC-4550, RLY-1971, BBP-398, ERAS-601, RG001 , GH-21 , SH3809 , ET0038 , ICP-189 , BT-102 , PF-07284892 , SNG-201 , (3S, 4S) -8- (6-amino-5- ( (2-amino-3-chloropyridin-4-yl) thio) pyrazin-2-yl) -3-methyl-2-oxa-8-azaspiro [4.5] decan-4-amine (TN0155) , or a pharmaceutically acceptable salt thereof; 6- (4-amino-4-methylpiperidin-l-yl) -3 - (2, 3 -dichlorophenyl) pyrazin -2-amine (SHP099) or a pharmaceutically acceptable salt thereof, and any one of pharmaceutical combination thereof. Preferably RMC-4630, or TNO-155.
In some embodiments, A “KRASG12C inhibitor” is a compound selected from the compounds detailed in WO2013/155223, WO2014/143659, WO2014/152588, WO2014/160200, WO2015/054572, WO2016/044772, WO2016/049524, WO2016164675, WO2016168540, W02017/058805, WO2017015562, WO2017058728, WO2017058768, WO2017058792, W02017058805, W02017058807, W02017058902, WO2017058915, WO2017087528, W02017100546, WO2017/201161, WO2018/064510, WO2018/068017, WO2018/119183, WO2018/217651, W02018/140512, W02018/140513, W02018/140514, WO2018/140598, WO2018/140599, W02018/140600, WO2018/143315, WO2018/206539, WO2018/218070, W02018/218071, WO2019/051291, WO2019/099524, WO2019/110751, W02019/141250, W02019/150305, WO2019/155399, WO2019/213516, WO2019/213526, WO2019/217307 and WO2019/217691. In some embodiments of the disclosure, the KRASG12C inhibitor is selected from AMG 510, MRTX849, RMC-6291, GH-35 , LY-3537982 , BEBT-607 , BPI-421286, D-1553, YL-15293, JDQ-443, 1 - (4- (6-chloro-8-fluoro-7- (3-hydroxy-5 -vinylphenyl) quinazolin-4-yl) piperazin-1 -yl) prop-2-en-l -one-methane (1/2) ; (S) -l- (4- (6-chloro-8-fluoro-7- (2-fluoro-6-hydroxyphenyl) quinazolin-4-yl) piperazin-l-yl) prop-2-en-l-one ; 2- ( (S) -l-acryloyl-4- (2- ( ( (S) -l-methylpyrrolidin-2 -yl) methoxy) -7- (naphthalen-l-yl) -5, 6, 7, 8-tetrahydropyrido [3, 4-d] pyrimidin-4-yl) piperazin-2-yl) acetonitrile, and any one of pharmaceutical combination thereof.
The term "antibody" is meant to include intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity. In another embodiment, "antibody" is meant to include soluble receptors that do not possess the Fc portion of the antibody. In one embodiment, the antibodies are humanized monoclonal antibodies and fragments thereof made by means of recombinant genetic engineering.
Another class of immune checkpoint inhibitors include polypeptides that bind to and block PD-1 receptors on T-cells without triggering inhibitor signal transduction. Such peptides include B7-DC polypeptides, B7-H1 polypeptides, B7-1 polypeptides and B7-2 polypeptides, and soluble fragments thereof, as disclosed in U.S. Pat. 8,114,845.
Another class of immune checkpoint inhibitors include compounds with peptide moieties that inhibit PD-1 signaling. Examples of such compounds are disclosed in U.S. Pat. 8,907,053 and have the structure:
or a pharmaceutically acceptable salt thereof, wherein the compound comprises at least 5 amino acids useful as therapeutic agents capable of inhibiting the PD-1 signaling pathway.
Another class of immune checkpoint inhibitors include inhibitors of certain metabolic enzymes, such as indoleamine 2, 3 dioxygenase (IDO) , which is expressed by infiltrating myeloid cells and tumor cells. The IDO enzyme inhibits immune responses by depleting amino acids that are necessary for anabolic functions in T cells or through the synthesis of particular natural ligands for cytosolic receptors that are able to alter lymphocyte functions. Pardoll, Nature Reviews. Cancer 72: 252-64 (2012) ; Lob, Cancer Immunol Immunother 55: 153-57 (2009) . Particular IDO blocking agents include, but are not limited to levo-l-methyl typtophan (L-1MT) and 1 -methyl-tryptophan (1MT) . Qian et al, Cancer Res 69: 5498-504 (2009) ; and Lob el al, Cancer Immunol Immunother 55: 153-7 (2009) .
In one embodiment, the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, STI-A1110, avelumab, atezolizumab, durvalumab, STI-A1014, ipilimumab, tremelimumab, GSK2831781, BMS-936559 or MED14736.
In another embodiment there is provided a pharmaceutical composition or commercial package (e.g. a kit-of-parts) comprising the pharmaceutical combination of the invention, and at least one pharmaceutically acceptable carrier.
In another aspect, the present application provides a use of the pharmaceutical combination defined herein and/or the pharmaceutical composition or the commercial package of the present invention for the manufacture of a medicament.
In some embodiments, the medicament prepared can be used for the treatment or prevention of cancer or cancer metastasis.
In some embodiments, wherein the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof. In some embodiments, the skin cancer is a melanoma (e.g., a refractory melanoma) .
In some embodiments, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
In another aspect, the present application provides a use of the pharmaceutical combination of defined herein or the pharmaceutical composition or the commercial package of the present invention, wherein a medicament prepared can be used for the treatment or prevention of cancer or cancer metastasis.
In some embodiments, the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer,
non-Hodgkin lymphoma, or any of combination thereof. In some embodiments, the skin cancer is a melanoma (e.g., a refractory melanoma) .
In some embodiments, the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
The pharmaceutical combination of defined herein or the pharmaceutical composition or the commercial package of the present invention, for use in the treatment of cancer or the prevention of cancer metastasis.
In some embodiments, the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof. In some embodiments, the skin cancer is a melanoma (e.g., a refractory melanoma) .
In some embodiments, the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
The pharmaceutical combination of defined herein and/or a pharmaceutical composition or the commercial package of the present invention, which is used in therapy.
The pharmaceutical combination of defined herein and/or a pharmaceutical composition or the commercial package of the present invention which is used as a medicament.
The present invention relates to a method of treating cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof, in a mammal comprising administering to a mammal in need of such treatment an effective amount of the pharmaceutical combination of defined herein, and/or a pharmaceutical composition of the present invention.
In some embodiments, the glutamine antagonist is administered to the patient according to an intermittent dosing schedule. In some embodiments, the glutamine antagonist is subcutaneously administered to the patient according to an intermittent dosing schedule. In some embodiments, the glutamine antagonist is intravenously administered to the patient according to an intermittent dosing schedule.
In some embodiments, the glutamine antagonist is administered prior to the immune checkpoint inhibitor, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks prior to the administration of the immune checkpoint inhibitor.
In some embodiments, the glutamine antagonist is administered after the immune checkpoint inhibitor, e.g., 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks after the administration of the immune checkpoint inhibitor.
In some embodiments, the glutamine antagonist, and the immune checkpoint inhibitor are administered concurrently but on different schedules, e.g, the glutamine antagonist is administered daily while the immune checkpoint inhibitor is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the glutamine antagonist is administered once a day while the immune checkpoint inhibitor is administered once a week, once every two weeks, once every three weeks, or once every four weeks.
The therapeutic methods provided herein comprise administering a glutamine antagonist to a cancer patient in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, the glutamine antagonist is administered in an amount from about 0.05 mg/kg to about 500 mg/kg, about 0.05 mg/kg to about
100 mg/kg, about 0.05 mg/kg to about 50 mg/kg, or about 0.05 mg/kg to about 10 mg/kg. The dosage of a composition can be at any dosage including, but not limited to, about 0.05 mg/week to about 25 mg/week. Particular doses include 0.05, 1, 2, 5, 10, 20, 50, and 100 mg/kg once weekly. In one embodiment, the glutamine antagonist is administered once a week. These dosages are exemplary, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this disclosure. In practice, the physician determines the actual dosing regimen that is most suitable for an individual patient, which can vary with the age, weight, and response of the particular patient. In one embodiment, about 0.1 mg/kg to about 2 mg/kg of DON is administered to the subject.
The unit oral dose of the glutamine antagonist may comprise from about 0.01 to about 1000 mg, e.g., about 0.01 to about 100 mg of the glutamine antagonist. In one embodiment, the unit oral dose of the glutamine antagonist is 0.05 mg, 1 mg, 3 mg, 5 mg, 7 mg, 9 mg, 10 mg 12 mg, 14 mg, 15 mg, 17 mg, 20 mg, 22 mg, 25 mg, 27 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg. The unit dose may be administered one or more times daily, e.g., as one or more tablets or capsules. The unit does may also be administered by IV or subcutaneously to the subject. In practice, the physician determines the actual dosing regimen that is most suitable for an individual patient, which can vary with the age, weight, and response of the particular patient.
In addition to administering the glutamine antagonist as a raw chemical, it may be administered as part of a pharmaceutical preparation or composition. In some embodiments, the pharmaceutical preparation or composition can include one or more pharmaceutically acceptable carriers, excipients, and/or auxiliaries. In some embodiments, the one or more carriers, excipients, and auxiliaries facilitate processing of the glutamine antagonist into a preparation or composition which can be used pharmaceutically. The preparations, particularly those preparations which can be administered orally, subcutaneously, intravenously, or topically, and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, and shampoos, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, subcutaneous injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound (s) , together with the one or more carriers, excipients, and/or auxiliaries.
The pharmaceutical compositions of provided herein may be administered to any subject which may experience the beneficial effects of the glutamine antagonist. Foremost among such subjects are mammals, e.g., humans, although the methods and compositions provided herein are not intended to be so limited. Other subjects include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like) . In one embodiment, the subject is a human cancer patient.
The pharmaceutical preparations provided herein are manufactured by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries can be suitable flow-regulating agents and lubricants. Suitable auxiliaries include, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
The present disclosure encompasses the use of solvates of the glutamine antagonist. Solvates typically do not significantly alter the physiological activity or toxicity of a compound, and as such may function as pharmacological equivalents. The term "solvate" as used herein is a combination, physical association and/or solvation of the glutamine antagonist with a solvent molecule such as, e.g ., a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to the glutamine antagonist is about 2: 1, about 1 : 1 or about 1 : 2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, "solvate" encompasses both solution-phase and isolatable solvates. the glutamine antagonist can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, ethanol, and the like, and it is intended that the disclosure includes both solvated and unsolvated forms of the glutamine antagonist. One type of solvate is a hydrate. A "hydrate" relates to a particular subgroup of solvates where the solvent molecule is water. Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M. Caira et al, J. Pharmaceut. Sci., 93 (3) : 601-611 (2004) , which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E. C. van Tonder et al., AAPS Pharm. Sci. Tech., 5 (1) : Article 12 (2004) , and A. L. Bingham et al ., Chem. Commun. 603-604 (2001) . A typical, non-limiting, process of preparing a solvate involves dissolvingthe glutamine antagonist in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20℃ to about 25℃, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g ., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
Therapeutically effective amounts of the glutamine antagonist, and the immune checkpoint inhibitor formulated in accordance with standard pharmaceutical practices, are administered to a human patient in need thereof. Whether such a treatment is indicated depends on the individual case and is subject to medical assessment (diagnosis) that takes into consideration signs, symptoms, and/or malfunctions that are present, the risks of developing particular signs, symptoms and/or malfunctions, and other factors.
The glutamine antagonist, and the immune checkpoint inhibitor can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracistemal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and/or surgical implantation at a particular site) administration. Parenteral administration can be accomplished using a needle and syringe or using a high pressure technique. In one embodiment, the glutamine antagonist is administered subcutaneously to the subject. In one embodiment, the glutamine antagonist is administered intraveneously to the subject.
Pharmaceutical compositions include those wherein the glutamine antagonist, and the immune checkpoint inhibitor are administered in an effective amount to achieve its intended purpose. The exact formulation, route of administration, and dosage is determined by an individual physician in view of the diagnosed condition or disease. Dosage amount and interval can be adjusted individually to provide levels of the glutamine antagonist, and the immune checkpoint inhibitor that is sufficient to maintain therapeutic effects.
Toxicity and therapeutic efficacy of the glutamine antagonist, and the immune checkpoint inhibitor can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) of a compound, which defines as the highest dose that causes no toxicity in a patient. The dose ratio between the maximum tolerated dose and therapeutic effects (e.g. inhibiting of tumor growth) is the therapeutic index. The dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
A therapeutically effective amount of the glutamine antagonist, and the immune checkpoint inhibitor required for use in therapy varies with the nature of the condition being treated, the length of time that activity is desired, and the age and the condition of the subject, and ultimately is determined by the attendant physician. For example, dosage amounts and intervals can be adjusted individually to provide plasma levels of the glutamine antagonist, and immune checkpoint inhibitor that are sufficient to maintain the desired therapeutic effects. The desired dose conveniently can be administered in a single dose, or as multiple doses administered at appropriate intervals, for example as one, two, three, four or more subdoses per day. Multiple doses often are desired, or required. For example, the glutamine antagonist, and immune checkpoint inhibitor can be administered at a frequency of: one dose per day; four doses delivered as one dose per day at four-day intervals (q4d x 4) ; four doses delivered as one dose per day at three-day intervals (q3d x 4) ; one dose delivered per day at five-day intervals (qd x 5) ; one dose per week for three weeks (qwk3) ; five daily doses, with two days rest, and another five daily doses (5/2/5) ; or, any dose regimen determined to be appropriate for the circumstance.
The immune checkpoint inhibitor is administered in therapeutically effective amounts. When the immune checkpoint inhibitor is a monoclonal antibody, 1-20 mg/kg is administered as an intravenous infusion every 2-4 weeks. For example, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 1900 mg and 2000 mg of the antibody may be administered.
For example, when the immune checkpoint inhibitor is the anti-PD-1 antibody nivolumab, 3 mg/kg may be administered by intravenous infusion over 60 minutes every two weeks. When the immune checkpoint inhibitor is the anti-PD-1 antibody pembrolizumab, mg/kg may be administered by intravenous infusion over 30 minutes every two or three weeks. When the immune checkpoint inhibitor is the anti-PD-Ll antibody avelumab, 10 mg/kg may be administered by intravenous infusion as frequently as every 2 weeks. Disis et al ., J Clin Oncol. 33 (2015) (suppl; abstr 5509) . When the immune checkpoint inhibitor is the anti-PD-Ll antibody MPDL3280A, 20 mg/kg may be administered by intravenous infusion every 3 weeks. Herbst et al., Nature 575: 563-80 (2014) . When the immune checkpoint inhibitor is the anti-CTLA-4 antibody ipilumumab, 3 mg/kg may be administered by intravenous infusion over 90 minutes every 3 weeks. When the immune checkpoint inhibitor is the anti-CTLA-4 antibody tremelimumab, 15 mg/kg may be administered by intravenous infusion every 12 weeks. Naido et al., British Journal of Cancer 777: 2214-19 (2014) ; Drugs R D , 70: 123-32 (2010) . When the immune checkpoint inhibitor is the anti-LAG3 antibody GSK2831781, 1.5 to 5 mg/kg may be administered by intravenous infusion over 120 minutes every 2-4 weeks. When the immune checkpoint inhibitor is an anti-TIM3 antibody, 1-5 mg/kg may be administered by intravenous infusion over 30-90 minutes every 2-4 weeks. When an inhibitor of indoleamine 2, 3 -di oxygenase (IDO) pathway is inhibitor indoximod in combination with temozolomide, 18.5 mg/kg/dose BID with an escalation to 27.7 mg/kg/dose BID of indoximod with 200 mg/m2 every 5 days of temozolomide.
In one embodiment, the immune checkpoint inhibitor is an antibody and 1-20 mg/kg is administered by intravenous infusion every 2-4 weeks. In another embodiment, 50-2000 mg of the antibody is administered by intravenous infusion every 2-4 weeks. In another embodiment, the glutamine antagonist is administered prior to administration of the antibody. In another embodiment, the glutamine antagonist is administered 3-7 days prior to the day of administration of the antibody. In another embodiment, the glutamine antagonist is also administered the day the antibody is administered and on consecutive days thereafter until disease progression or untilthe glutamine antagonist administration is no longer beneficial.
In one embodiment, the cancer patient receives 2 mg/kg pembrolizumab administered by intravenous infusion every three weeks and about 0.1 to 100 mg of the glutamine antagonist administered for 1-7 days prior to pembrolizumab administration, optionally, on the day of pembrolizumab administration, and, optionally, thereafter until disease progression or until there is no therapeutic benefit.
In another embodiment, the cancer patient receives 3 mg/kg nivolumab administered by intravenous infusion every 2 weeks and about 0.1 to 100 mg of the glutamine antagonist administered for 1-7 days prior to nivolumab administration, optionally, on the day of nivolumab administration, and, optionally, thereafter until disease progression or until there is no therapeutic benefit.
In another embodiment, the cancer patient receives 3 mg/kg nivolumab administered by intravenous infusion every 2 weeks and about 0.1 to 100 mg of the glutamine antagonist administered for 1-7 days prior to nivolumab administration, optionally, on the day of nivolumab administration, and, optionally, thereafter until disease progression or until there is no therapeutic benefit.
In another embodiment, the treatment of the cancer patient with a glutamine antagonist, and an immune checkpoint inhibitor induces anti proliferative response faster than when the immune checkpoint inhibitor is administered alone.
Definitions:
The term “halogen” , as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo. The preferred halogen groups include F, Cl and Br. The terms "haloC1-6alkyl" , "haloC2-6alkenyl" , "haloC2-6alkynyl" and "haloC1-6alkoxy" mean a C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C1-6alkoxy in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. In some embodiment, preferred are fluoroC1-6alkyl, fluoroC2-6alkenyl, fluoroC2-6alkynyl and fluoroC1-6alkoxy groups, in particular fluoroC1-3alkyl, for example, CF3, CHF2, CH2F, CH2CH2F, CH2CHF2, CH2CF3 and fluoroC1-3alkoxy groups, for example, OCF3, OCHF2, OCH2F, OCH2CH2F, OCH2CHF2 or OCH2CF3, and most especially CF3, OCF3 and OCHF2.
As used herein, unless otherwise indicated, alkyl includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl, n-pentyl, 3- (2-methyl) butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-hexyl, 2-methylpentyl and cyclohexyl. Similary, C1-8, as in C1-8alkyl is defined to identify the group as having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or branched arrangement.
Alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. For example, methylene (i.e., -CH2-) , ethylene (i.e., -CH2-CH2-or –CH (CH3) -) and propylene (i.e., -CH2-CH2-CH2-, -CH (-CH2-CH3) -or –CH2-CH (CH3) -) .
Alkenyl and alkynyl groups include straight, branched chain or cyclic alkenes and alkynes. Likewise, “C2-8alkenyl" and “C2-8alkynyl" means an alkenyl or alkynyl radicals having 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a linear or brached arrangement. Alkenyl group include, but are not limited to, for example, ethenyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, hepetenyl, octenyl and the like. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl and the like.
Alkoxy radicals are oxygen ethers formed from the previously described straight, branched chain or cyclic alkyl groups.
The term “aryl” , as used herein, unless otherwise indicated, refers to an unsubstituted or substituted mono-or polycyclic ring system containing carbon ring atoms. The preferred aryls are mono cyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
The term “heterocyclic ring” or “heterocyclyl” , as used herein, unless otherwise indicated, refers to unsubstituted and substituted mono-or polycyclic non-aromatic ring system containing one or more heteroatoms. Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides. Preferably the ring is three to eight membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two or three, are included within the present definition.
Examples of such heterocyclic groups include, but are not limited to azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxoazepinyl, azepinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone and oxadiazolyl.
The term “heteroaryl” , as used herein, unless otherwise indicated, represents an aromatic ring system containing carbon (s) and at least one heteroatom. Heteroaryl may be monocyclic or polycyclic, substituted or unsubstituted. A monocyclic heteroaryl group may have 1 to 4 heteroatoms in the ring, while a polycyclic heteroaryl may contain 1 to 10 hetero atoms. A polycyclic heteroaryl ring may contain fused, spiro or bridged ring junction, for example, bycyclic heteroaryl is a polycyclic heteroaryl. Bicyclic heteroaryl rings may contain from 8 to 12 member atoms. Monocyclic heteroaryl rings may contain from 5 to 8 member atoms (cabons and heteroatoms) . Examples of heteroaryl groups include, but are not limited to thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adeninyl, quinolinyl or isoquinolinyl.
The term “cycloalkyl” refers to a substituted or unsubstituted monocyclic, bicyclic or polycyclic non-aromatic saturated ring, which optionally includes an alkylene linker through which the cycloalkyl may be attached. Examplary "cycloalkyl" groups includes but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and so on.
The term “carbonyl” , “=O” , “-C=O” , “C=O” , “-CO” , “-C (O) ” and “” CO refers to the group
The term “oxo” refers to the radical =O.
Whenever the term “alkyl” or “aryl” or either of their prefix roots appear in a name of a substituent (e.g., aralky or dialkylamino) it shall be interpreted as including those limitations given above for “alkyl” and “aryl” . Designated numbers of carbon atoms (e.g., Cl-6) shall refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
wherein the term "substituted" refers to a group mentioned above in which one or more (preferably 1-6, more preferably 1-3) hydrogen atoms are each independently replaced with the same or different substituent (s) . Typical substituents include, but are not limited to, X, Cl-6alkyl, Cl-6alkoxy, C3-20 cycloalkyl, -OR13, SR13, =O, =S, -C (O) R13, -C (S) R13, =NR13, -C (O) OR13, -C (S) OR13, -NR13R14, -C (O) NR13R14, cyano, nitro, -S (O) 2R13, -OS (O2) OR13, -OS (O) 2R13, or -OP (O) (OR13) (OR14) ; wherein each X is independently a halogen (F, Cl, Br or I) , and R13 and R14 is independently selected from -H, C1-6 alkyl and C1-6 haloalkyl. In some embodiments, the substituent (s) is independently selected from the group consisting of -F, -Cl, -Br, -I, -OH, trifluromethoxy, ethoxy, propyloxy, iso-propyloxy, n-butyloxy, isobutyloxy, t-butyloxy, -SCH3 , -SC2H5 , formaldehyde group, -C (OCH3) , cyano, nitro, CF3 , -OCF3, amino, dimethylamino, methyl thio, sulfonyl and acetyl. Particularly preferred substituent (s) is -F, -Cl or -Br.
Compounds described herein, such as certain compounds of Formula I, I-A, I-B, I-C, II, III, IV, V, VI, VII, or VIII, may contain asymmetrically substituted carbon atoms (or chiral centers) in the R or S configuration. The present invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers.
The compounds described herein, when specifically designated as the R-or S-isomer, either in a chemical name or in a drawing, should be understood as an enriched R-isomer or S-isomer, respectively. For example, in any of the embodiments described herein, such enriched R-or S-designated isomer can be substantially free (e.g., with less than 5%, less than 1%, or non-detectable, as determined by chiral HPLC) of the other isomer for the respective chiral center. The enriched R-or S-isomers can be prepared by methods exemplified in this application, such as by using a chiral auxiliary such as R-or S-tert-butylsulfinamide in the synthetic process. Other methods for prepaing the enriched R-or S-isomers herein include, but are not limited to, chiral HPLC purifications of a stereoisomeric mixture, such as a racemic mixture. General methods for separating stereoisomers (such as enantiomers and/or diastereomers) using HPLC are known in the art.
Compounds described herein can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to 2H, 3H, 13C, 14C, 15N, 18O, 32P, 35S, 18F, 36Cl, and 125I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention. In some embodiments, one or more hydrogen atoms of any of the compounds described herein can be substituted with deuterium to provide the corresponding deterium-labeled or -enriched compounds.
Compounds described herein may have different isomeric forms. For example, any asymmetric carbon atom may be present in the (R) -, (S) -or (R, S) -configuration, preferably in the (R) -or (S) -configuration. Substituents at a double bond or especially a ring may be present m cis- (= Z-) or trans (= E-) form. The compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as pure diastereomers or pure enantiomers.
Where the plural form (e.g. compounds, salts) is used, this includes the singular (e.g. a single compound, a single salt) . “A compound” does not exclude that (e.g. in a pharmaceutical formulation) more than one compound of the invention (or a salt thereof) is present, the "a" merely representing the indefinite article. “A” can thus preferably be read as “one or more” , less preferably alternatively as “one” .
The term “composition” , as used herein, is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from pharmaceutical combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
The compounds of the present invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts” . The pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts. The pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic. Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
The present invention includes within its scope the prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required
compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs” , ed. H. Bundgaard, Elsevier, 1985.
It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques know in the art as well as those methods set forth herein.
The present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.
When a tautomer of the compounds of the invention exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
When the compounds of the invention and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. A type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.
The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous) . Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the pharmaceutical combination of the invention, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.
The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.
A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet
preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient. For example, a formulation intended for the oral administration to humans may contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about lmg to about 2g of the active ingredient, typically 25mg, 50mg, l00mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or l000mg.
Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol) , vegetable oils, and suitable mixtures thereof.
Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing The pharmaceutical combination of the invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt%to about 10wt%of the compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier (s) followed by chilling and shaping in molds.
In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing The pharmaceutical combination of the invention, , or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
Generally, dosage levels on the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 7g per patient per day. For example, inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS) , may be effectively treated by the administration of from about 0.01 to 50mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day.
It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug pharmaceutical combination and the severity of the particular disease undergoing therapy.
The term “subject” or “patient” as used herein is intended to include animals, which are capable of suffering from or afflicted with a cancer or any disorder involving, directly or indirectly, a cancer. Examples of subjects include mammals, e.g., humans, apes, monkeys, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In an embodiment, the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from cancers.
The term “treating” or “treatment” as used herein comprises a treatment relieving, reducing or alleviating at least one symptom in a subject or effecting a delay of progression of a disease. For example, treatment can be the diminishment of one or several symptoms of a disorder or complete eradication of a disorder, such as cancer. Within the meaning of the present disclosure, the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
As used herein, the term "glutamine antagonist" refers to a glutamine analog that interfers with a glutamine metabolic pathway, e.g., the inhibition or blocking of a metabolic pathway downstream of glutamine in which glutamine acts as a precursor of one or more non-glutamine compounds. Examples of such metabolic pathways are well known (see, e.g., Hensley et al, "Glutamine and cancer: cell biology, physiology, and clinical opportunities" J Clin Invest. 2013; 123 (9) : 3678-3684; DeBerardinis et al, "Q's next: the diverse functions of
glutamine in metabolism, cell biology and cancer" Oncogene. 2009; 29 (3) : 313-324; and Medina et al, "Relevance of glutamine metabolism to tumor cell growth" Mol Cell Biochem. 1992; 113 (1) : 1 -15) . In some contexts, the term glutamine antagonist also includes glutamine analogs that inhibit glutamine uptake by cells, thereby reducing its biological activity. Diseases or conditions wherein excess and/or aberrant glutamine.
A “therapeutically effective amount” when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
The terms “comprising” and “including” are used herein in their open-ended and non-limiting sense unless otherwise noted.
The terms “a” and “an” and “the” and similar references in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Where the plural form is used for compounds, salts, and the like, this is taken to mean also a single compound, salt, or the like.
The term “pharmaceutical combination therapy” or “in pharmaceutical combination with” refers to the administration of two or more therapeutic agents to treat a condition or disorder described in the present disclosure (e.g., cancer) . Such administration encompasses co -administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients. Alternatively, such administration encompasses coadministration in multiple, or in separate containers (e.g., capsules, powders, and liquids) for each active ingredient. Powders and/or liquids may be reconstituted or diluted to a desired dose prior to administration. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner, either at approximately the same time or at different times. In either case, the treatment regimen will provide beneficial effects of the drug pharmaceutical combination in treating the conditions or disorders described herein.
The combination therapy can provide “synergy” and prove “synergistic” , i.e., the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately. A synergistic effect can be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined, unit dosage formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect can be attained when the compounds are administered or delivered sequentially, e.g., by different injections in separate syringes. In general, during alternation therapy, an effective dosage of each active ingredient is administered sequentially, i.e., serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.
The term “pharmaceutical combination” as used herein refers to either a fixed pharmaceutical combination in one dosage unit form, or non-fixed pharmaceutical combination or a kit of parts for the combined administration where two or more therapeutic agents may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the pharmaceutical combination partners show a cooperative, e.g. synergistic effect.
The term “synergistic effect” as used herein refers to action of two or more therapeutic agents such as, for example, a glutamine antagonist, and the immune checkpoint inhibitor, producing an effect, for example, slowing the symptomatic progression of a proliferative disease, particularly cancer, or symptoms thereof, which is greater than the simple addition of the effects of each drug administered by themselves. A synergistic effect can be calculated, for example, using suitable methods such as the Sigmoid-Emax equation (Holford, N. H. G. and Scheiner, L. B., Clin. Pharmacokinet. 6: 429-453 (1981) ) , the equation of Loewe additivity (Loewe, S. and Muischnek, H., Arch. Exp. Pathol Pharmacol. 114: 313-326 (1926) ) and the median-effect equation (Chou, T. C. and Talalay, P., Adv. Enzyme Regul. 22: 27-55 (1984) ) . Each equation referred to above can be applied to experimental data to generate a corresponding graph to aid in assessing the effects of the drug pharmaceutical combination. The corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and pharmaceutical combination index curve, respectively.
The pharmaceutical combination of the invention, a glutamine antagonist and an immune checkpoint inhibitor, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have one or more atoms replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the glutamine antagonist and the immune checkpoint inhibitor include isotopes of hydrogen, carbon, nitrogen, oxygen, and chlorine, for example, 2H, 3H, nC, 13C, 14C, 15N, 35S, 36C1. The invention includes isotopically labeled a glutamine antagonist and a immune checkpoint inhibitor, for example into which radioactive isotopes, such as3H and14C, or non-radio active isotopes, such as 2H and13C, are present. Isotopically labelled the glutamine antagonist and the immune checkpoint inhibitor are useful in metabolic studies (with 14C) , reaction kinetic studies (with, for example2H or3H) , detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques
known to those skilled in the art or by processes analogous to those described in the accompanying Examples using appropriate isotopically-labeled reagents.
These and other aspects will become apparent from the following written description of the invention.
Fig. 1 shows anti-tumor effect of the test compound alone and in combination with Anti-PD-1 mAb in MC38 Model
Fig. 2 shows survival curve for different treatment groups in MC38 Model
Fig. 3 shows body weight change of different treatment groups in MC38 Model
Fig. 4 shows anti-tumor effect of the test compound alone and in combination with Anti-PD-L1 mAb in H22 Model
Fig. 5 shows the tumor volume of Individual Mice in H22 Model
Fig. 6 shows survival curve for different treatment groups in H22 Model
Fig. 7 shows body weight change of different treatment groups in H22 Model
The following abbreviations have been used in the examples:
Intermediate A1
Intermediate A1 was prepared referring to the compound 3 in WO2017023774 in Scheme 1 at page 82.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate B1
Step a: To a solution of 7-Fluoroindole (308 mg, 2.279 mmol) and Ytterbium (III) triflate hydrate (219 mg, 343.119 μmol) in Chloroform (3 mL) was added (2S) -Methylglycidate (121 mg, 1.185 mmol) under N2. The mixture was heated to 85℃ and stirred for 3 h. The reaction mixture was cooled to RT. The reaction mixture was quenched with Na2CO3 (aq) (10 mL) , and adjusted the pH to 5-6 with 2M HCl. The aqueous layer was separated and extracted with DCM (2×10 mL) . The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica chromatography eluting with EtOAc/Hexane (1: 2) to afford methyl (2S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxy-propanoate (136 mg, 573.292 μmol) . MS: m/z 238 (M+H) +.
Step b: To a solution of methyl (2S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxy-propanoate (136 mg, 573.292 μmol) in water (1 mL) was added LiOH (2M solution in water, 1 mL) . The mixture was stirred for overnight at RT-60℃, Citric acid (solid) was added, diluted with water (5 mL) and extracted with EA (2×10 mL) . The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (2S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxy-propanoic acid (165 mg, 739.247 μmol) which was used in next step without any further purification. MS: m/z (224) +.
Intermediate B2
Step a: To a solution of Indole (302 mg, 2.578 mmol) in DMF (3 mL) was added NaH (217 mg, 9.043 mmol) at ice-water bath for 1h . (2S) -Methylglycidate (685 mg, 6.710 mmol) was added and the mixture was stirred over night at RT. The reaction mixture was quenched with H2O, and adjusted the pH to 3-4 with citric acid. The aqueous layers were extracted with EA. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FLASH with H2O/MeCN (5%-95%) to afford (S) -2-hydroxy-3- (1H-indol-1-yl) propanoic acid (222 mg, 1.082 mmol) . MS: m/z 206 (M+H) +.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate C1
Step a: To a solution of Methyl (S) - (-) -lactate (1099 mg, 10.5567 mmol) , Iodoethane (3726 mg, 23.8900 mmol) in Diethyl ether (10 mL) was added Ag2O (4772 mg, 20.5925 mmol) under N2. The reaction mixture was stirred over night at RT by light-avoiding. The reaction mixture was monitored by TLC. The reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved by THF (3 mL) , MeOH (3 mL) , H2O (3 mL) and then the reaction mixture was added LiOH (246 mg, 10.2721 mmol) . The reaction mixture was stirred for 3h at RT. The reaction mixture was monitored by TLC and adjusted the pH to 2 with 1N HCl. The reaction mixture was concentrated under reduced pressure to 5 mL. The aqueous layers were extracted with EA (3×10 mL) . The combined organic layers were washed with saturated solution of NaCl (3×10 mL) and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (S) -2-ethoxypropanoic acid (772 mg, 6.5351 mmol) . MS: m/z 119 (M+H) +.
Intermediate C2
Step a: To a solution of 2-hydroxy-4- (methylthio) butanoic acid (0.68 g, 4.5274 mmol) , CH3I (3.35 g, 23.6019 mmol) in Diethyl ether (10 mL) was added Ag2O (4.41 g, 19.0303 mmol) . The reaction mixture was stirred over night at RT. The reaction mixture was monitored by LC-MS. The reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved by MeOH (6 mL) , H2O (2 mL) and then the reaction mixture was added NaOH (318 mg, 7.9506 mmol) . The reaction mixture was stirred for 3h at RT. The reaction mixture was monitored by TLC and adjusted the pH to 3 with 1M HCl. The reaction mixture was concentrated under reduced pressure to 5 mL. The aqueous layers were extracted with EA (3×10 mL) . The combined organic layers were washed with saturated solution of NaCl (3×10 mL) and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 2-methoxy-4- (methylthio) butanoic acid (128 mg, 779.4318 μmol) . MS: m/z 165 (M+H) +.
Intermediate C3
Step a: To a solution of 2-hydroxy-3- (1H-indol-3-yl) propanoic acid (152 mg, 740.706 μmol) in THF (10 mL) was added NaH (55 mg, 2.292 mmol) . The reaction mixture was stirred for 20 min at RT and then CH3I (370 mg, 2.607 mmol) was added. The reaction mixture was monitored by LC-MS. CH3I (358 mg, 2.522 mmol) was added again. The reaction mixture was monitored by LC-MS. The reaction mixture was stirred for 3h at 40℃. The
reaction mixture was added H2O (5 mL) and extracted with EA (10 mL) . The aqueous layers were combined and purified by FLASH with H2O/MeCN (0%-100%, 40min, C18) . The product layers were concentrated under reduced pressure to afford 2-methoxy-3- (1-methyl-1H-indol-3-yl) propanoic acid (119 mg, 510.155 μmol) . MS: m/z 234 (M+H) +.
The following compounds were synthesized using the above procedure or modification procedure with the corresponding starting materials.
Intermediate D1
Step a: To a solution of methyl (S) -2-hydroxy-3- (1H-indol-3-yl) propanoate (2 g, 9.123 mmol) in DCM (20 mL) was added Imidazole (2061 mg, 30.274 mmol) and TBDMS-Cl (2980 mg, 19.772 mmol) . The mixture was stirred for overnight at RT. The reaction mixture was quenched with Water (10 mL) and extracted with DCM (10 mL). The reaction mixture was separated and organic extracts were collected. The aqueous solution was extracted with DCM (2×10 mL) . The residue was purified by wet column chromatography with EA/Hex (0-20%) . The product’s solution was concentrated under reduced pressure. The methyl (S) -2- ( (tert-butyldimethylsilyl) oxy) -3- (1H-indol-3-yl) propanoate (3099 mg) was obtained. MS: m/z 334 (M+H) +.
Step b: To a -78℃ solution of methyl (S) -2- ( (tert-butyldimethylsilyl) oxy) -3- (1H-indol-3-yl) propanoate (3.099g, 9.292 mmol) in THF (30 mL) was added LiHMDS (10.5 mL, 10.491 mmol) . The mixture was stirred for 30min at -78℃. Then Carbobenzyloxy chloride (4623 mg, 27.100 mmol) was dropped into the mixture at -78℃. The reaction mixture was stirred for 1h at this temperature. Quenched the reaction with sat. NH4Cl, and the aqueous solution was extracted with EA (2×10 mL) . The combined organic extracts were washed with brine (3×10 mL), dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure. The benzyl (S) -3- (2- ( (tert-butyldimethylsilyl) oxy) -3-methoxy-3-oxopropyl) -1H-indole-1-carboxylate (4345 mg) was obtained. MS: m/z 468 (M+H) +.
Step c: To a solution of benzyl (S) -3- (2- ( (tert-butyldimethylsilyl) oxy) -3-methoxy-3-oxopropyl) -1H-indole-1-carboxylate (4.345 g, 9.292 mmol) in THF (30 mL) was added Tetrabutylammonium fluoride (5 mL) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by FLASH with EA/Hex (0-60%) . The product’s solution was concentrated under reduced pressure. The benzyl 3- [ (2S) -2-hydroxy-3-methoxy-3-oxo-propyl] indole-1-carboxylate (2.21 g) was obtained. MS: m/z 354 (M+H) +.
Step d: To a solution of benzyl 3- [ (2S) -2-hydroxy-3-methoxy-3-oxo-propyl] indole-1-carboxylate (103 mg, 291.481 μmol) , and 4A molecular sieve in CH3I (1mL) was added Silver oxide (216 mg, 932.098 μmol) . The mixture was stirred for overnight at RT. The reaction mixture was concentrated under reduced pressure. The reaction mixture was diluted with EA (5mL) and filtered, the filtrate was concentrated to afford benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (107.088 mg, 100.000%yield) . MS: m/z 368(M+H) +.
Step e: To a solution of benzyl (S) -3- (2, 3-dimethoxy-3-oxopropyl) -1H-indole-1-carboxylate (0.107g, 291.240
μmol) in THF (5 mL) and MeOH (5mL) was added NaOH (3mL, 3M/L) . The mixture was stirred for 1h at RT. The reaction mixture was adjusted the pH to 3 with 1M HCl. The aqueous solution was extracted with EA (2×10 mL) . The combined organic extracts were washed with brine (3×10 mL) , dried over anhydrous Na2SO4. The organic phase was concentrated under reduced pressure and (S) -3- (1H-indol-3-yl) -2-methoxypropanoic acid (71 mg) was obtained. MS: m/z 220 (M+H) +.
The following compounds were synthesized using intermediate D1 and the above procedure or modification procedure with the corresponding starting materials.
EXAMPLE 1
Isopropyl (S) -6-diazo-2- ( (S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxypropanamido) -5-oxohexanoate (Compound 1)
To a solution of (2S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxy-propanoic acid (0.165 g, 739.247 μmol) and isopropyl (2S) -2-amino-6-diazo-5-oxo-hexanoate (123 mg, 576.834 μmol) in DCM (2 mL) was added N, N'-Diisopropylcarbodiimide (95 mg, 752.779 μmol) , 2, 4, 6-Collidine (115 mg, 949.008 μmol) and Ethyl cyanoglyoxylate-2-oxime (83 mg, 584.044 μmol) at 0℃. The mixture was stirred at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC, and concentrated under reduced pressure to afford isopropyl (2S) -6-diazo-2- [ [ (2S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxy-propanoyl] amino] -5-oxo-hexanoate (41.6 mg, 99.422 μmol) by lyophilization. MS: m/z 419 (M+H) +, 1H NMR (400 MHz, CDCl3) δ 8.47 –8.39 (m, 1H) , 7.47 (d, J = 7.9 Hz, 1H) , 7.21 –7.19 (m, 1H) , 7.16 (d, J = 7.8 Hz, 1H) , 7.05 (td, J = 7.9, 4.8 Hz, 1H) , 6.93 (dd, J = 10.8, 7.8 Hz, 1H), 5.09 (s, 1H) , 5.03 (dt, J = 12.5, 6.3 Hz, 1H) , 4.53 –4.45 (m, 1H) , 4.43 (s, 1H) , 3.29 (ddd, J = 21.3, 14.8, 5.4 Hz, 2H) , 2.73 –2.60 (m, 1H) , 2.43 –2.25 (m, 1H) , 2.18 –1.98 (m, 2H) , 1.97 –1.80 (m, 1H) , 1.30 –1.22 (m, 6H) . EXAMPLE 2
Isopropyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (Compound 2)
To a solution of (S) -2-methoxypropanoic acid (267 mg, 2.565 mmol) and isopropyl (2S) -2-amino-6-diazo-5-oxo-hexanoate (0.152 g, 712.835 μmol) in DMF (5 mL) was added N,N'-Diisopropylcarbodiimide (327 mg, 2.591 mmol) , 2, 4, 6-Collidine (412 mg, 3.400 mmol) and Ethyl cyanoglyoxylate-2-oxime (375 mg, 2.639 mmol) at 0℃. The mixture was stirred at RT for 15 h. The reaction mixture was quenched with saturated NH4Cl (50 mL) and extracted with EA (20 mL×3) . The combined organic layers were washed with brine (50 mL×3) and concentrated under reduced pressure. The residue was purified by pre-HPLC (C18, MeCN/H2O=5-100%, 40min) and concentrated under reduced pressure to afford isopropyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (60.2 mg, 201.1211 μmol, easily dissolved in water) . MS:m/z 300 (M+H) +, 1H NMR (400 MHz, CDCl3) δ 7.22 –7.08 (m, 1H) , 5.12 –5.01 (m, 1H) , 4.57 (td, J = 8.7, 4.8 Hz, 1H) , 3.77 (dt, J = 6.7, 5.7 Hz, 1H) , 3.45 (s, 3H) , 2.82 –2.58 (m, 1H) , 2.50 –2.22 (m, 2H) , 2.09 –1.85 (m, 1H) , 1.44 –1.35 (m, 3H) , 1.31 –1.26 (m, 6H) .
EXAMPLE 3
Methyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (Compound 3)
To a solution of (S) -2-methoxypropanoic acid (2.06 g, 19.7879 mmol) and methyl (S) -2-amino-6-diazo-5-oxohexanoate (2308 mg, 12.4635 μmol) in DMF (5 mL) was added NMM (3.73 g, 36.8770 mmol) and HATU (6.26 g, 16.4637 mmol) at 0℃. The mixture was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC (C18, MeCN/H2O=0-100%, 40 min) and concentrated under reduced pressure to afford methyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (2.87 g, 10.5799 mmol, easily dissolved in water) . MS:m/z 272 (M+H) +, 1H NMR (400 MHz, CD3OD) δ 5.82 (s, 1H) , 4.46 (dd, J = 8.9, 4.8 Hz, 1H) , 3.79 –3.74 (m, 1H), 3.72 (s, 3H) , 3.40 (s, 3H) , 2.43 (s, 2H) , 2.33 –2.15 (m, 1H) , 2.08 –1.90 (m, 1H) , 1.33 (d, J = 6.7 Hz, 3H) .
EXAMPLE 4
(S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoic acid (Compound 4)
To a solution of methyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (0.96 g, 3.5389 mmol) in THF (10 mL) was added a solution of NaOH (176 mg, 4.4003 mmol) in water (5 mL) at 0℃. The mixture was stirred at RT for 40 min. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC (C18, MeCN/H2O=0-80%, 30 min) and concentrated under reduced pressure to afford (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoic acid (866 mg, 3.3665 mmol, easily dissolved in water) . MS:m/z 258 (M+H) +, 1H NMR (400 MHz, CD3OD) δ 5.82 (s, 1H) , 4.27 (t, J = 5.8 Hz, 1H) , 3.72 (q, J = 6.6 Hz, 1H), 3.40 (s, 3H) , 2.46 –2.27 (m, 2H) , 2.28 –2.13 (m, 1H) , 2.06 –1.91 (m, 1H) , 1.33 (d, J = 6.7 Hz, 3H) .
EXAMPLE 5
Isopropyl (S) -2- ( (S) -2-acetoxy-3- (7-fluoro-1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate (Compound 5)
To a solution of isopropyl (S) -6-diazo-2- ( (S) -3- (7-fluoro-1H-indol-3-yl) -2-hydroxypropanamido) -5-oxohexanoate (0.166 g, 396.7325 μmol) in DMF (3.5 mL) was added pyridine (189 mg, 2.3894 mmol) and acetic anhydride (104 mg, 1.0187 mmol) at RT. The mixture was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC (C18, MeCN/H2O=2-80%) and concentrated under reduced pressure to afford isopropyl (S) -2- ( (S) -2-acetoxy-3- (7-fluoro-1H-indol-3-yl) propanamido) -6-diazo-5-oxohexanoate (75.2 mg, 163.3196 μmol) . MS: m/z 461 (M+H) +, 1H NMR (400 MHz, CD3OD) δ 7.39 (d, J = 7.9 Hz, 1H) , 7.17 (s, 1H) , 6.96 (dd, J = 13.4, 6.4 Hz, 1H) , 6.88 –6.76 (m, 1H) , 5.24 (t, J = 5.4 Hz, 1H) , 4.96 (dt, J = 12.4, 6.3 Hz, 1H) , 4.27 (d, J = 8.7 Hz, 1H) , 3.28 (d, J = 5.6 Hz, 2H) , 2.26 –2.13 (m, 1H) , 2.10 (s, 3H) , 2.05 (d, J = 10.2 Hz, 2H) , 1.88 –1.75 (m, 1H) , 1.22 (t, J = 6.8 Hz, 6H) .
EXAMPLE 6
Ethyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (Compound 6)
To a solution of (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoic acid (104 mg, 404.2870 μmol) and EtOH (96 mg, 2.0839 mmol) in DMF (5 mL) was added NMM (117 mg, 1.1567 mmol) and HATU (237 mg, 623.3081 μmol) at 0℃. The mixture was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC (C18, MeCN/H2O=0-100%, 30 min) and concentrated under reduced pressure to afford ethyl (S) -6-diazo-2- ( (S) -2-methoxypropanamido) -5-oxohexanoate (0.0332 g, 116.3705 μmol, easily dissolved in water) . MS: m/z 286 (M+H) +, 1H NMR (400 MHz, CD3OD) δ 4.49 –4.35 (m, 1H), 4.23 –4.13 (m, 2H) , 3.83 –3.71 (m, 1H) , 3.44 –3.35 (m, 3H) , 2.43 (s, 2H) , 2.30 –2.15 (m, 1H) , 2.08 –1.93 (m, 1H) , 1.36 –1.31 (m, 3H) , 1.29 –1.24 (m, 3H) .
The following compounds were synthesized using the above procedure or modification procedure of the aboved schemes with the corresponding starting materials.
EXAMPLE A: Efficacy of Compound 2 in Combination with Anti-PD-1 mAb in MC38 Syngeneic Model
Test Compound:
Compound 2; Physical description: Powder; Purity > 95%; Storage condition: 4 ℃.
InVivoMAb anti-mouse PD-1 (Anti-PD-1) ; Supplier: BioXcell; Physical description: Liquid; Purity > 95%; Storage condition: 4 ℃.
Each C57BL/6 mouse was inoculated subcutaneously in the right flank region with MC38 cells (1 x 106) for tumor development. The treatments were started when the mean tumor size reached approximately 75 mm3. The experimental animals were divided using stratified randomization with 7 mice per group based upon their tumor volumes. The treatment was started from the day of randomization, Group 1 was treated with Vehicle s. c. QD, Group 2 was treated with anti-PD-1 10 mg/kg i. p. BIW, Group 3 was treated with Compound 2 1.2 mg/kg s.c. Q2D, Group 4 was treated with Compound 2 1.2 mg/kg s. c. Q2D and anti-PD-1 10 mg/kg i. p. BIW. The in vivo efficacy was examined according to tumor growth inhibition (TGI) and the safety was evaluated according to weight change and survival in mice.
The result showed that Compound 2 alone had a significant anti-tumor effect in the MC38 syngeneic model, and combination with anti-PD-1 mAb further inhibited tumor growth and significantly prolonged the survival time. At day 22 post tumor implantation, the TGI were 57.2%, 76.2%and 89.7%, respectively (p =0.151, 0.019 and 0.008 compared to the vehicle group, respectively) . The tumor growth curves are shown in Fig. 1.
Treatments were ended at day 26 and survival curves from different groups were analyzed. Median survival of the groups was 26 days, 29 days, 33 days and 40 days, respectively. The result showed that combination of Compound 2 and anti-PD-1 further improved mouse survival compared to single agent treatment. The survival curves are shown in Fig. 2.
All the treatments were well-tolerated without any adverse effects observed in the MC38 tumor-bearing mice. The body weight curves are shown in Fig. 3.
In this study, Compound 2 in combination with anti-PD-1 mAb further enhanced tumor growth inhibition and showed improved survival compared to single agent treatment in MC38 model.
EXAMPLE B: Efficacy of Compound 2 in Combination with Anti-PD-L1 mAb in H22 Syngeneic Model
Test Compound:
Compound 2; Physical description: Powder; Purity > 95%; Storage condition: 4 ℃.
InVivoMAb anti-mouse PD-L1 (Anti-PD-L1) ; Supplier: BioXcell; Physical description: Liquid; Purity >95%; Storage condition: 4 ℃.
Each BALB/c mouse was inoculated subcutaneously in the right flank region with H22 cells (1 x 106) for tumor development. The treatments were started when the mean tumor size reached 146 mm3. The experimental animals were divided using stratified randomization with 8 mice per group based upon their tumor volumes.
The treatment was started from the day of randomization. Group 1 was treated with Vehicle s. c. QD, Group 2 was treated with anti-PD-L1 5 mg/kg i.p. BIW, Group 3 was treated with Compound 2 1.2 mg/kg s.c. 5 days on/2 days off, Group 4 was treated with Compound 2 1.2 mg/kg s.c. 5 days on/2 days off and anti-PD-L1 5 mg/kg i.p. BIW. The in vivo efficacy was examined according to tumor growth inhibition (TGI) and the safety was evaluated according to weight change and survival in mice.
The result showed that Compound 2 alone had a significant anti-tumor effect in the H22 syngeneic model, and combination with anti-PD-L1 mAb further inhibited tumor growth and significantly prolonged the survival time. At day 17 post tumor implantation, the TGI were 34.4%, 87.7%and 92.3%, respectively (p = 0.807, 0.022 and 0.018 compared to the vehicle group, respectively) . The tumor growth curves are shown in Fig. 4.
Treatments were ended at day 20 and survival curves from different groups were analyzed. Median survival of the groups was 20 days, 24 days, 42 days and undefined, respectively. The result showed that combination of Compound 2 and anti-PD-L1 further improved mouse survival compared to single agent treatment. The tumor growth curves of individual mice are shown in Fig. 5. The survival curves are shown in Fig. 6.
All the treatments were well-tolerated without any adverse effects observed in the H22 tumor-bearing mice. The body weight curves are shown in Fig. 7.
In this study, Compound 2 in combination with anti-PD-L1 mAb further enhanced tumor growth inhibition and showed improved survival compared to single agent treatment in H22 model.
The compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration. Such pharmaceutical compositions and processes for preparing the same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds., 19th ed., Mack Publishing Co., 1995) . The combinations are generally effective over a wide dosage range.
For example, dosages per day normally fall within the range of about 1 mg to about 200 mg total daily dose, preferably 0.2 mg to 50 mg total daily dose, more preferably 0.2 mg to 20 mg total daily dose. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed. The above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
It is understood that the Examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.
Claims (35)
- a pharmaceutical combination comprising:(i) a glutamine antagonist, or a pharmaceutical acceptable salt thereof; and(ii) an immune checkpoint inhibitor.
- The pharmaceutical combination of claim 1, wherein the immune checkpoint inhibitor is selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, or a TIM3 inhibitor.
- The pharmaceutical combination of claim 1 or 2, wherein the immune checkpoint inhibitor is a PD-1 inhibitor.
- The pharmaceutical combination of claim 3, wherein the PD-1 inhibitor is an anti-PD-1 antibody.
- The pharmaceutical combination of claim 4, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, STI-A1110, PDR001, MEDI-0680, AGEN2034, BGB-A317, AB122, TSR-042, PF-06801591, cemiplimab, SYM021, JNJ-63723283, HLX10, LZM009, and MGA012.
- The pharmaceutical combination of claim 1 or 2, wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.
- The pharmaceutical combination of claim 6, wherein the PD-L1 inhibitor is an anti-PD-Ll antibody.
- The pharmaceutical combination of claim 7, wherein the anti-PD-Ll antibody is selected from the group consisting of avelumab, atezolizumab, durvalumab, and STI-A1014.
- The pharmaceutical combination of claim 1 or 2, wherein the immune checkpoint inhibitor is a an anti-CTLA-4 inhibitor.
- The pharmaceutical combination of claim 9, wherein the anti-CTLA-4 inhibitor is an anti-CTLA-4 antibody.
- The pharmaceutical combination of claim 10, wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab.
- The pharmaceutical combination of claim 1 or 2, wherein the immune checkpoint inhibitor is a LAG3 inhibitor.
- The pharmaceutical combination of claim 12, wherein the LAG3 inhibitor is an anti-LAG3 antibody.
- The pharmaceutical combination of claim 13, wherein the anti-LAG3 antibody is GSK2831781.
- The pharmaceutical combination of claim 1 or 2, wherein the immune checkpoint inhibitor is a TIM3 inhibitor.
- The pharmaceutical combination of claim 15, wherein the TIM3 inhibitor is an anti-TIM3 antibody.
- The pharmaceutical combination of any one of claims 1-16, wherein the glutamine antagonist is a compound of formula I, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic substitution thereof,
wherein,Z is OR1 or SR1; R1 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, C1-6alkoxy, -C3-8cycloalkyl, -C0-6alkylene-C3-8heterocyclyl, -C0-6alkylene-NH-C0-6alkylene C6-10aryl, -C0-6alkylene-NH-C0-6alkylene-5-12membered heteroaryl, -C0-6alkylene-C6-10aryl and -C0-6alkylene-5-12 membered heteroaryl; each of which can be optional substituted with one or more substituents independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl, -CO-C1-6alkyl; and each of the heteroaryl and heterocyclyl contains 1, 2 or 3 heteroatoms selected from N, O or S;X is selected from the group consisting of hydrogen, deuterium, C1-6alkyl, -C (=O) -G, -C (=O) -W- (CRX1RX2) m-O-RX3, -C (=O) -W- (CRX1RX2) m-S-RX3, C (=O) -W- (CRX1RX2) m-SO-RX3, C (=O) -W- (CRX1RX2) m-SO2-RX3, -C (=O) -W- (CRX1RX2) m-G, -C (=O) -W- (CRX1RX2) m-NR5R5’, -P (=O) (OR6) p (NHR7) q, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -R8, -C (=O) -W- (CRX1RX2) m-G-O-R8, -C (=O) -O- (CRX1RX2) m-O-C (=O) -R9, -C (=O) -O-R7, -C (=O) -W- (CRX1RX2) m-G-O-C (=O) -G, and -C (=O) -W- (CRX1RX2) m-G-NR5R5’;W is oxygen, CO or a bond;m is selected from 1, 2, 3, 4, 5, 6, 7 or 8;p and q are each independently selected from 0, 1 or 2 provided that the sum of p and q is 2;RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, NH2, C1-6 alkyl, C1-6alkoxy, C4-10 cycloalkyl, -C (=O) -C1-6alkyl, C5-12aryl, -C1-6 alkylene-C5-12aryl, -5-12 membered heteroaryl, and –C1-6 alkylene-5-12 membered heteroaryl, and wherein said C1-6 alkyl, said C1-6alkoxy, said C4-10 cycloalkyl, said C5-12aryl, said–C1-6 alkylene-C5-12aryl, said -5-12 membered heteroaryl, and said–C1-6 alkylene-5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, -S-C1-6alkyl, carboxyl; and each of the heteroaryl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;or RX1 and RX2 together with the carbon atom to which they are attached form C3-10carbocyclic ring, C3-10 membered heterocyclyl, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -NH2, -CN, -OH, -NO2, carbonyl, =O, oxo, carboxyl, C1-6alkoxy, C1-6alkyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;RX3 is independently selected from the group consisting of hydrogen, deuterium, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, -C (=O) -C1-6 alkyl, and -C1-6alkylenen-C5-12 aryl, wherein said C1-6 alkyl, said C1-6 alkoxy, said C3-8 cycloalkyl, said -C (=O) -C1-6 alkyl, and said -C1-6alkylenen-C5-12 aryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl, 4-8 membered heterocyclyl, -C6-12aryl, -C (=O) -C1-6alkyl, -NH-C (=O) -C1-6alkyl, -C (=O) -NH2, -C (=O) -NH-C1-6alkyl, -C (=O) -N (C1-6 alkyl) 2;or RX1 and RX3 together with the carbon atom and the oxygen atom to which they are attached respectively form a 5-12 membered heterocyclyl, wherein said 5-12 membered heterocyclyl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl; and each of the heterocyclyl independently optionally contains 1, 2 or 3 heteroatoms selected from N, O or S;R5 and R5’ are each independently selected from the group consisting of hydrogen, deuterium, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, C5-12 aryl, 5-12 membered heteroaryl, 5-12 membered heterocyclyl, and wherein said -C1-6 alkyl, said -C1-6 alkoxy, said -C3-8 cycloalkyl, said C5-12 aryl, said 5-12 membered heteroaryl, said 5-12 membered heterocyclyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;each of R6 is independently selected from the group consisting of hydrogen, deuterium, -C1-6 alkyl, -C3-8 cycloalkyl, 5-12 membered heterocyclyl ring, -C1-6 alkenyl, and -C3-8 cycloalkenyl, and wherein said -C1-6 alkyl, said -C3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said -C1-6 alkenyl, and said -C3-8 cycloalkenyl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;or R6 together with the oxygen atom to which it is attached forms a purine or pyrimidine nucleoside;each of R7 is independent selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, C3-8 cycloalkyl, 5-12 membered heterocyclyl ring, C1-6 alkenyl, C3-8 cycloalkenyl, C5-12 aryl, and 5-12 membered heteroaryl, and wherein said C1-6 alkyl, said C3-8 cycloalkyl, said 5-12 membered heterocyclyl ring, said C1-6 alkenyl, said C3-8 cycloalkenyl, said C5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;R8 and R9 are each independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, monosaccharide, acylated monosaccharide, C5-12 aryl, and 5-12 membered heteroaryl, and wherein said C1-6 alkyl, said C3-8 cycloalkyl, said monosaccharide, said acylated monosaccharide, said C5-12 aryl, and said 5-12 membered heteroaryl, can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;G is C5-12 aryl, or 5-12 membered heteroaryl, wherein C5-12 aryl, and 5-12 membered heteroaryl can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;R3 and R3’ are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;Y is a bond, oxygen, or - (CRY1RY2) n-;n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;RY1 and RY2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N(C1-6alkyl) 2, carboxyl;R4 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl;R10 is selected from the group consisting of hydrogen, deuterium, halogen, C1-6 alkyl, and C1-6 alkoxy, and wherein said C1-6 alkyl, and said C1-6 alkoxy can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, halogen, -OH, oxo, -CN, -C1-6 alkyl, -C1-6 alkoxy, -C3-8 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-6alkyl) 2, carboxyl. - The pharmaceutical combination of any one of claims 1-17, wherein the glutamine antagonist is a compound, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, an isotopic substitution thereof, whereinthe compound is of Formula I-A:
the compound is of Formula I-B:wherein X, Y, R1, R2, R3, R3’, R4, and R10 are the same as defined in claim 17;preferably, the compound is of formula I-C,
wherein Q is O, S, SO, or SO2; Z, RX1, RX2, RX3, and m are the same as defined in claim 17;or the compound is of formula II,wherein Z, RX1, RX2, RX3, and m are the same as defined in claim 17; orthe compound is of formula III,wherein Z, RX1, RX2, RX3, and m are the same as defined in claim 17; orthe compound is of formula IV,wherein R1, RX1, RX2 and RX3 are the same as defined in claim 17; orthe compound is of formula V,wherein R1, RX1, RX2 and RX3 are the same as defined in claim 17; orthe compound is of formula VI,wherein R1, RX1, RX2 and RX3 are the same as defined in claim 17; orthe compound is of formula VII,wherein R1, RX1, RX2 and RX3 are the same as defined in claim 17; orthe compound is of formula VIII,wherein R1, RX1, RX2, and RX3 are the same as defined in claim 17. - The pharmaceutical combination of any one of claims 1-18, whereinone or more hydrogen in R1 or RX3 is substituted with deuterium, preferably, all hydrogens on one or more methyl groups, methylene groups, or methane groups are substituted with deuterium;R1 is selected from the group consisting of hydrogen, deuterium, hydrogen, deuterium, C1-3 alkyl, C1-3 alkoxy, and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy;RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, CN, OH, C1-4alkyl, C1-3alkoxy, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-6 alkyl) , -N (C1-3alkyl) 2, -S-C1-3alkyl; orRX3 is independently selected from the group consisting of hydrogen, deuterium, C1-3 alkyl, C1-3 alkoxy, each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, -C1-3 alkyl, -C1-3 alkoxy, -C3-6 cycloalkyl, -NH2, -NH (C1-3 alkyl) , -N (C1-3alkyl) 2, carboxy, -S-C1-3alkyl;Preferably,R1 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; and each of which can be optional substituted with one or more substituents, which are independently selected from the group consisting of deuterium, F, Cl, Br, I, -OH, oxo, -CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy;RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, CN, CF3, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, cyclobutyl, and each of which is independently optionally subsitituted with deuterium, -F, -Cl, -Br, -I, -NH2, -CN, -OH, oxo, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy; orRX3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, each of which can be substituted with deuterium;More preferably,R1 is seleted from hydrogen, deuterium, isopropyl, methyl, ethyl, -tert-butyl, isopentyl, -CD3, -CH2CD3, -CD2CD3, -CD (CD3) 2, -CH (CD3) 2,RX1 and RX2 are each independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, butyl, sec-butyl, iso-butyl, tert-butyl, orRX3 is independently selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, tert-butyl, -CD3, -CH2CD3, -CD2CD3.
- The pharmaceutical combination of any one of claims 1-19, wherein the glutamine antagonist is a compound in table 3, or a pharmaceutically acceptable salt thereof.
- The pharmaceutical combination of any one of claims 1-20, wherein the glutamine antagonist is selected from:
or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof. - The pharmaceutical combination of any one of claims 1-21, wherein the glutamine antagonist and the immune checkpoint inhibitor, or a pharmaceutically acceptable salt thereof, are in the same formulation.
- The pharmaceutical combination of any one of claims 1-21, wherein the glutamine antagonist and the immune checkpoint inhibitor, or a pharmaceutically acceptable salt thereof, are in the separate formulation.
- The pharmaceutical combination of any one of claims 1-23, wherein the pharmaceutical combination of the invention is for simultaneous or sequential (in any order) administration.
- A pharmaceutical composition or commercial package (e.g. a kit-of-parts) comprising the pharmaceutical combination of any one of the preceding claims and at least one pharmaceutically acceptable carrier.
- A use of a pharmaceutical combination of any one of claims 1 to 24 and/or a pharmaceutical composition or the commercial package of claim 25 for the manufacture of a medicament.
- The use of pharmaceutical combination of any one of claims 1 to 24 or the pharmaceutical composition or the commercial package of claim 25, wherein a medicament prepared can be used for the treatment or prevention of cancer or cancer metastasis.
- The use of pharmaceutical combination or the pharmaceutical composition or the commercial package of claim 27, wherein the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof; preferably, the skin cancer is a melanoma (e.g., a refractory melanoma) .
- The use of pharmaceutical combination or the pharmaceutical composition or the commercial package of claim 27 or 28, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
- The pharmaceutical combination of any one of claims 1 to 24 or the pharmaceutical composition or the commercial package of claim 25, for use in the treatment of cancer or the prevention of cancer metastasis.
- The pharmaceutical combination or the pharmaceutical composition or the commercial package for use of claim 30, wherein the cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof; preferably, the skin cancer is a melanoma (e.g., a refractory melanoma) .
- The pharmaceutical combination or the pharmaceutical composition or the commercial package for use of claim 30 or claim 31, wherein the cancer is selected from hepatocellular carcinoma, glioblastoma, lung cancer, breast cancer, head and neck cancer, prostate cancer, melanoma, lymphoma, kidney cancer, and colorectal cancer.
- The pharmaceutical combination of any one of claims 1 to 24 and/or a pharmaceutical composition or the commercial package of claim 25, which is used in therapy.
- The pharmaceutical combination of any one of claims 1 to 24 and/or a pharmaceutical composition or the commercial package of claim 25 which is used as a medicament.
- A method of treating cancer is selected from a breast cancer (e.g., a triple negative breast cancer) , a colorectal cancer (e.g., a microsatellite stable colorectal cancer (MSS CRC) ) , acute lymphoblastic leukemia, acute myelogenous leukemia, advanced soft tissue sarcoma, brain cancer, metastatic or aggressive breast cancer, bronchogenic carcinoma, choriocarcinoma, chronic myelocytic leukemia, colon carcinoma, Ewing's sarcoma, gastrointestinal tract carcinoma, glioma, glioblastoma multiforme, hepatocellular carcinoma, Hodgkin's disease, intracranial ependymoblastoma, large bowel cancer, leukemia, liver cancer, lung cancer, Lewis lung carcinoma, lymphoma, lymphangioma, lymphangiosarcoma, malignant fibrous histiocytoma, a mammary tumor, melanoma, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, a pontine tumor, premenopausal breast cancer, prostate cancer, rhabdomyosarcoma, reticulum cell sarcoma, sarcoma, small cell lung cancer, a solid tumor, stomach cancer, testicular cancer, uterine carcinoma, skin cancer, a gastric cancer, a gastroesophageal cancer, lung cancer, cervical cancer, head and neck cancer, esophageal cancer, non-small cell lung cancer, non-Hodgkin lymphoma, or any of combination thereof, in a mammal comprising administering to a mammal in need of such treatment an effective amount of the pharmaceutical combination of any one of claims 1 to 24, and/or a pharmaceutical composition of claim 25.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022088050 | 2022-04-21 | ||
CNPCT/CN2022/088050 | 2022-04-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023202652A1 true WO2023202652A1 (en) | 2023-10-26 |
WO2023202652A9 WO2023202652A9 (en) | 2023-11-30 |
Family
ID=88419265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/089400 WO2023202652A1 (en) | 2022-04-21 | 2023-04-20 | Pharmaceutical combination and use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023202652A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017062354A1 (en) * | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
WO2017201501A1 (en) * | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
CN108290827A (en) * | 2015-07-31 | 2018-07-17 | 约翰霍普金斯大学 | The prodrug of glutamine analogues |
CN108348492A (en) * | 2015-07-31 | 2018-07-31 | 约翰霍普金斯大学 | Use the method for cancer and immunotherapy of the glutamine analogues including DON |
WO2019089952A1 (en) * | 2017-11-03 | 2019-05-09 | Calithera Biosciences, Inc. | Conjoint therapy with glutaminase inhibitors |
WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
-
2023
- 2023-04-20 WO PCT/CN2023/089400 patent/WO2023202652A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108290827A (en) * | 2015-07-31 | 2018-07-17 | 约翰霍普金斯大学 | The prodrug of glutamine analogues |
CN108348492A (en) * | 2015-07-31 | 2018-07-31 | 约翰霍普金斯大学 | Use the method for cancer and immunotherapy of the glutamine analogues including DON |
WO2017062354A1 (en) * | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
WO2017201501A1 (en) * | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
WO2019089952A1 (en) * | 2017-11-03 | 2019-05-09 | Calithera Biosciences, Inc. | Conjoint therapy with glutaminase inhibitors |
WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
Also Published As
Publication number | Publication date |
---|---|
WO2023202652A9 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111801334B (en) | Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors | |
CN102471275B (en) | SMAC mimetic | |
KR101905208B1 (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
TW201808298A (en) | Treatment cancers using a combination comprising BTK inhibitors | |
CN111377871B (en) | FAK inhibitor and combined medicine thereof | |
JP6557744B2 (en) | Antitumor agent and antitumor effect potentiator | |
JP2022515077A (en) | CD70 and Venetoclax, BCL-2 Inhibitors, Combination Therapy for the Treatment of Acute Myeloid Leukemia | |
WO2016133903A2 (en) | Combination therapy for cancer treatment | |
WO2019204257A1 (en) | Ep4 inhibitors and use thereof | |
TW201805024A (en) | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer | |
CN111712242A (en) | Combination therapy using chemokine receptor 2(CCR2) antagonists and PD-1/PD-L1 inhibitors | |
WO2022133731A1 (en) | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers | |
WO2018117177A1 (en) | Brk INHIBITOR COMPOUND | |
KR20230161447A (en) | Exatecan derivatives, linker-payloads and conjugates thereof | |
JP2023503050A (en) | immune modulator | |
WO2023202652A1 (en) | Pharmaceutical combination and use thereof | |
CN106232602B (en) | Deuterated quinazolinone compound and pharmaceutical composition containing same | |
EP4316492A1 (en) | Combined use of multikinase inhibitor | |
EP2780011B1 (en) | Combination therapy for ovarian cancer | |
KR20200112904A (en) | Compositions and methods for treating cancer | |
TW202406539A (en) | Pharmaceutical combination and use thereof | |
EP3679932A1 (en) | METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR | |
WO2022078462A1 (en) | Novel glutamine analogs | |
EP4245301A1 (en) | Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor | |
CA3075717A1 (en) | Combination treatment for cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23791306 Country of ref document: EP Kind code of ref document: A1 |